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ABSTRACT
Dihydrofolate reductase (DHFR) is a key enzyme in cellular anabolism. It 
catalyses the reduction of 7,8-dihydrofolate (H2F) to 5,6,7,8-tetrahydrofolate 
(H4F) via hydride transfer from the C4 position of NADPH to the C6 position of 
H2F accompanied with protonation at the N5 position of H2F. Due to the 
importance of DHFR as an anticancer and antimicrobial target, the catalytic 
mechanism of DHFR has long been the focus of intense research. Kinetic isotope 
effect (KIE) measurements can provide insight into the mechanism of DHFR 
catalysis and guide the rational design of novel anti-DHFR drugs. However, 
because of a lack of a practical strategy to introduce heavy atoms (15N, 13C) into 
H2F, current research is mostly restrained to the study of hydrogen isotope 
effects. In this thesis, a fourteen step, one-pot chemoenzymatic synthesis of 
labelled H2F is reported. The flexibility of this synthetic approach enables the 
production of various isotopically enriched H2Fs from simple starting materials 
such as D-glucose. The labelled substrates were used to measure, for the first 
time, heavy atom KIEs and to derive information about the transition state of the 
chemical step during DHFR catalysis. This methodology is widely applicable to 
other biochemically important substrates and cofactors and it can be used for a 
wide variety of in vitro and in vivo investigations.
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1.1 The role of enzymes in biology and drug discovery
Life is defined as a “condition that distinguishes animals and plants from inorganic 
matter, including the capacity for growth, reproduction, functional activity, and 
continual change preceding death” (1). Chemistry underpins all the phenomena 
observed in life. A countless number of finely tuned chemical reactions occur at
precise points inside a living cell. Nucleic acid and protein biosynthesis,
production and storage of energy, CO2 fixation and glucose metabolism are a few 
examples of all chemistry that takes place inside an organism. For life to be 
sustainable, a chemical reaction must also occur within a reasonable time scale. 
Hence, as catalysts designed by nature, enzymes are the foundation of the 
hierarchy of life. Whereas under neutral conditions the half-times of chemical 
reactions that have biological importance range between 5 s (CO2 hydration) and
1.1 billion years (amino acid decarboxylation), enzymes are capable of 
accelerating the reaction rates up to a factor of 1019 with an average turnover 
number (kcat) of ~10 s-1 and a catalytic efficiency (kcat/KM) of ~105 M-1 s-1 (2, 3) by 
providing a reaction path that has a lower overall energy barrier (Figure 1.1). 
Considering that nearly all fundamental cellular events with tight spatial and 
temporal control are dictated by enzymes, it is not surprising that nearly half 
(47%) of the drugs currently employed in medicine are enzyme modulators 
(Figure 1.2) (4, 5). Depending on the source (human, bacterial, parasitic, viral) 
and role of an enzyme in a determined physio-pathological condition, small-
molecules modulating enzymatic activity can be used to address a broad range 
of disorders. Some examples include inflammatory, cancerous, cardiovascular 
and neurodegenerative diseases as well as bacterial, parasitic and viral infections 
(Table 1.1). 
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Figure 1.1. Reaction coordinate diagram of an uncatalysed chemical reaction compared 
to its enzyme-catalysed counterpart. In an enzyme-catalysed reaction, the free energy 
barrier is lowered by providing an alternative pathway where the activation energy 
needed to reach the transition state (S‡) is stabilised by the enzyme through the 
formation of the enzyme-substrate active complex (ES‡) which collapsed to yield the 
product (P).
Figure 1.2. Pharmacological target families according to Imming et al. (4).
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Table 1.1. Enzymes as pharmacological targets and their modulators in clinical use
(shown in bold) (6).
HUMAN
Acetylcholinesterase (Physostigmine), Aldehyde dehydrogenase (Disulfiram), 
Angiotensin-converting enzyme (Captopril), Carbonic anhydrase (Dorzolamide),
Dihydrofolate reductase (Methotrexate), Hydrogen potassium ATPase
(Omeprazole), Lipase (Orlistat), GABA transaminase (Valproic acid), DOPA 
decarboxylase (Levodopa), Tyrosine kinase (Imatinib), Phosphodiesterase III
(Milrinone), Phosphodiesterase V (Sildenafil), DNA polymerase (Fluorouracil), 
HMG-CoA reductase (Lovastatin), Vitamin K epoxide reductase (Warfarin), 
Cyclooxygenase (Aspirin), Lipoxygenase (Mesalazine), 5α-testosterone reductase
(Finastereide)
BACTERIAL
Alanine racemase (D-cycloserine), Enoyl reductase (Isoniazid), Serine protease
(Amoxicillin), Dihydrofolate reductase (Trimethoprim), Peptidyl transferase
(Phosphomycin), Dihydropteroate synthase (Sulphamethoxazole), 
Phosphoenolpyruvate transferase (Chloramphenicol), DNA gyrase
(Fluoroquinolones)
VIRAL
Aspartyl protease (Darunavir), Reverse transcriptase (Efavirenz), Glycosidase
(Zanamivir), RNA polymerase (Sofosbuvir), DNA polymerase (Acyclovir)
PARASITIC
Δ14-Sterol reductase (Amorolfin), Dihydrofolate reductase (Proguanil)
To transform an enzymatic modulator into a drug, there are three 
pharmacological requirements: efficacy, tolerability and safety. Ideally, a drug 
must be specific acting only on its biological target and restoring homeostasis
from a pathological condition (efficacy). Any side (tolerability) or toxic (safety) 
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effects arising from the disruption of other concomitant biological processes must 
be avoided. In other words, selectivity is an exceptionally crucial issue in drug 
development, as it dictates whether or not a biologically active compound will be 
a potential drug candidate (7, 8). In early stages of drug discovery (Figure 1.3), 
efforts are primarily focused on optimising an active molecule’s selectivity and 
suppressing its undesirable off-target effects through the design, synthesis and 
screening of compound libraries. This is in general a cost-demanding process 
with low success rate (8). To reduce the costs and increase the probabilities of 
developing a drug suitable for the pharmaceutical market, a detailed knowledge 
on how the target enzyme functions in its own physiological framework by 
physical, chemical and biological investigations is fundamental. 
Figure 1.3. The process of drug discovery. Small molecules are tested in vitro on a 
suitable biological entity (e.g. enzyme) for therapeutic intervention. Compounds showing 
the best selectivity/activity profile progress into in vivo studies as drug candidates. 
Eventually, the drug candidate will be approved and launched on the market. 
In modern drug discovery, inhibition is the most common approach to modulate 
enzymes for therapeutic intervention. Linus Pauling in 1946 was first to point out 
that “many chemotherapeutic agents exercise their activity by acting as inhibitors 
to an enzymatic reaction through competition with an essential metabolite of 
Introduction
6
similar structure” (9). Today, this remark has matured into the general concept
that a small-molecule mimicking the transition-state of an enzyme-catalysed 
reaction provides both powerful inhibition and high selectivity required for a drug 
candidate that is suitable to progress throughout clinical investigations (10, 11).
In the reaction pathway from substrate (S) to product (P) of an enzyme-catalysed 
reaction (Figure 1.1), the transition-state (ES‡) represents the highest energy and 
most unstable transient structure involved. Enzyme active sites, by providing the 
optimal shape and electrostatic environment, bind to S‡ structure to form the ES‡
complex with high selectivity and dissociation constants estimated between 10-14
and 10-23 M, significantly lower than those for S and P (12). Consequently, a 
stable molecule that is most structurally and electrostatically similar to S‡ is
expected to bind tightly to the enzyme’s active site.
Information derived from mechanistic studies of enzyme catalysis has been 
directly used in the design of clinically used drug molecules. This includes the 
development of HIV-protease inhibitors (e.g. darunavir) (13, 14). Being used 
during the maturation of essential viral enzymes from their inactive polyprotein 
precursors, including reverse transcriptase, RNase H and integrase (15), HIV-
protease has a pivotal role in the progression of the life cycle of HIV and hence 
is an anti-viral target (16). This enzyme is an aspartyl protease that cleaves a 
peptide bond through a general acid-base mechanism where a water molecule, 
activated by an aspartate residue, performs a nucleophilic attack at the carbonyl 
group of the peptide bond (Figure 1.4) (14). The consequential tetrahedral
intermediate collapses to yield a carboxylate and amine as hydrolysis products.
In the rational design of HIV-protease inhibitors, the sp3 carbon of the oxyanion 
intermediate can be mimicked by replacing it with noncleavable isosteres such 
as hydroxyethylene, reduced amide and dihydroxyethylene moieties (14).
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Figure 1.4. Mechanism of peptide bond hydrolysis catalysed by HIV-protease and 
examples of non-cleavable isosteres employed in the development of HIV-protease 
inhibitors. Figure adapted from ref (14) and (17).
The transition-state analysis approach has also been used in the development of 
zanamivir and oseltamivir which target neuraminidase (NA) from influenza virus 
(18, 19). NA is a glycosidase (or sialidase) needed to remove sialic acid from 
glycoproteins through the cleavage of an α-ketosidic bond (Figure 1.5). Because 
this reaction is fundamental to spread virions from infected cells to healthy hosts, 
inhibition of NA eventually results in halting of the influenza virus life cycle. 
Zanamivir and oseltamivir are proposed to mimic the NA oxocarbenium ion 
transition-state intermediate the existence of which was first hypothesised based
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on the results obtained from kinetic isotope effect (KIE) measurements, nuclear 
magnetic resonance (NMR) and molecular dynamics studies (19, 20).
Figure 1.5. Sialic acid cleavage catalysed by neuraminidase (NA). Zanamivir and 
oseltamivir are proposed to mimic the NA oxocarbenium ion transition-state 
intermediate. Figure adapted from ref (19).
The discovery of immucillin-H (Forodesine), a powerful purine nucleoside 
phosphorylase (PNP) inhibitor with picomolar affinity, is a classic example of the 
full potential of inventing drug candidates by combining fundamental enzymology
with drug discovery (21, 22). PNP catalyses the phosphorolysis of 
ribonucleosides (e.g. inosine) or deoxyribonucleosides (e.g. deoxyguanosine) to 
ribose- or deoxyribose-1-phosphate and the respective purine base (23). It was 
established that a complete inhibition of PNP in human T-cells causes an 
accumulation of deoxyguanosine, which eventually leads to cell death due to 
altered DNA metabolism (24). Because in human tissues only T-cells undergo 
apoptosis upon PNP inhibition, this represents an opportunity to address the 
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treatment of malignant and autoimmune diseases including T-cell lymphomas
(25). However, PNP inhibition must be exceptionally tight for deoxyguanosine to 
reach toxic intracellular concentrations (26). To this end, Schramm and co-
workers, guided by a detailed transition-state map of PNP structural and 
electronic features, designed the transition-state analogue immucillin-H, which 
inhibits human PNP with a pM inhibition constant (Ki) (Figure 1.6) (22).
Immucillin-H showed a good safety and tolerability profile even at high dosage
during phase I and II clinical trials (27, 28), providing an important proof of 
concept about the potential applications of transition-state analysis to drug 
design.
Figure 1.6. PNP-catalysed phosphorolysis of inosine and its corresponding transition-
state analogue, Immucillin-H.
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1.2 Kinetic isotope effect: a powerful tool to dissect transition-states on an 
atomic scale.
The transition-state of an enzyme-catalysed reaction is a metastable, short-lived 
species with a lifetime of ~10-14 s (12), and thus its characterisation is a non-trivial 
task. Its features, including the structural and electronic rearrangements
occurring in the ES‡ complex, need to be experimentally verified under nearly 
physiological conditions. Because of these strict requirements, the measurement 
of kinetic isotope effects (KIEs) is the physical technique that can provide 
accurate information about the transition state species. KIE is defined as “the 
effect on the rate constant of two reactions that differ only in the isotopic 
composition of one or more of their otherwise chemically identical components”
(29). This difference in reaction rates reflects the different contribution to the 
stabilization of the transition state between “light” (e.g. 1H, 12C, 14N) and “heavy” 
(e.g. 2H, 13C, 15N) isotopes in terms of vibrational energies at the zero point
(Figure 1.7), and it is defined as:
where kL and kH denote the reaction rate constants for the light and heavy isotope, 
respectively. When reactants approach the transition state, there is progressive
distortion of their atomic framework with altered bond lengths and electrostatics.
In general, atoms directly involved in the formation and/or breakage of chemical 
bonds during the transition-state yield relatively high KIE values and they are
therefore defined as “primary”. Although to a lesser extent, atoms directly 
adjacent to the reaction centre contribute to stabilization as well, and they are 
defined as “secondary”. Hydrogen KIEs are measured by replacing 1H with either 
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deuterium (2H) or tritium (3H), and they are relatively easy to measure because 
of the significant mass difference between the isotopes. Isotope effect involving 
12C/13C, 14N/15N, 16O/18O are generally referred to as heavy-atom KIEs and they 
are more difficult to detect compared to hydrogen KIEs (30).
Figure 1.7. Reaction coordinate diagram illustrating the difference in vibrational energy 
between light (black) and heavy (red) isotopes to reach the transition-state.
In the transition-state analysis of the PNP-catalysed reaction, hydrogen and 
heavy-atom KIEs were measured for each atomic position participating to the 
formation of the transition state with an accuracy of better than 0.5% (Figure 1.8)
(31). This required the synthesis of isotopically labelled substrates to probe the 
KIE for each position. Although KIE values do not represent a direct observation 
of the transition-state, they can be used to construct a computational model, using 
both quantum mechanical and semi-empirical approaches, by matching bond 
length and atoms to the experimental KIEs. The electronic distribution at the van 
der Waals surface was computed for the resulting structure, which has eventually 
been used in the design of immucillin-H (22, 32).
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Figure 1.8. Kinetic isotope effect map for the reaction catalysed by human PNP. Isotope 
effects were measured for the PNP-catalysed arsenolysis of inosine. Atoms for which 
the isotope effects were measured are highlighted in blue (N) and red (C and H), 
respectively. Figure was adapted from ref (32).
In addition to the construction of transition-state models, results obtained from 
KIE measurements can provide a diverse range of information that is useful in 
drug discovery. The investigation of neuraminidinase (NA) by KIE measurements 
has revealed that the substrate contains significant oxocarbenium character 
during the chemical transformation; based on these findings, an oxocarbenium 
intermediate, zanamivir, was designed (18-20). KIE measurements are also
valuable in understanding mechanistic aspects related to drug resistance. 
Resistance against HIV-protease inhibitors is an emblematic example. More than 
10 HIV-protease inhibitors with a Ki between nano- and picomolar concentration 
have been developed and marketed from 1995. However, because of the high 
viral replication rate combined to a poor proof-reading ability of HIV reverse 
transcriptase (33), the use of these inhibitors has selected HIV-protease variants 
that are resilient to inhibition (34). It is estimated that mutation of approximately 
37 residues out of the 99-residue sequence can yield an HIV-protease variant 
resistant to protease inhibitors (35). Most importantly, these mutations may be 
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additive, implying an impressive combination of possible cross mutations. Hence, 
it has become difficult to define a common mechanism of resistance on a 
molecular level (35). Although X-ray crystallography studies helped to spot
altered inhibitor-enzyme interactions (34), comparing transition-state maps 
between wild-type HIV-protease and its mutants based on KIE measurements 
showed that resistance is not related to the catalytic mechanism itself, but rather 
to a different stabilization of intermediates along the reaction pathway (17).
1.3 The role of dihydrofolate reductase (DHFR) in pharmacotherapy and 
drug design.
Though often found to be useful in drug discovery, rational design of enzymatic 
inhibitors aided by KIE interpretation and transition-state analysis remains an
underexploited approach (36, 37), mainly because the synthesis of specifically 
isotopic labelled substrates needed for KIE measurements is challenging.
Accordingly, this render to the use of inhibitors not resembling the transition-state
or not capturing any transition-state binding energy; instead, they are small-
molecules occupying the active site with an affinity constant higher than the 
natural substrate. Although a systematic and scientifically acceptable approach 
to the discovery of new drugs began in the early 1900s (38, 39), the use of rational 
design for drug development is relatively recent. In 1980s, when protein 
crystallography and computational chemistry were established methodologies, 
the design of a small-molecules using enzyme’s active sites as a footprint
became the dominant strategy to the discovery of new drugs by structure-based, 
computer-aided and fragment-based drug design approaches (40-42). Before
these advancements, drugs were mostly discovered either serendipitously or
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through blind screening, that is without any useful knowledge about the enzymatic 
target to allow a rational design approach (43).
The development of inhibitors of the pharmacological target dihydrofolate 
reductase (DHFR) highlights the need of producing isotopically labelled 
substrates for KIE measurement. Found in almost all organisms – from bacteria 
and protozoa to mammals – DHFR catalyses the reduction of dihydrofolate (H2F) 
to tetrahydrofolate (H4F) via hydride transfer from C4 of NADPH to C6 of H2F and 
protonation of N5 of H2F (Figure 1.9) (44). 
Figure 1.9. Reduction of 7,8-dihydrofolate (H2F) to 5,6,7,8-tetrahydrofolate (H4F) 
catalysed by dihydrofolate reductase (DHFR). The pro-R hydride from C4 of NADPH is 
transferred to the Re-face on C6 accompanied with protonation of N5 of H2F.
H4F is the source of a series of structurally-related coenzymes involved in the 
one-carbon metabolism, in which single carbon units activated in different 
oxidation states are shuttled within a cell to sustain fundamental anabolic 
processes (Figure 1.10) (45). 5-Methyl-tetrahydrofolate (5-methyl-H4F) is the 
cofactor needed by methionine synthase (MS) to regenerate methionine from 
homocysteine, which is required for S-adenosylmethionine (SAM) biosynthesis. 
In the cell, SAM acts as donor for methyl group transfer reactions, including DNA 
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and histones methylation (46). Folate metabolism also has an important role in 
keeping a balanced pool of serine and glycine amino acids (47). Because
cancerous cells are highly dependent on serine, it is hypothesised that carbon 
units shuttled in the folate metabolism are mainly provided by this amino acid
(48). Notably, the one-carbon cycle is essential to sustain nucleic acid production. 
5,10-Methylene-tetrahydrofolate (5,10-methylene-H4F) is needed in pyrimidine 
biosynthesis by thymidylate synthase (TS) to generate deoxythymidine
monophosphate (dTMP) from deoxyuridine monophosphate (dUMP). 10-Formyl-
tetrahydrofolate (10-formyl-H4F) is employed in two biochemical reactions
catalysed by glycinamide ribonucleotide (GART) and aminoimidazole 
carboxamide ribonucleotide (AICART) formyltransferases for the de novo
biosynthesis of purines. Given the central importance of the one-carbon 
metabolism in sustaining cellular proliferation, disruption of the DHFR catalytic 
cycle has life-threatening consequences for a cell.
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Figure 1.10. Folate coenzymes constituting the one-carbon metabolism. Connections to 
key metabolic pathways are highlighted.  1, Dihydrofolate reductase (DHFR); 2, 10-
Formyl-H4F synthetase (FTHFS); 3, 10-Formyl-H4F dehydrogenase (FDH); 4, 5,10-
Methenyl-H4F cyclohydrolase (MTHFC); 5, 5,10-Methylene-H4F dehydrogenase 
(MTHFD); 6, 5,10-Methylene-H4F reductase (MTHFR); 7, Methionine synthase (MS); 8, 
Serine hydroxymethyltransferase (SHMT); 9, Thymidylate synthase (TS); 10, 5,10-
Methenyl-H4F synthetase (MTHFS); 11, Formimino-H4F cyclodeaminase (FTCD). Figure 
adapted from ref (49).
Inhibition of human or microbial DHFR is an effective strategy to stem
uncontrolled cellular growth typical of malignancies as well as eradicate microbial 
infections. Indeed, DHFR was the first enzymatic target to be exploited in cancer 
therapy, since aminopterin was reported in 1948 to reverse childhood acute 
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leukaemia (50). A decade later, methotrexate (MTX) was introduced to treat
choriocarcinoma (51, 52), and it remains one of the most used anticancer drugs 
to date. A series of small-molecules targeting parasitic DHFRs were reported as 
well. Proguanil, developed through a British research programme during the 
Second World War, was shown to have antimalarial properties (53, 54); this was
followed by the discovery of pyrimethamine in 1951 (55). Trimethoprim, 
introduced in the late 1960s, preferentially inhibits bacterial DHFRs (56). It is 
worthwhile to point out that all antifolate drugs (aminopterin, MTX, proguanil, 
pyrimethamine, trimethoprim) discussed here (Figure 1.11) are neither the result 
of rational drug design nor was their mechanism of action fully understood at the 
time of their discovery (57). It was only during 1990s, with the aim to tackle 
resistance to MTX, that a “next generation” antifolates, including pemetrexed,
were (at least in part) rationally designed (58-61). 
Figure 1.11. Antifolate drugs employed in the treatment of cancer, malaria and bacterial 
diseases.
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Drug resistance is one of the socioeconomic and health challenges that drives 
the scientific community to design new antifolate drugs (60, 61). Unfortunately, 
this issue is not only related to the increasing failure of MTX in treating cancer, 
but it is common to all anti-DHFR drugs. While in the last decades there has been 
a satisfactory output of novel antifolates for anticancer therapy (60), new 
generation of drugs targeting malarial and bacterial DHFRs has yet to come (62). 
In general, mechanisms of antimicrobial resistance are classified in three main 
categories (63): (1) reduction of an antibiotic’s intracellular concentration either
by preventing its cell uptake through a reduced permeability or by increasing 
cellular expulsion through efflux pumps located in the cell’s membrane; (2) 
antibiotic metabolisation to inactive compounds via enzyme-catalysed 
biochemical modifications including hydrolysis and phosphorylation; and (3) 
mutations of the gene codifying the target enzyme.   
Resistance against microbial anti-DHFR drugs predominantly occurs by
mutations of the chromosomal gene resulting in an enzyme having decreased 
affinity to the inhibitor (62, 64). Additionally, bacteria can also acquire plasmid-
encoded resistant DHFR through the horizontal transfer of exogenous DNA (65).
To minimise the development of drug resistance, trimethoprim or proguanil are 
commonly co-administered with other drugs that act on other targets, e.g.
dihydropteroate synthase (DHPS, figure 1.13). Because DHPS is involved in the 
de novo biosynthesis of H2F (section 1.6), its inhibition causes a sharp fall of the 
intracellular H2F concentration which negatively affects the one-carbon 
metabolism. Combination of trimetroprim with DHPS-targeting sulfamethoxazole 
(Co-trimoxazole) is used in the treatment of urinary, lung and ear infections (66). 
Association of proguanil with the DHPS-targeting drug dapsone is instead a valid 
option for prophylaxis and treatment of malaria (67). 
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1.4The catalytic mechanism of DHFR from Escherichia coli
DHFR from E. coli (EcDHFR) is one of the most investigated enzymes. While the 
first X-ray crystal structure of EcDHFR was reported in 1977 (68), to date about 
90 structures, including enzyme-ligand complexes with NADP+, folic acid and 
various inhibitors (e.g. MTX, trimethoprim), are available in the Protein Data 
Bank. The wealth of structural details prompted the use of EcDHFR as a preferred 
model in the discovery of antimicrobial DHFR inhibitors, including structure-based 
drug design (69-72) and high-throughput screening campaigns of large 
compound libraries (73, 74).
EcDHFR is a monomeric protein composed of 159 amino acids (17,999 amu) 
(UniProtKB – P0ABQ4) folded into an eight-stranded β-sheet (βA - βH) and four 
α-helices (αB, αC, αE and αF) (Figure 1.12) (75). Strands βA - βG are parallel 
whereas βH is antiparallel (75). Two structural subdomains divided by the active 
site cleft, the adenosine binding domain (ABD) and loop domain (LP), were
identified (76). ABD (residues 38-88) binds the adenosine moiety of NADPH, 
while three loops, M20 (residues 9-24), F-G (residues 116-132) and G-H 
(residues 142-150), constitute overall the LD region interacting with H2F. Within 
the active site, at the interface between ABD and LP subdomains, H2F pterin ring 
lies in between helices αB and αC, close to NADPH nicotinamide moiety. 
The binding of EcDHFR to its ligands (NADPH, NADP+, H2F and H4F) was 
determined by pre-steady state kinetics studies, allowing to depict its catalytic 
cycle under physiological conditions (Figure 1.13) (77). E:NADPH:H2F is the 
catalytically productive Michaelis complex, where NADPH C4 hydride is 
transferred to H2F C6 yielding the product ternary complex (E:NADP+:H4F). After 
hydride transfer, NADP+ is first released forming the product binary complex 
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(E:H4F). Subsequently, NADPH binds to the enzyme forming the product release 
complex (E:NADPH:H4F) where H4F is thereafter discharged to produce the 
E:NADPH holoenzyme. EcDHFR holoenzyme eventually loads the next H2F 
substrate starting a new catalytic cycle.
Figure 1.12. Cartoon representation of the neutron crystal structure of EcDHFR ternary 
complex with NADP+ and folate (PDB 4PDJ). (A) EcDHFR secondary structure β-sheets 
(blue) and α-helices (orange) moieties are highlighted. (B) The adenosine binding 
domain (brown) as well as M20 (red), F-G (blue), G-H (purple) moieties from the loop 
domain are highlighted.
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Figure 1.13. EcDHFR kinetic scheme adapted from ref (77). Five intermediate species 
(Michaelis complex, product ternary complex, product binary complex, product release 
complex and holoenzyme) constituting the catalytic cycle are highlighted. E = enzyme; 
H2F = dihydrofolate.
X-ray crystallography and NMR studies of the five enzyme-substrate 
intermediates participating in the catalytic cycle revealed that major 
conformational changes occur during EcDHFR catalysis (78, 79). In particular, 
the M20 loop switches from a “closed” conformation in the Michaelis complex to 
an “occluded” conformation in the product ternary complex (Figure 1.14) (79).
The M20 loop is in the closed conformation in the Michaelis complex and shields 
both substrates from solvent interference, forming a microenvironment where the 
nicotinamide moiety of NADPH and the pterin ring of H2F are juxtaposed for 
hydride transfer. The reduction of H2F to H4F concomitant to oxidation of NADPH 
to NADP+ is accompanied by a conformational change of the M20 loop from the 
closed to the occluded state, in which Met16 partially occupies the active site of 
EcDHFR by replacing NADP+ pyridine ring (78). Such conformational changes 
were shown to be essential to EcDHFR catalysis, and it has been proposed that 
M20 loop movements contribute to the stabilization of the transition state (78, 80, 
81). Because of this relationship between protein motions and catalysis, EcDHFR 
is extensively used as a model in fundamental enzymology (82).
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Figure 1.14. Closed (green) and occluded (red) conformations of the M20 loop adopted 
during EcDHFR catalytic cycle. Both holoenzyme and Michaelis complex are in the 
closed conformation, whereas the product ternary, binary and release complexes are in 
the occluded conformation. Structures representing closed and occluded conformations
are adapted from PDB 1RX2 and 1RX6, respectively. 
During EcDHFR catalysis, protonation of H2F N5 is a chemical event intimately 
connected to NADPH pro-R hydride transfer to C6 H2F Re-face, and pH-
dependency of enzymatic kinetic parameters underlines the importance of N5 
protonation for catalytic efficiency (83). Interestingly, all DHFRs contain a single 
ionisable carboxylic acid residue within their active site, being either glutamic acid 
in vertebrates or aspartic acid in bacteria (84). While H2F N5 pKa is 6.5 in 
EcDHFR Michaelis complex (77), mutation of Asp27 to Ser, the only acidic 
residue within the active site, causes a dramatic shift of the pKa value to 3.8, 
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resulting in impaired catalysis at neutral pH (85). Nevertheless, Asp27-mutated
EcDHFR can still function at a sufficiently acidic pH, suggesting that protonated 
H2F (H3F+) coming from the solvent is the active species required for catalysis
(85). This hypothesis was further supported by the increase of kcat value with 
decreasing pH for both wild-type and Asp27-mutated EcDHFRs (85). It is also 
worthwhile to note that at physiological conditions H4F release is the rate limiting 
step in EcDHFR catalysis, whilst at pH > 9 hydride transfer becomes rate limiting
(77). 
Since Asp27 is the only acidic residue inside the active site cavity, it is reasonable
to propose that this residue acts as the proton source during catalysis. However, 
X-ray crystallographic studies performed by Bystroff et al. showed that Asp27
stabilises the pterin ring of H2F via hydrogen bonding to N3 and the amino group 
attached to C2 rather than being in proximity of H2F N5 (86). In an attempt to 
explain the role of Asp27 in catalysis, an indirect protonation mechanism was 
initially proposed where Asp27 promotes enolisation of H2F pterin from keto- to 
enol-form, so that a water molecule buried within the active site can donate a 
proton to H2F N5 (86). However, energy minimisations and molecular dynamics 
simulation studies performed by Shrimpton & Allemann did not support such a 
mechanism (87). Recently, Wan et al. solved the ultra-high-resolution X-ray 
structure of the EcDHFR pseudo-Michaelis complex with folate and NADP+,
providing experimental evidences that definitely exclude the keto-enol 
mechanism proposed by Bystroff et al. (88). In Wan et al. work, Asp27 was shown 
to be negatively charged while the folate pterin ring lies within the active site in 
the keto-form. Folate N5 position was found protonated by a nearby water 
molecule, of which access into the active site is facilitated by M20 loop 
movements (Figure 1.15). To date, it is accepted EcDHFR facilitates H2F 
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protonation through the modulation of H2F N5 pKa rather than providing an acidic 
proton within the active site, and this is consistent with the fact H2F N5 pKa is 
elevated from 2.6 to 6.5 when bound to EcDHFR (89, 90).
Figure 1.15. EcDHFR reaction mechanism proposed by Wan et al. Figure readapted 
from Ref (88).
Even though the protonation mechanism has been sufficiently explained, the 
evolution of transition-state during EcDHFR catalysis needs to be further 
investigated. Based on the chronological order of protonation and hydride 
transfer, three mechanistic possibilities can be deduced (chapter 4, section 4.5, 
figure 4.19). In the simplest case, protonation and hydride transfer occur in a 
concerted fashion. Alternatively, these chemical events are separated from each 
other, where hydride transfer precedes N5 protonation of H2F or vice versa. More 
than three decades ago, Stone & Morrison provided experimental evidences that 
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support the stepwise mechanism in which H3F+ is effectively the reacting species 
during hydride transfer (83); these conclusions were mainly based on the
interpretation of primary hydrogen and solvent isotope effect (SKIE) data at pH 
values from 7.0 to 10.0. Analyses of EcDHFR catalysis by quantum 
mechanics/molecular mechanics (QM/MM) and molecular dynamics simulations
also suggest N5 protonation precedes the step of hydride transfer (91-95). Liu et 
al. has recently provided further experimental evidences supporting this model,
by probing and comparing solvent and hydrogen KIEs of Asp27- and Tyr100-
mutated EcDHFRs to the wild-type enzyme at pH values from 4.0 to 12.0 (96). 
Although experimental evidences provided by Liu et al. are more convincing than 
those by Stone & Morrison, the use of mutated EcDHFRs in the experimental 
design inevitably raises the question on whether the catalytic behaviour of these 
mutated unnatural enzymes produces an altered reaction path (97). Furthermore, 
D2O was used in the SKIE measurement and it is known to modify the enzyme 
catalytic behaviour by changing solvent viscosity (98, 99). To unambiguously 
verify the catalytic mechanism of the DHFR reaction, heavy atom KIE 
measurement is therefore essential. 
1.5 Synthesis of isotopically labelled folates
In addition to KIE measurement, isotopic labelling of natural products such as 
H2F can be used as an approach to gain insights into folate metabolism (44, 77, 
83, 90, 96, 100-125) and physiology (126-132). In a molecule, replacement of 
natural abundant atoms with their heavy counterparts confers the unique 
advantage to collect atomic-scale information on a given system under 
investigation with a negligible effect on its chemistry. This is because neutron 
number differences between isotopes reflect on their physical properties which 
Introduction
26
can be probed by techniques such as KIE, NMR, mass spectrometry, and IR.
While the first chemical synthesis of [14C]-folic acid ([14C]-FA) was reported in 
1951 (133), preliminary in vivo investigations of human folate metabolism with 
[3H]-FA were described nearly a decade later (126). Since then, about thirty 
synthetic procedures designated to label folates with either radioactive or stable 
isotopes have been reported (110, 112, 115-117, 134-156). Such a large number 
of procedures is justified by folate’s chemical complexity and the lack of highly 
selective reactions, as each synthetic strategy would only allow a discrete pattern 
of isotopic substitutions. Besides, these syntheses are often laborious and costly
due to the shortage of suitable labelled starting materials, and the picture is 
further complicated when reduced folates (e.g. H2F) are considered, as most of 
them are notoriously unstable towards oxygen, light, heat and non-physiological 
pH values (157-160). Consequently, despite half a century of remarkable efforts, 
only small number of folate isotopologues are easily accessible, and this perhaps 
explains why many paths of research in folate biology are still unexplored. 
1.5.1 Isotopic labelling of folate’s pterin moiety
During the reduction of H2F to H4F catalysed by DHFR, both key chemical events
(protonation and hydride transfer) and enzyme-substrate interactions occur on 
folate’s pterin moiety, particularly at positions N5, C6, C7 and C9. The use of 
folates with isotopic label specifically located in the pterin moiety is therefore 
essential in studying DHFR catalysis. However, the synthesis of labelled folates 
remains non-trivial, and isotopic enrichment of atoms constituting the pterin 
moiety (e.g. N5, C6, C7 and C9) is a challenging task.
Folate and its derivatives, in general, can be synthesised by connecting pterin, p-
aminobenzoate (pABA) and glutamate in a sequential order. To incorporate an 
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isotope label into pterin in a regio-specific manner, various synthetic strategies 
have been derived. Cocco et al. reported the synthesis of [2-13C]-FA to probe the
protonation state of  folate’s pterin moiety in complex with DHFR by 13C-NMR 
spectroscopy (116). In this synthetic procedure (Figure 1.16), 13C-guanidine is 
condensed with 2-amino-3-cyano-5-(acetoxymethyl)pyrazine (1) to yield 2,4-
diamino pteridine-6-methanol (2). 2,4-Diamino-6-(bromoethyl)pteridine (3), 
generated in situ by bromination of 2, is subsequently condensed to p-
aminobenzoyl-L-glutamic acid (pABA-Glu) yielding [2-13C]-aminopterin. Alkaline 
hydrolysis of [2-13C]-aminopterin eventually produces [2-13C]-FA with 13% overall 
yield.
Figure 1.16. Synthesis of [2-13C]-folic acid by Cocco et al. (116).The reported overall 
yield is ~13%.
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To further probe the protonation state of folic acid bound to DHFR by means of 
NMR spectroscopy, [5-15N]- and [6-13C]-folic acid were synthesised as well by 
Selinsky et al. (117). In this synthetic route (Figure 1.17), the pteridine ring is 
assembled by condensing 2,4,5,6-tetraminopyridine (5) with dihydroxyacetone to 
yield 2. Similar to the procedure described by Cocco et al., isotopically labelled
folic acid is synthesised from 2 in three additional chemical steps with an overall 
yield of ~5%. To synthesise [5-15N]-FA, 5 was prepared from 2,3,6-
triaminopyrimidine (4) using isotopically labelled sodium nitrite (Na15NO2), while 
[2-13C]-dihydroxyacetone needed for the synthesis of [6-13C]-FA was produced
from [2-13C]-glucose following a chemoenzymatic procedure (161).
Figure 1.17. Synthetic route for the production of [5-15N]-folic acid or [6-13C]-folic acid 
reported by Selinsky et al. (89).The overall yield is ~5%. 
To date, folate specifically labelled with 15N and 13C at the respective N5, C2 and 
C6 positions have been made using the synthetic routes described by Cocco et 
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al. and Selinsky et al. Nevertheless, because symmetric reagents guanidine and 
dihydroxyacetone are used in these pathways, regioselective isotope labelling of 
other positions of FA’s pterin moiety, including C7 and C9, cannot be achieved.
1.6How folates are made by nature: the folate de novo biosynthetic pathway
A fundamental difference in folate metabolism between mammals, parasites and 
bacteria is that mammalian cells do not possess a biosynthetic machinery to 
produce H2F, which is supplied through dietary intake as folic acid (vitamin B9).  
On the other hand, microbes in general synthesise H2F from guanosine 
triphosphate (GTP) in 7 biochemical reactions catalysed by the folate de novo
biosynthetic pathway enzymes (Figure 1.18). Assuming the folate de novo
pathway from E. coli as a general model, the first committed biosynthetic step in 
folate biosynthesis is rearrangement of GTP into 7,8-dihydroneopterin 
triphosphate (DHNTP) through four tandem reactions: hydrolysis of C8 in the 
purine ring yielding a formyl intermediate, consequential deformylation, Amadori 
rearrangement of the ribose moiety, followed by a ring closure reaction (Figure 
1.19). DHNTP is then dephosphorylated to 7,8-dihydroneopterin (DHN) in two 
steps, the first specifically catalysed by 7,8-dihydroneopterin triphosphate 
pyrophosphatase (DHNTPase) while the intermediate 7,8-dihydroneopterin 
monophosphate (DHNMP) is believed to be hydrolysed into DHN by a non-
specific phosphatase (162, 163). Dihydroneopterin aldolase (DHNA) then 
transforms DHN into 6-hydroxymethyl-7,8-dihydropterin (HMDP), which is then 
pyrophosphorylated to 6-hydroxymethyl-7,8-dihydropterin pyrophosphate 
(HMDPpp) by 6-hydroxymethyl 7,8-dihydropterin pyrophosphokinase (HPPK). 
HMDP pyrophosphorylation serves the forthcoming nucleophilic substitution 
catalysed by dihydropteroate synthase (DHPS), where HMDPpp is combined 
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with pABA to yield 7,8-dihydropteroate (H2Pte). Dihydrofolate synthase (DHFS) 
eventually synthesises H2F by forming a peptide bond between the α-amino 
group of glutamic acid (Glu) and the carboxylic group of H2Pte.
Figure 1.18. Folate de novo biosynthetic pathway.
Figure 1.19. Sequence of chemical reactions catalysed by GTP cyclohydrolase I (GTP-
CH-I) from Escherichia coli.
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1.7Aims
The main goal of this investigation is to provide insight into DHFR catalysis
through heavy-atom KIE measurements using isotopically labelled H2Fs. Heavy-
atom KIE data provides unambiguous information about the chronological order 
of protonation and hydride transfer in DHFR catalysis, and it is crucial to build a 
transition-state model for the design of novel anti-DHFR drugs. Because of its 
prominent role in drug discovery and fundamental enzymology, heavy-atom KIE 
studies will be conducted firstly on EcDHFR. It is worthwhile to note that both N5 
and C6 position of H2F have never been investigated via heavy-atom KIE, mainly 
because current synthetic routes to introduce heavy atoms (15N, 13C) into H2F 
pterin moiety are laborious and costly (section 1.5) (116, 117). Therefore, there 
is a need to develop a practical synthetic procedure to produce site-specifically
labelled H2F at any position of the pterin moiety by using simple and readily-
available starting materials. 
In vitro metabolic engineering offers a cost-effective way to produce high-value 
complex natural products through the appropriate combination of enzymes from 
different organisms (164, 165). Enzymes are designed by nature to perform 
chemical transformations with unmatched chemo-, regio- and enantio-selectivity, 
making their use to site-specific isotopic labelling particularly attractive (166, 
167). Nevertheless, their application to folate chemistry is surprisingly restricted 
to a small number of examples (135, 138, 140, 142, 156), that is a rational 
approach fully exploiting the many inherited benefits of biocatalysis (mild 
conditions, eco-compatibility, versatility, easier product separation) for the site-
specific isotopic labelling of folates must be addressed.
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In this work, a one-pot chemo-enzymatic synthesis to the production of H2Fs 
labelled at N5, C6, C7 and C9 positions of the pterin ring using enzymes from the 
folate de novo biosynthetic pathway is reported. Because guanosine triphosphate 
(GTP) is the key intermediate to locate isotopic labels on H2F pterin moiety, efforts 
were primarily focused on establishing a biosynthetic procedure to generate 
guanosine nucleotides that is compatible to the folate de novo pathway enzymes 
to yield H2F. Additionally, an efficient and versatile cofactor regeneration system 
for NADP+ based on glutaredoxin/glutathione reductase redox couple has been 
developed. 
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2. A DISULFIDE-BASED NADP+ RECYCLING SYSTEM WITH 
A HIGH TURNOVER NUMBER*
*This chapter summarises the work published on ACS Catal., 2017, 7 (2), pp 1025-1029 (DOI: 
10.1021/acscatal.6b03061). Authors of this article include Antonio Angelastro, William M. 
Dawson, Louis Y. P. Luk, and Rudolf K. Allemann. AA, the author of this PhD thesis, is the only 
first author for this article. 
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2.1Preface
Cofactor recycling is an essential aspect of biocatalysis, as many enzymes such 
as transferases and oxidoreductases, which are often employed in the 
manufacturing of high-value chemicals in both industrial and laboratory settings,
require cofactors. Cofactors are additional chemical components employed by an 
enzyme to perform a range of chemical transformations such as reductions, 
oxidations and phosphorylation. Implementing cofactor regeneration schemes 
reduces the use of these structurally complex and expensive compounds from 
stoichiometric to catalytic quantities. Importantly, as many cofactor-dependent 
enzymes catalyse reversible reactions, cofactor recycling systems drive 
biochemical reactions to completion by preventing accumulation of their 
bioproducts that may inhibit enzymatic activity, according to Le Chatelier’s 
principle. A practical parameter to quantify the efficiency of a cofactor recycling 
system is the total turnover number (TTN), which is the total number of moles of 
product formed per mole of cofactor (168-170) :
The TTN value puts in relationship the cost of mole of cofactor needed for each 
mole of product formed, and it should be in the range of 104 to 106 for a recycling 
system to be considered efficient on a laboratory scale and economically viable 
on an industrial scale (168-170).
In the biosynthetic works described in chapters 3 and 4, at least six enzymes 
require the use of adenosine triphosphate (ATP) or oxidised adenine dinucleotide 
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nicotinamide phosphate (NADP+) as cofactors. Hexokinase (HK), ribose-
phosphate pyrophosphokinase (PRS), guanylate kinase (GK) and 6-
hydroxymethyl 7,8-dihydropterin pyrophosphokinase (HPPK) utilise ATP to 
donate either a phosphate or diphosphate group to their substrates, generating 
respectively adenosine diphosphate (ADP) and adenosine monophosphate 
(AMP) as by-products. ATP regeneration was achieved as previously described 
(169, 170). On the other hand, glucose 6-phosphate dehydrogenase (G6PDH) 
and 6-phosphogluconate dehydrogenase (6PGDH) reduce NADP+ while 
performing their catalytic function. This chapter describes a new NADP+ 
regeneration system which has a TTN significantly higher than those reported 
previously in the literature. 
2.1.1 ATP recycling systems
Several enzymatic procedures for regenerating ATP from ADP have been 
reported, including the use of acetate kinase (AK), pyruvate kinase (PK), 
carbamate kinase (CarK) and creatine kinase (CreK) (Figure 2.1 A) (169, 170). 
Among those, regeneration of ATP fuelled by phosphoenolpyruvate (PEP) under 
the action of PK is considered one of the most efficient (169). ATP recycling from 
AMP can be accomplished by coupling an additional enzyme to PK, myokinase 
(MK), which produces 2 ADP molecules from ATP and AMP, that are further 
phosphorylated by PK to regain ATP (Figure 2.1 B) (171).
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Figure 2.1. (A) Recycling systems for ATP from ADP. (B) Recycling system for ATP from 
AMP by coupling of pyruvate kinase (PK) with myokinase (MK).
2.1.2 NADP+ recycling systems
While ATP regeneration systems are well established, recycling of NADP+ from 
NADPH is significantly less developed as few recycling schemes have been 
reported. Use glutamate dehydrogenase (GDH), one of the first regeneration 
methods for NADP+, is still the most used notwithstanding its drawbacks (166, 
167, 172, 173). This enzyme oxidises NADPH to NADP+ to convert α-
ketoglutarate and ammonium to glutamate (Figure 2.2). Unfortunately, GDH has 
an maximal steady-state turnover number of only ~40 s-1 thus limiting its recycling 
efficiency (173, 174). Moreover, its maximal TTN is less than 103 (171). 
Accordingly, other regeneration schemes, including the D-lactate dehydrogenase 
(LDH) (175), NADPH oxidase (NOX)(176, 177) and the laccase/mediator system 
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(178), have been developed in attempts to replace GDH. However, the TTNs 
determined for LDH and NOX (from 100 to 300) are even lower than those for
GDH, whereas the laccase/mediator system was not tested for recycling NADP+ 
(178). 
Figure 2.2. Current recycling systems for NADP+. Figure adapted from ref (179).
In evaluating a possible implementation of these NADP+ recycling schemes for
the in vitro biosynthesis of H2F, both the NOX and laccase/mediator system would 
be incompatible due to their oxygen-dependency, as reduced pterins including 
H2F are prone to oxygen-dependent oxidation (157, 158). Additionally, reduced 
pterins easily degrade in acidic conditions (157), but the laccase/mediator system 
functions only at acidic pH (between 3.0 and 6.0) with an optimum of 3.5 (178). 
Therefore, only the GDH and LDH recycling systems would be an option for the 
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chemo-enzymatic synthesis of H2F, but their low TTNs pose a serious limit to the 
overall biosynthetic efficiency. 
2.1.3 The glutaredoxin (GRX) system: an ideal recycling scheme for NADP+
A recycling system characterised by a high TTN that uses simple and inert 
oxidising reagents is ideally needed for NADP+ regeneration in the chemo-
enzymatic synthesis of H2F. In nature, NADP+ is mainly regenerated through the 
enzymatic reduction of disulfide bonds (180). One such example is the 
glutaredoxin (GRX) system, which is composed of a pair of tandem enzymes, 
glutaredoxin (GRX) and glutathione reductase (GR), which react with a pair of 
redox reagents, glutathione (GSH) and its oxidized counterpart GSSG (181). In 
the GRX system, GRX reduces the disulfide bonds to yield thiols using the 
reducing power of GSH, which is then oxidised to GSSG (182, 183). GSSG is 
recycled back to GSH in the concomitant oxidation of NADPH to NADP+ by GR 
(Figure 2.3).  
Figure 2.3. The glutaredoxin system. Figure taken from ref (179).
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The GRX system is an appropriate NADP+ recycling scheme for H2F 
biosynthesis, as glutathione and its oxidised counterpart are relatively inert 
compared to oxygen. Importantly, the GRX system can employ a wide range of 
disulfide compounds including 2-hydroxyethyl disulfide (HED or oxidised β-
mercaptoethanol) and cystine (Figure 2.3 A) as the latent oxidising reagent (184, 
185). Such substrate promiscuity is particularly attractive, as the latent oxidising 
reagent can be in general tailored for the biocatalytic system under investigation. 
This therefore avoids any possible complications related to chemical 
incompatibilities or product isolation. The reduced thiol by-product generated by 
the GRX system can also serve as a reducing agent protecting both substrates 
and biocatalysts from oxidative damages. Though this system requires the use 
of two coupling enzymes, it provides competitive advantages that cannot be 
offered by the currently available NADP+ recycling systems.
2.2 Construction of the glutaredoxin system for NADP+ recycling
Because of their favourable kinetic properties, glutathione reductase from 
Saccharomyces cerevisiae (ScGR) and glutaredoxin 2 from Escherichia coli
(EcGRX2) were employed in this work to reconstitute in vitro the GRX system for 
means of NADP+ recycling (186-189). ScGR shows a high steady-state turnover 
number (kcat) of 240 s-1 at pH 7.0 (187) whereas the experimental kcat for EcGRX2 
is ~550 s-1 for HED at pH 7.0 (188). Based on these kinetic parameters, the GRX 
system formed by the ScGR/EcGRX2 pair is expected to recycle NADP+ 8.64 x 
105 times (240 s-1 x 60 x 60) per hour.
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To test its efficiency, ribulose-5-phosphate (Ru5P) was generated in situ from 
glucose by coupling HK to the two NADP+-dependent enzymes that will be 
required for both of guanosine phosphates (chapter 3) and H2F (chapter 4)
chemo-enzymatic syntheses, G6PDH and 6PGDH. The TTN of the GRX system 
was determined by 13C-NMR spectroscopy using 13C6-D-glucose as starting 
material.
2.2.1 Gene expression, purification and characterisation of recombinant 
glutaredoxin 2 (GRX2) and 6-phosphogluconate dehydrogenase 
(6PGDH)
While HK, G6PDH and GR are readily available from commercial sources, 
recombinant EcGRX2 and 6PGDH were produced from the genes for GRX2 and 
6PGDH, grxB and gnd respectively. The constructs were amplified by PCR 
reaction using E.coli K-12 chromosomal DNA as template and subsequently 
cloned into the NdeI and XhoI sites of pET28-a vector (chapter 6, section 6.2). 
Recombinant enzymes, bearing a N-terminal hexahistidine tag, were 
overproduced in E. coli BL21(DE3) and purified by Ni2+ affinity chromatography 
(chapter 6, section 6.3). 
2.2.1.1 Characterisation and activity assay of 6PGDH
Production and purification of recombinant 6PGDH was followed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis (Figure 
2.4 A). 6PGDH catalyses the decarboxylative oxidation of 6-phosphogluconate 
(6-PG) to ribulose-5-phosphate (Ru5P) and CO2/bicarbonate using NADP+ as the 
final electron acceptor (Figure 2.4 C). Accordingly, enzymatic activity can be 
measured by UV-vis spectroscopy by following NADPH absorbance at 340 nm 
(Figure 2.4 B). To assess the most appropriate way for storing purified 6PGDH 
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without causing any activity loss, enzymatic activities of fresh, 50% glycerol stock 
and freeze dried 6PGDH were compared (Figure 2.4 B). While 6PGDH stored in 
50% glycerol at -20°C retains an enzymatic activity comparable to that of the 
freshly purified enzyme, freeze dried 6PGDH suffers of substantial activity loss. 
Figure 2.4. (A) SDS-PAGE of purified 6PGDH (MW = 53.6 kDa; fractions 1-4) compared 
to cell lysate (Lys) before and after (FT) purification. (B) Activity assay of 6PGDH through 
UV-vis spectroscopy by monitoring NADPH increase at 340 nm. Freeze dried 6PGDH 
(black) shows a marked activity loss compared to fresh (or 50% glycerol stock) 6PGDH. 
6PGDH assay principle is shown in (C). 
2.2.1.2 Characterisation and activity assay of EcGRX2
Recombinant EcGRX2 was analysed by SDS-PAGE (Figure 2.5 A). In addition, 
pure recombinant enzyme was subjected to mass spectrometry analysis (Figure 
2.6). Because EcGRX2 activity cannot be directly assayed by UV-vis 
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spectroscopy, the recombinant enzyme was coupled to ScGR using a procedure 
described by Holmgren which monitors the consumption of NADPH by measuring 
UV absorbance at 340 nm (Figure 2.5 B and C) (190). To ensure that NADPH 
consumption was a direct consequence of EcGRX2 activity, ScGR activity was 
monitored before addition of EcGRX2 into the same reaction mixture. Activity of 
freeze dried EcGRX2 was found significantly lower than its glycerol stock 
counterpart, therefore the enzyme was routinely stored at -20°C in 50% glycerol.
Figure 2.5. (A) SDS-PAGE of purified GRX2 (MW = 26.4 kDa; fractions 1-3) compared 
to cell lysate (Lys) before and after (FT) purification. (B) EcGRX2 activity monitored by 
UV-vis spectroscopy following NADPH decrease at 340 nm. Because GRX2 does not 
directly oxidise NADPH, ScGR is coupled to the recombinant enzyme in presence of 
catalytic quantities of GSH. Oxidation of GSH to GSSG is therefore directly linked to 
EcGRX2 resulting into the reduction of HED to β-ME concomitant to the oxidation of 
NADPH to NADP+. The assay principle is shown on panel (C). Compared to fresh (or 
50% glycerol stock) EcGRX2, freeze dried EcGRX2 (green) suffers of activity loss. 
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Figure 2.6. Positive ESI-MS of purified EcGRX2. Deconvoluted experimental molecular 
weight of the recombinant enzyme was 26,383 amu (calculated 26,368 amu). 
2.2.2 In vitro assembly of the GRX system and determination of the 
maximal TTN
To determine the experimental TTN of the ScGR/EcGRX2 redox couple, HK and 
G6PDH were combined to oxidise D-glucose into 6-PG in two biochemical steps 
(Figure 2.7 A). In the first HK-catalysed reaction, ATP donates a phosphate group 
to D-glucose to yield glucose-6-phosohate (G6P) and ADP. Therefore, PK and 
stochiometric amounts of PEP were included to recycle ATP. G6PDH mediates
the oxidation of G6P by NADP+ to generate one equivalent of 6-PG and NADPH
in each catalytic cycle; this enzymatic reaction merits the use of the GRX system 
to regenerate NADP+. Accordingly, the NADP+ regenerating system was included 
by adding ScGR and EcGRX2, catalytic GSH and a stochiometric amount of the 
latent oxidizing reagent HED (or cystine). Use of 13C6-D-glucose allowed to 
precisely monitor the course of the reaction by NMR spectroscopy. When NADP+
was added to the reaction mixture, the substrate was efficiently converted to the 
product 6-PG, in which the corresponding C1 signal in the 13C-NMR spectrum 
shifted from ~96 and 92 ppm (64% β- and 36% α-anomer, respectively) to ~178 
ppm (Figure 2.7 C). 
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To assess the maximal number of TTN that could be achieved by the 
ScGR/EcGRX2 system, different concentrations of NADP+ were used ranging 
from 0.1 mM to 1 nM (Table 2.1). Noticeably, full conversion of substrate to 
product was observed when the concentration of NADP+ decreased to 10 nM 
corresponding to a TTN of 5 x 105 (Figure 2.7 C). On the other hand, D-
glucose/NADP+ ratios corresponding to a TTN value superior to 5 x 105 lead to a 
partial conversion of starting material into product (Figure 2.7 D). Consequently, 
it is concluded that the TTN of the ScGR/EcGRX2 recycling system can reach a 
TTN up to 5 x 105, a value that has not been achieved by other existing NADP+
recycling systems. It should also be noted that this enzyme pair is compatible 
with the PK/PEP ATP-recycling system used for adding the phosphate at the C-
6 position of glucose (171). Additionally, cystine, though sparingly soluble, can 
act as a latent oxidizing reagent as well.  
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Figure 2.7. (A)  Conversion of D-glucose to 6-phosphogluconate (6-PG) by hexokinase 
(HK) and glucose 6-phosphate dehydrogenase (6GPDH). The ATP/ADP and the NADP+
recycling (highlighted in red) systems are composed of pyruvate kinase (PK), glutathione 
reductase (ScGR) and glutaredoxin 2 (EcGRX2). Conversion of substrate to product has 
been monitored by 13C-NMR spectroscopy using 13C6-D-glucose as starting material (B). 
While at TTN = 5 x 105 there was a complete conversion of 13C6-D-glucose to 13C6-6-PG 
(C), at TTN = 8 x 105 residual peaks from G6P at 96 and 92 ppm indicate an incomplete 
conversion (D).
Table 2.1. Experimental TTN value of the GRX system tested for NADP+ recycling 
determined by 13C-NMR spectroscopy.
NADP+
concentration
TTN Conversion of 13C6-glucose to 13C6-PG
0.1 mM 50 Complete
5 μM 103 Complete
0.5 μM 104 Complete
50 nM 105 Complete
10 nM 5 x 105 Complete
6 nM 8 x 105 Incomplete
1 nM 1 x 106 Incomplete
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To further examine the compatibility of the ScGR/EcGRX2 recycling system, 
6PGDH was incorporated to the model pathway as an additional NADP+-
dependent enzyme. Upon the addition of 6PGDH, the intermediate 6PG 
underwent a complete oxidative decarboxylation; the two characteristic downfield 
chemical shifts correspond to the C3 of Ru5P (δ = 160 ppm) and the byproduct 
bicarbonate (δ = 213 ppm). This indicated that the ScGR/EcGRX2 recycling 
system can readily double its workload by incorporating another set of NADP+-
dependent enzyme (Figure 2.8).
Figure 2.8. Conversion of D-glucose to ribulose-5-phosphate (Ru5P) by hexokinase 
(HK), glucose 6-phosphate dehydrogenase (6GPDH) and phosphogluconate 
dehydrogenase (6PGDH). 
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2.3Conclusion
A novel NADP+ recycling system based on the ScGR/EcGRX2 redox couple was 
developed. The GRX system showed its ability to drive a glucose-utilising 
biosynthetic pathway yielding important synthons including 6-PG and Ru5P. By 
using small organic sulfides as latent oxidising reagents, the ScGR/EcGRX2 pair 
could regenerate NADP+ using hydride ions from NAPDH to produce thiols via
glutathione. Although this system is composed of two enzymes, GRX accepts 
organic disulfides including HED and cystine, converting them into β-
mercaptoethanol and cysteine, both of which are useful 'byproducts' protecting 
the enzymes, reagents and products from unwanted oxidative damage. 
Moreover, GRX is known to enhance protein stability by preventing them from 
oxidative misfolding and aggregation (191-193). Accordingly, this system is 
atomically economical, as there are reagents (e.g. HED) serving more than one 
role. Unlike the NAD(P)H oxidases (NOXs) and the laccase/mediator system, the 
ScGR/EcGRX2 are functional in both aerobic and anaerobic environment, so that 
these enzymes can operate with oxygen-sensitive biocatalysts and biosynthetic 
intermediates such as reduced pterins and H2F. Indeed, the durable antioxidant 
environment built on NADPH is one of the main advantages of GRX system. Most 
importantly, both ScGR and EcGRX2 are highly active offering TTNs of up to 5 x
105 outperforming the currently available NADP+ recycling systems. Accordingly, 
the NADP+ recycling system sustained by ScGR/EcGRX2 is superior than all of 
the currently available systems and offers many advantages for commercial and 
academic users.
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3. CHEMO-ENZYMATIC SYNTHESIS OF ISOTOPICALLY 
LABELLED GUANOSINE NUCLEOTIDES
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3.1 Preface
Guanosine is one of the four natural nucleosides comprising of a purine base 
(guanine) covalently linked to ribose at the C1 via a β-N9-glycosidic bond. In living 
organisms, guanosine is mainly found as guanosine monophosphate (GMP), 
guanosine diphosphate (GDP) or guanosine triphosphate (GTP). Additionally, 
deoxyguanosine nucleotides (dGMP, dGDP and dGTP), where the 2’-hydroxyl is 
reduced, are commonly present within the cellular environment (Figure 3.1 A). 
Both guanosine and deoxyguanosine nucleotides participate in a wide range of 
biological and biosynthetic processes, including cell signalling, RNA and DNA 
biosynthesis. 
GTP is perhaps the most important phosphorylated derivative of guanosine from 
a biosynthetic point of view. In addition to being employed in RNA biosynthesis, 
GTP is the first intermediate of many biosynthetic pathways from various 
organisms to the production of a variety of natural products including pigments 
(194, 195), toxins (196), non-canonical nucleotides (197) and cofactors (196, 
198-201). Notably, GTP participates in the first committed step in the biosynthesis 
of flavin (201), molybdopterin (196, 198), tetrahydrobiopterin (199), and 
dihydrofolate (H2F, section 1.6) cofactors (Figure 3.1 B). 
For the scope of this thesis, production of site-specifically labelled GTP is 
fundamental to the enzymatic synthesis of isotopically enriched H2F for heavy-
atom KIE studies on DHFR. Besides, isotopically enriched guanosine nucleotides 
have many applications in biochemical studies including RNA structural and 
functional analysis (202-204). In this chapter, a simplified approach to the chemo-
enzymatic synthesis of guanine nucleotides is described. The biosynthetic 
procedure reported herein, which includes the newly developed cofactor 
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recycling scheme reported in Chapter 2, has been designed for being highly 
compatible to H2F biosynthesis. 
Figure 3.1. (A) Structure of guanosine and deoxyguanosine nucleotides. (B) Cofactors 
such as tetrahydrobiopterin, dihydrofolate, riboflavin and molybdopterin are 
biosynthetically derived from guanosine triphosphate (GTP). Atoms derived from GTP 
are highlighted in red.
3.1.1 Background: the de novo and salvage pathway of guanosine 
nucleotides
In cells, guanosine nucleotides are mainly biosynthesised de novo from ribose-
5-phosphate (R5P), which is provided by the pentose phosphate pathway from 
D-glucose (Figure 3.2). In the first step of purine de novo biosynthesis, the 
anomeric carbon of R5P is pyrophosphorylated to phosphoribose pyrophosphate 
(PRPP) with consumption of ATP by ribose-phosphate pyrophosphokinase 
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(PRS). PRPP is then converted into 5-phospho-β-D-ribosylamine (PRA) by 
glutamine phosphoribosylpyrophosphate amidotransferase (GPAT) where an 
amino group from glutamine is donated to PRPP. Glycine is subsequently 
connected to PRA to yield glycinamide ribonucleotide (GAR) by glycinamine 
ribonucleotide synthetase (GARS). A one-carbon unit provided by 10-formyl-H4F 
is transferred to GAR by GAR transformylase (GARTFase) to form 
formyglylcineamide ribonucleotide (FGAR). FGAR is converted into 
formylglycinamide ribonucleotide (FGAM) by FGAR amidotransferase with 
consumption of glutamine and ATP. FGAM is then cyclised to 5-aminoimidazole 
ribonucleotide (AIR) by FGAM cyclase. Addition of CO2 to AIR by AIR 
carboxylase leads to the formation of carboxyamino-imidazole ribonucleotide 
(CAIR). An aspartate residue is added to CAIR to yield N-succinyl-5-
aminoimidazole-4-carboxamide ribonucleotide (SAICAR) by the action of the 
enzyme SAICAR synthetase. SAICAR lyase removes a fumarate molecule from 
SAICAR to yield 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). A 
second carbon unit from N10-formyl-H4F is donated to AICAR by AICAR 
transformylase to yield N-formylaminoimidazole-4-carboxamide ribonucleotide 
(FAICAR). Cyclisation of FAICAR to inosinate by IMP synthase yields inosinate 
monophosphate (IMP). Conversion of IMP to GMP is achieved in two biochemical 
steps catalysed by IMP dehydrogenase (IMPDH) and XMP-glutamine 
amidotransferase. 
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Figure 3.2. Biosynthesis of GTP through the purine de novo pathway.
GMP can also be produced from R5P using the preformed guanine base (Figure 
3.3) via the salvage pathway. Similar to the de novo pathway, R5P is added with 
a diphosphate group yielding PRPP. The guanine base is then combined to 
PRPP by a specific enzyme, xanthine-guanine phosphoribosyl transferase 
(XGPRT), to yield GMP in a single biochemical step. While 6 ATP, 3 Gln, 2 N10-
formyl-H4F, NAD+, Gly, Asp and CO2 are needed for assembling the purine ring 
de novo from RP5, only one ATP molecule and guanine are needed in the 
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corresponding salvage pathway. Considering that nucleotide biosynthesis is in 
general an energetically demanding process, it is not surprising that nature has 
developed such a system to recover preformed purine bases from cellular 
degradation processes.
Figure 3.3. Biosynthesis of GMP through the purine salvage pathway.
3.2 Chemo-enzymatic synthesis of guanosine nucleotides
Site-specific isotopic labelling of guanosine nucleotides has been investigated 
previously, particularly for structural and functional analysis of ribonucleic acids 
through NMR spectroscopy (166, 167, 202-207). Production of specifically 
labelled GMP, GDP and GTP via chemoenzymatic procedures is particularly 
attractive for the unmatched chemo-, regio- and enantio-selectivity of enzymatic 
catalysts. 
Because it would be simple to reproduce the purine salvage pathway in vitro, the 
logical option to produce purine nucleotides chemo-enzymatically is by employing 
the purine salvage enzymes, as previously reported by Tolbert et al. (205). 
Unfortunately, guanine has low solubility which turned out to be a limiting factor 
for an efficient GMP biosynthesis. In an attempt to minimise this problem, it was 
proposed to combine an excess of the insoluble purine base with high amounts 
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of enzymes and long reaction times, ranging between 4 h and 70 h (202, 205). 
Nevertheless, this biosynthetic route remains impractical due to a lack of 
reproducibility. To circumvent the problem, Schultheisz et al. engineered the 
purine de novo biosynthetic pathway in a one-pot synthesis (166). In this elegant 
work, purine nucleotides isotopically labelled at specific positions were produced 
using very simple starting materials (e.g. D-glucose) with yields up to 66%. 
However, the synthetic procedure requires a minimum of 28 enzymes, 5 cofactor 
recycling systems and various reagents making it difficult to be expanded for the 
synthesis of other relevant natural products such as folate.
Because the main goal of this research is to develop an enzymatic one-pot 
synthesis of site-specifically labelled folate through the generation of the key 
intermediate GTP from D-glucose, the enzymatic assembly of the guanosine 
nucleotide must be simple, yet efficient. Due to the complex setup, a hypothetical 
implementation of the de novo purine synthesis described by Schultheisz et al. to 
the H2F biosynthetic pathway is difficult (166). Consequently, in this work efforts 
were focused on synthesising isotopically labelled GMP by combining the 
pentose phosphate and purine salvage pathways enzymes. Accordingly, it will 
allow us to further extend the biosynthetic pathway to produce other natural 
products including H2F. Moreover, given the importance of labelled guanosine 
nucleotides have for biochemical studies, the scientific community would benefit 
from a facile chemo-enzymatic procedure for the synthesis of isotopically labelled 
GMP/GDP/GTP.
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3.3Synthesis of isotopically labelled guanine
In the chemo-enzymatic assembly of GMP that uses purine salvage pathway 
enzymes, D-glucose and guanine are employed as starting materials. While D-
glucose isotopically enriched on various positions is available from commercial 
sources, site-specifically labelled guanine can be synthesised in house following 
well-established procedures (208). In general, guanine is assembled through the 
cyclisation of either a substituted pyrimidine (Figure 3.4 A) or an imidazole 
derivative (Figure 3.4 B).
Figure 3.4. General scheme of guanine assembly from either (A), a substituted 
pyrimidine, or (B), an imidazole derivative.
3.3.1 Traube purine synthesis of guanine
The first method to synthesise guanine was developed by Wilhelm Traube in 
1900 (209). The “Traube purine synthesis” (Figure 3.5 A) involves the nitrosation 
of 2,4-diamino-6-hydroxypyrimidine (6) at C5 to yield the intermediate 2,4-
diamino-6-hydroxy-5-nitrosopyrimidine (7). Reduction with sodium dithionite 
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under aqueous conditions leads to 2,4,5-triamino-6-hydroxypyrimidine (8) which 
is subsequently cyclised to guanine with formic acid under reflux. 
In addition to the use of formic acid reported in the original work, other procedures 
involving the use of reagents such as formamide, trimethylorthoformate and 
morpholine for the ring closure step were described (208, 210). Aiming to achieve 
the highest possible yield, all these reported modifications have been tested 
(Figure 3.5 B). Cyclisation of 8 with either formamide or trimethylorthormate under 
conditions reported in (208) did not yield the desired product. Ring closure using 
formic acid resulted in 40% guanine whilst a mixture of formic acid and 
morpholine doubled the yield to 85%. It has been proposed that formation of 4-
formylmorpholine facilitates the formylation step required for 8 to be transformed
in guanine (Figure 3.5 C) (210).
Figure 3.5. (A) Traube purine synthesis of guanine (209). (B) Experimental conditions 
and yields for cyclisation of (8) to guanine. (C) Ring closure mechanism proposed by 
Sharma et al. (210) for the morpholine-catalysed reaction.
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3.3.1.1 Synthesis of [7-15N] and [6-13C,7-15N] Guanine
Because simple starting materials such as sodium nitrite and formic acid are 
employed the Traube synthesis, [7-15N]- and [6-13C,7-15N]-guanine can be cost-
effectively synthesised (chapter 6, section 6.6.1). The use of Na15NO2 during 
nitrosation of 6, followed by reduction with dithionite, leads to the intermediate [5-
15N]-2,4,5-triamino-6-hydroxypyrimidine (9), which has been characterised by 
both 15N-NMR spectroscopy (δ = 24 ppm, singlet) and MS (Figure 3.6). The 
labelled compound shows a mass increase of ~1 amu compared to that with 
isotopes of natural abundance.
Figure 3.6. (A) Positive ESI-MS of (A) natural abundance and (B) 15N-labelled 2,4,5-
triamino-6-hydroxypyrimidine (9). 
Cyclisation of 9 with formic acid in morpholine yields guanine labelled at N7 
(Figure 3.7). This is evident by the mass increase of ~1 amu in the spectrum and 
the spin-spin long range coupling between 15N and the C8 proton which leads a 
doublet at 7.56 ppm (2JNH = 10 Hz). Additionally, the 15N-NMR spectrum shows a 
peak at 214 ppm.
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Figure 3.7. (A) Positive ESI-MS and 1H-NMR of (A) natural abundance and (B) 15N-
labelled guanine. 
Condensation of 9 with 13C formic acid in morpholine as solvent results in [6-13C,
7-15N]-guanine (Figure 3.8). Compared to guanine with isotopes of natural 
abundance, positive ESI-MS of the double-labelled compound shows a mass 
increase of ~2 amu (Figure 3.8 A). The proton attached to C8 appears at ~7.5 
ppm as a doublet of doublets (1JCH = 186 Hz, 2JNH = 10 Hz) in the 1H-NMR 
spectrum, due to the spin-spin coupling to both N7 and C8 (Figure 3.8 B). 13C-
NMR shows a doublet at 148 ppm (2JCN = 3.0 Hz) while in the 1H-15N-HMBC 
experiment N7 correlates to the C8 proton at 219.3 ppm (Figure 3.8 C). 
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Figure 3.8. (A) Positive ESI-MS, (B) 1H-NMR and (C) 1H-15N-HMBC of [7-15N,8-13C]-
guanine.
3.3.2 Synthesis of guanine from 5-amino-4-imidazolecarboxamide
Yamazaki et al. developed an approach to prepare guanine from 5-amino-4-
imidazolecarboxamide (14) through the intramolecular cyclisation 5-cyanoamido-
4-imidazolecarboxamide (11), which is generated in situ by heating of 5-(N’-
benzoyl-S-methylisothiocarbamoyl)amino-4-imidazolecarboxamide (10) in strong 
alkaline conditions (Figure 3.9) (211, 212). Benzoyl isothiocyanate (13), freshly 
prepared by reacting benzoyl chloride (12) and KSCN, is added to 14 yielding 5-
(N’-benzoylisothiocarbamoyl)amino-4-imidazolecarboxamide (15). Treatment of 
15 with methyl iodide leads to the formation of 10 which is subsequently heated 
at 100°C in 6M NaOH to trigger the cyclisation to guanine. In the original synthetic 
strategy, both intermediates 10 and 15 were purified before proceeding to the 
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next synthetic step. In this work, a modified version of this synthetic route was 
developed where only the final product was purified with an overall yield of 29%, 
similar to that of Yamazaki et al. (31% overall) (211, 212).
Figure 3.9. (A) Mechanism proposed by Yamazaki et al. (212) for the cyclisation of 5-
(N’-benzoyl-S-methylisothiocarbamoyl)amino-4-imidazolecarboxamide (10) to guanine 
through the in situ formation of 5-cyanoamido-4-imidazolecarboxamide (11). (B) 
Synthesis of guanine from 5-amino-4-imidazolecarboxamide (14).
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3.3.2.1 Synthesis of [2-13C]-guanine
[2-13C]-guanine was prepared following the synthetic route described in section 
3.3.2 by replacing natural abundance KSCN with its 13C counterpart (chapter 6, 
section 6.6.2.1). Similar to [7-15N]-guanine (section 3.3.1.1), MS characterisation 
of [2-13C]-guanine showed a mass increase of ~1 amu (Figure 3.10). 13C-NMR 
experiment showed a singlet peak at 159 ppm.
Figure 3.10. Positive ESI-MS of [2-13C]-guanine.
3.4 Chemo-enzymatic synthesis of GMP
A total of 10 enzymes have been combined for the biosynthesis of GMP 
described in this work. As discussed in chapter 2, D-glucose is converted into the 
intermediate Ru5P by the action of enzymes from the pentose phosphate 
pathway, namely HK, G6PDH and 6PGDH (Figure 3.11). Here, the biosynthetic 
cascade continues with the isomerisation of Ru5P to R5P catalysed by 
phosphoriboisomerase (PRI). R5P is the connection between the pentose 
phosphate and purine salvage pathways, where PRRP is linked to the purine 
moiety by XGPRT to yield the final product GMP. The newly developed NADP+
recycling system based on the GR/GRX2 redox couple (chapter 2) was used in 
this biosynthetic procedure. 
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Figure 3.11. Chemo-enzymatic synthesis of guanosine monophosphate (GMP). 
A serious issue regarding GMP biosynthesis is the low solubility of guanine. Here, 
a system where the guanine concentration is kept just below saturation has been 
developed (Figure 3.12 A). A reservoir of the purine base dissolved in alkali 
solution (50 mM KOH) is flowed into the reaction mixture with a syringe pump. 
The guanine injected into the system is then converted into soluble GMP. To 
maintain the pH of the reaction mixture within the optimum range, the ratio 
between amounts of alkali needed to dissolve guanine and buffer was determined 
experimentally. With this approach, substrates are employed in stoichiometric 
amounts, reaction times are shortened and there is no need for high amounts of 
enzymes to shift the equilibrium towards product formation.
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Figure 3.12. (A) Syringe-pump system for controlling guanine concentration. 
Comparison between (B) GMP synthesised by controlled flow of alkaline guanine into 
the reaction mixture and (C) without syringe pump.
3.4.1 Synthesis of [1’,2’,3’,4’,5’-13C5]-, [1’,2’,3’,4’,5’-13C5,7-15N]-, 
[1’,2’,3’,4’,5’-8-13C6,7-15N]- and [2-13C]-GMP
The guanine biosynthetic pathway assembled in this work allowed us to 
synthesise various isotopically labelled GMPs (Table 3.1) in one day with yields 
ranging between 70% and 80%. In addition to 6PGDH and GRX2 (chapter 2, 
section 2.2.1), recombinant PRS and XGPRT were employed. Genes cloned in 
a pET expression system have been expressed and purified as previously 
reported (166, 213). Because the GRX recycling system for NADP+ may use 
either HED or cystine as the final electron acceptor (chapter 2), the biosynthetic 
efficiency for GMP synthesis was tested by varying those reagents; in either case 
yields were similar, and no substantial difference was found.  
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All synthesised compounds were purified by anion exchange chromatography 
(chapter 6, section 6.6) and quantified through the Beer-Lambert law (chapter 6, 
section 6.3.4.5.2). All compounds were characterised by high-resolution mass 
spectrometry (HR-MS); accurate masses are listed in Table 3.1 whereas full 
spectra are reported in chapter 8. Use of D-13C6-glucose and guanine as starting 
material lead to [1’,2’,3’,4’,5’-13C5]-GMP. This was shown by 13C-NMR
spectroscopy, where carbons C1’ (doublet, 86 ppm), C2’ (triplet, 74 ppm), C3’ 
(triplet, 71ppm), C4’ (triplet, 84 ppm), C5’ (doublet, 63 ppm) couple to each other 
between 100 ppm and 50 ppm (Figure 3.13 B). 
While in [1’,2’,3’,4’,5’-13C5,7-15N]-GMP the 13C-NMR spectrum is identical to that 
of [1’,2’,3’,4’,5’-13C5]-GMP (Figure 3.14 C), the C8 proton at 8.00 ppm on 1H-NMR 
splits as a doublet for the spin-spin coupling to 15N (2JNH= 12 Hz, Figure 3.14 A 
and B). Additionally, the 1H-15N-HMBC experiment shows the long-range 
correlation between C8 proton (δ = 8.00 ppm) to the N7 at 235 ppm (Figure 3.14 
D). 
The C8 proton [1’,2’,3’,4’,5’,8-13C6, 7-15N]-GMP further splits as a doublet of 
doublets (1JCH= 213 Hz, 2JNH= 12 Hz) in the 1H-NMR spectrum (Figure 3.15 A and 
B), and this pattern of splitting is also evident in the corresponding 1H-15N-HMBC 
spectrum (Figure 3.15 D) due to the high 1JCH coupling constant. 13C-NMR 
spectrum shows the C8 carbon at 135 ppm along with C1’, C2’, C’3’, C4’ and C5’ 
ribose carbons (Figure 3.15 C). 
Because no spin active atom is near C2 of [2-13C]-GMP, the 13C-label can only 
be seen through 13C-NMR at 161 ppm as a singlet (Figure 3.16 B).
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Table 3.1. Isotopically labelled GMPs synthesised in this work. 13C is highlighted in red
Starting Material Labelled GMP Accurate Mass [M+H]+
(amu)
D-13C6-Glucose 
+ 
Guanine
369.0811 
D-13C6-Glucose
+ 
[7-15N]-Guanine
370.0795 
D-13C6-Glucose 
+ 
[7-15N,8-13C]-Guanine
371.0793 
D-Glucose 
+ 
[2-13C]-Guanine
365.0674
Figure 3.13. (A)1H-NMR and (B) 13C-NMR of [1’,2’,3’,4’,5’-13C5]-GMP.
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Figure 3.14. (A)1H-NMR of [1’,2’,3’,4’,5’-13C5,7-15N]-GMP. (B) Purine C8 proton splits as 
a doublet for the spin-spin coupling to N7 (2JNH= 12 Hz). (C) Isotopically labelled carbons 
from the ribose moiety are shown by 13C-NMR, while (D) 1H-15N-HMBC experiment 
shows a correlation between C8 proton (δ = 8.00 ppm) to the N7 at 235 ppm.
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Figure 3.15. (A)1H-NMR of [1’,2’,3’,4’,5’,8-13C6,7-15N]-GMP. (B) Purine C8 proton splits 
as a doublet of doublets for the spin-spin coupling to both C8 and N7 atoms (1JCH= 213 
Hz, 2JNH= 12 Hz). (C) Isotopically labelled carbons from the ribose moiety are shown by 
13C-NMR between 100 ppm and 50 ppm, while C2 of the purine ring resonates at 135 
ppm. (D) 1H-15N-HMBC experiment shows a correlation between C8 proton to the N7 at 
235 ppm.
Figure 3.16. (A)1H-NMR and (B) 13C-NMR of [2-13C]-GMP. 
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3.5Chemo-enzymatic synthesis of GTP 
Synthesis of GTP is a continuation of GMP biosynthesis where two additional 
phosphate groups on GMP C5’ position are added stepwise (figure 3.17). 
Consequently, the experimental setup for synthesising GTP is essentially 
identical to that described for GMP (section 3.4) except for the presence of an 
additional enzyme, guanylate kinase (GK), which transfers a phosphate group 
from ATP to GMP yielding ADP and GDP. The GDP intermediate is then further 
phosphorylated into GTP by the action of the ATP-recycling enzyme PK, which 
in this case also functions as a biosynthetic enzyme. 
Figure 3.17. Continuation of guanosine monophosphate (GMP) biosynthesis illustrated
in figure 3.11 to the formation of guanosine triphosphate (GTP).
3.5.1 Gene expression, purification and characterisation of recombinant 
guanylate kinase (GK)
The gene codifying for guanylate kinase (gmk) was amplified by PCR reaction 
using E. coli K-12 chromosomal DNA as template and subsequently cloned into 
the NdeI and XhoI sites of pET28-a vector (chapter 6, section 6.2). The 
recombinant enzyme, bearing a N-terminal hexahistidine tag, was overproduced 
in E. coli BL21(DE3) and purified by affinity chromatography (chapter 6, section 
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6.3.4.1). Sequencing of the cloned gmk gene revealed a point mutation of causing 
the shift of the Arg152 codon in Gly (R152G), and this was confirmed by mass 
spectrometry analysis (Figure 3.18). Nevertheless, the mutated enzyme was 
found active (Figure 3.19) and it therefore did not cause any difference for 
purposes of the work described here. GK activity has been tested by UV-vis 
spectroscopy by coupled assay with PK and lactate dehydrogenase (LDH) as 
previously described (214) (Figure 3.19 B and C). Briefly, ATP consumed by GK 
is regenerated by PK which in turn produces pyruvate as a by-product. In the 
presence of NADH, LDH reduces pyruvate to lactate, and this enzymatic step can 
be detected by following the decrease of NADH absorbance at 340 nm.
Figure 3.18. ESI-MS+ of purified GK R152G mutant. Deconvoluted experimental 
molecular weight of the recombinant enzyme was 25,526 amu (calculated 25,525 amu). 
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Figure 3.19. (A) SDS-PAGE of purified GK (MW = 25.5 kDa; fractions 1-2) compared to 
cell lysate (Lys) before and after (FT) purification. (B) GK activity monitored by UV-vis 
spectroscopy following NADH decrease at 340 nm. The assay principle is shown on 
panel (C). Compared to fresh (or 50% glycerol stock, red) GK, freeze dried GK (green) 
suffers of activity loss. 
3.6 Conclusion
In this chapter, a simple procedure for the biosynthesis of isotopically labelled 
guanosine nucleotides (GMP and GTP) is reported. Compared to previous 
procedures, two major modifications were made. Firstly, the highly efficient 
recycling system for NADP+ based on the GR/GRX redox couple (chapter 2) was 
implemented. By using small organic sulfides as latent oxidizing reagents, the 
GR/GRX system is able to produce useful ‘byproducts’ such as β-
mercaptoethanol to protect enzymes, reagents and products from unwanted 
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oxidative damage. Unlike other NADP+ recycling schemes such as the NOX and 
laccase/mediator systems, the GR/GRX pair is not dependent on oxygen and it 
is therefore functional under both aerobic and anaerobic conditions. 
A second modification is related to formation of GMP through the combination of 
PRPP with insoluble guanine by the purine salvage pathway enzyme XGPRT. 
Although it has been described that the reaction can proceed using guanine as a 
slurry (205), such reaction conditions require long reaction times and have poor 
reproducibility. Hence, in this work, guanine was stored in an alkaline buffer (50
mM KOH) and added to the reaction dropwise with a syringe pump. Under these 
modifications, approximately 70-80% of GMP can be obtained within 60 mins. 
[1’,2’,3’,4’,5’-13C5]-, [1’,2’,3’,4’,5’-13C5,7-15N]-, [1’,2’,3’,4’,5’-8-13C6,7-15N]- and [2-
13C]-GMP were synthesised and characterised. These compounds are currently 
in use in our lab to conduct in vivo experiments on Escherichia coli.
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4. CHEMO-ENZYMATIC SYNTHESIS OF ISOTOPICALLY 
LABELLED H2Fs AND INVESTIGATION OF EcDHFR 
CATALYSIS VIA HEAVY-ATOM ISOTOPE EFFECTS*
*This chapter summarises the work published on J. Am. Chem. Soc., 2017, 139 (37), pp 13047–
13054 (DOI: 10.1021/jacs.7b06358). Authors of this article include Antonio Angelastro, William 
M. Dawson, Louis Y. P. Luk, E. Joel Loveridge and Rudolf K. Allemann. AA, the author of this 
PhD thesis, is the only first author for this article. 
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4.1Preface
Mapping the transition-state of the DHFR-catalysed reduction of H2F by 
measuring heavy-atom isotope effects is fundamental to dissect the reaction 
mechanism on an atomic scale and to assist the rational design of novel DHFR 
inhibitors. To reach this goal, a set of H2Fs site-specifically labelled on N5, C6, 
C7 and C9 positions of the pterin moiety with either stable (15N, 13C) or radioactive 
isotopes (14C) must be synthesised. To date, despite half a century of efforts and 
nearly 30 synthetic procedures reported in the literature, synthesis of folates 
labelled on the pterin moiety can only be partially achieved through laborious and 
cost-demanding procedures (Chapter 1, section 1.5). This is mainly due to the 
shortage of suitably labelled starting materials and lack of regio-, stereo- and 
enantio-selectivity of key chemical reactions. The picture is further complicated 
when reduced folates (e.g. H2F) are considered as they are unstable toward 
oxygen, light, heat and non-physiological pH values (157-160). 
In this work, the folate de novo biosynthetic pathway of E. coli was redesigned in 
vitro in a one-pot chemo-enzymatic synthesis. This allows us to produce 
isotopically labelled folates from D-glucose, guanine and p-aminobenzoyl-L-
glutamic acid (pABA-Glu). Using this biosynthetic route, H2Fs enriched with 
stable isotopes at specific positions were synthesised in less than a week. The 
high degree of purity and isotopic enrichment (>97%) of these compounds has 
allowed us to perform, for the first time, single and multiple heavy-atom KIE 
measurements for EcDHFR catalysis and to derive unambiguous information 
about the chronological order of protonation and hydride transfer.
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4.2 Cloning, expression, purification and assay of recombinant enzymes 
constituting the H2F de novo pathway.
The folate de novo pathway (Chapter 1, section 1.6, figure 1.18) is constituted
overall by 6 known enzymes: GTP cyclohydrolase I (GTP-CH-I), 7,8-
dihydroneopterin triphosphate pyrophosphatase (DHNTPase), dihydroneopterin 
aldolase (DHNA), 6-hydroxymethyl 7,8-dihydropterin pyrophosphokinase 
(HPPK), dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS). 
None of these enzymes is commercially available and therefore they have all 
been produced in-house through molecular biology techniques (Chapter 6, 
section 6.2). Genes encoding for GTP-CH-I, DHNA, HPPK and DHPS were 
cloned by Dr William Dawson (213) and corresponding recombinant enzymes 
were overproduced in E. coli strains as previously reported (213). Additionally, 
the gene encoding for DHNTPase (nudB) has been amplified from E. coli K-12 
chromosomal DNA and cloned into the NdeI and XhoI sites of pET28-a vector 
(Chapter 6, Section 6.2). DHNTPase was overproduced in E. coli BL21(DE3)RP 
and purified by affinity chromatography (Chapter 6, section 6.3.4.1) (Figure 4.1). 
Chemo-enzymatic synthesis of isotopically labelled H2Fs and investigation of EcDHFR catalysis 
via heavy-atom kinetic isotope effects
75
Figure 4.1. SDS-PAGE of purified DNTPase by affinity chromatography (fractions 1-2) 
compared to cell lysate (Lys) before and after (FT) purification. After prolonged heating 
(right panel) the recombinant enzyme (MW = 19.500 kDa) shifts nearby the 18.4 kDa 
band of the marker.
4.2.1 Activity assay of recombinant enzymes constituting the H2F pathway
GTP-CH-I activity can be monitored by following the increase of absorbance at 
330 nm which corresponds to the formation of dihydropterin. Alternatively, the 
conversion of guanosine triphosphate (GTP) to 7,8-dihydroneopterin 
triphosphate (DHNTP) by GTP-CH-I can be visualised by acquiring UV spectra 
at defined intervals. As illustrated in Figure 4.2, the UV-vis spectrum at the 
beginning of the reaction (which corresponds to GTP) has profoundly 
transformed at the end of the reaction (which corresponds to DHNTP). 
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Figure 4.2. Formation of DHNTP from GTP catalysed by GTP-CH-I by UV-vis 
spectroscopy. UV spectra of starting material (blue) and product (red) are highlighted. 
Assaying recombinant DHNTPase, DHNA, HPPK and DHPS activities was 
particularly problematic as all the corresponding product intermediates DHNTP, 
7,8-dihydroneopterin monophosphate (DHNMP), 7,8-dihydroneopterin (DHN), 6-
hydroxymethyl-7,8-dihydropterin (HMDP) and 6-hydroxymethyl-7,8-dihydropterin 
pyrophosphate (HMDPpp) are chemically unstable and have not been clearly 
characterised. This problem was also reported by Dr William Dawson who could 
not prove activity for recombinant HPPK and DHPS because DHN oxidised to 
neopterin under his experimental conditions (213). In this work, the issue was 
circumvented by sequential coupling of each enzyme to GTP-CH-I without 
isolating intermediates. Furthermore, reduced pterins were found to be 
sufficiently stable in the presence of oxygen for a day when protected from light 
and in presence of radical scavengers such as thiols, allowing analytical 
characterisation of each intermediate. DHNTP and DHNMP possess a 
triphosphate and monophosphate group, respectively, and thus can be analysed
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by anion exchange chromatography (Figure 4.3). Coupling of DHNTPase with 
GTP-CH-I results in the formation of DHNMP from GTP (Figure 4.3 B). 
Dephosphorylation of DHNMP with alkaline phosphatase (ALP) yields the 
intermediate DHN which was identified by LC-MS (Figure 4.4). Addition of DHNA 
leads to the formation of HMDP from DHN, as indicated by LC-MS analysis 
(Figure 4.5). Similar to DHNTP and DHNMP, pyrophosphorylation of HMDP to 
HMDPpp by HPPK can be monitored by anion exchange chromatography (Figure 
4.6). Production of dihydropteroate (H2Pte) from HMDPpp and pABA mediated 
by DHPS catalysis was proven by LC-MS (Figure 4.7).
Figure 4.3. Anion exchange chromatograms of GTP (A) incubated with GTP-CH-I and 
(B) GTP-CH-I and DHNTPase.
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Figure 4.4. Positive ESI LC-MS of dihydroneopterin (DHN; MW = 255 amu) generated 
by GTP-CH-I, DHNTPase and ALP.
Figure 4.5. Positive ESI LC-MS of 6-hydroxymethyl-7,8-dihydropterin (HMDP; MW = 195 
amu) by GTP-CH-I, DHNTPase, ALP and DHNA.
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Figure 4.6. Anion exchange chromatogram of 6-hydroxymethyl-7,8-dihydropterin 
pyrophosphate (HMDPpp) generated by GTP-CH-I, DHNTPase, ALP, DHNA and HPPK.
Figure 4.7. Positive ESI LC-MS of H2Pte generated from 6-hydroxymethyl-7,8-
dihydropterin pyrophosphate (HMDPpp) and p-aminobenzoic acid (pABA) by 
dihydropteroate synthase (DHPS). 
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4.3 Design of H2F chemo-enzymatic synthesis
In the design of the enzymatic synthesis of H2F, two key issues had to be
considered: (1) use of simple building block of which isotopically labelled 
counterparts can be obtained; (2) establish a simple, versatile and fast procedure 
avoiding isolation of reaction intermediates. Attention was focused on labelling 
H2F N5, C6, C7 and C9 of the pterin moiety as these positions are directly 
involved in the formation of the transition-state during the DHFR-catalysed 
reduction of H2F to H4F (Chapter 1, section 1.3). All atoms composing the pterin 
moiety are derived from GTP, the first intermediate of the folate de novo pathway 
(Figure 4.8). Precisely, C1’, C2’, C3’, N1, C2, N3, C4, C5, C6, N7 and N9 
positions of GTP correspond to the C7, C6, C9, N3, C2, N1, C4b, C4a, C4, N5 
and N8 positions of H2F. The use of isotopically labelled GTP is crucial to produce 
H2F enriched on the positions of interest (N5, C6, C7 and C9), and site-specific 
isotopically labelled GTPs need to be synthesised. As discussed in chapter 3, a 
biosynthetic procedure for generating isotopically labelled GTP from D-glucose 
and guanine is available (Figure 4.8). The labelled nucleotides were generated
to prepare the corresponding H2Fs by combining a total of 17 enzymes. In this 
biosynthetic cascade, no intermediate needs to be isolated due to the general 
high substrate specificity of each enzyme. Also, because H2F and other pterin 
intermediates are prone to oxygen-dependent degradation (158), the 
biosynthesis was performed in an anaerobic environment, with an overall yield of 
30%.
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Figure 4.8. Biosynthetic strategy for the synthesis of H2F. Glucose and guanine are 
processed into the key intermediate guanosine triphosphate (GTP, Chapter 3), which is 
then reorganized into DHN by GTP-CH-I, DHNTPase and ALP. DHNA, HPPK and DHPS 
combine DHN with pABA-Glu to yield the final product H2F. Additionally, myokinase 
(MK), glutathione reductase (GR) and glutaredoxin 2 (GRX2), are used to constitute 
cofactor regeneration systems for ATP and NADP+ (171, 179).
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4.3.1 DHNATPase enhances GTP-CH-I activity
Reorganisation of GTP into DHNTP by GTP-CH-I is a metabolic branch point 
connecting the purine biosynthetic pathway to H2F de novo synthesis (215). In 
vitro manipulation of GTP-CH-I was challenging, mainly because of its low 
turnover constant (kcat = 0.05 s-1) (216) and the inherent chemical instability of 
DHNTP. Positive allosteric effectors like potassium and magnesium cations were 
reported to increase the GTP-CH-I rate up to 5-fold and they were included in the 
reaction buffer (217), whereas oxygen removal stabilises DHNTP allowing longer 
reaction times. Despite these adjustments, conversion of GTP to DHNTP 
remained incomplete (Figure 4.9).
Figure 4.9. Anion exchange analysis of GTP incubated with GTP-CH-I reveals a partial 
conversion of GTP into DHNTP. Formation of guanosine monophosphate (GDP) is due 
to the non-enzymatic hydrolysis of GTP the assay.
The second chemical transformation in folate biosynthesis is a partial 
dephosphorylation of DHNTP to DHNMP by DHNTPase (163, 218). Interestingly, 
deletion of the gene that encodes DNTPase strongly impairs E. coli folate 
metabolism (163). This therefore suggests that DHNTP hydrolysis is involved in 
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folate metabolic flux regulation. Considering that guanosine monophosphate 
(GMP) does not influence GTP-CH-I kinetics (219), it is plausible that DHNTPase 
acts as a positive effector on GTP-CH-I. That is, GTP-CH-I is inhibited by DHNTP 
but not DHNMP. To test the hypothesis, GTP-CH-I was assayed in vitro either in 
the absence or presence of DHNTPase (Figure 4.10). When coupled to 
DHNTPase, GTP-CH-I showed a marked rate enhancement and complete 
conversion to DHNMP (Figure 4.10 and 4.11). 
Figure 4.10. Comparison of GTP-CH-I activity in absence (black) and presence (red) of 
DHNTPase monitoring 7,8-dihydroneopterin formation absorbance at 330 nm by UV-Vis 
spectroscopy.
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Figure 4.11. Anion exchange analysis of GTP incubated with GTP-CH-I and DHNTPase 
shows total conversion of GTP to DHNMP.
4.3.2 DHPS substrate tolerance simplifies H2F biosynthesis
In H2F biosynthesis, DHNMP needs to be dephosphorylated to DHN. Currently, 
the natural enzyme responsible for converting DHNMP to DHN is not known (162, 
163). Non-specific alkaline phosphatase (ALP) was therefore used. DHN is then 
refined to HMDP by DHNA through a retro-aldol reaction. Then, HPPK catalyses 
the pyrophosphorylation of DHN to form HMDPpp with consumption of ATP (220). 
In E. coli, HMDPpp is first added with pABA and subsequently glutamate by the 
actions of two separate enzymes, DHPS and DHFS. These reactions yield 
dihydrofolate (H2F) as the product (Figure 4.12). DHPS has a relaxed substrate 
specificity and is also capable of accepting pre-assembled pABA-Glu instead of 
pABA (221), and therefore DHFS was omitted in the reaction pathway. This 
synthesis requires only one purification step as no intermediate needs to be 
isolated. However, ALP needed to be removed from the reaction mixture by 
ultrafiltration before the addition of DHNA, HPPK and DHPS, because ALP can
remove phosphate groups from ATP and HMDPpp. All reduced pterins 
compounds (DHNTP, DHNMP, DHN, HMDP, HMDPpp), including the final 
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product H2F, are oxygen-sensitive, therefore the synthetic pathway was 
performed within a N2-filled glove box system to ensure the removal of oxygen
(<0.5 ppm). Additionally, generation of antioxidant thiols by the NADP+ recycling 
system based on the GRX system (Chapter 2) helped to stabilise intermediates
that are unstable in the presence oxygen (e.g. H2F). For the H2F biosynthetic 
pathway, cystine is preferred over HED (oxidised β-mercaptoethanol) for the 
GR/GRX2 NADP+ regeneration system. Perhaps, β-mercaptoethanol made from 
the reduction of HED can interfere with other enzymatic reactions, such as the 
chelation of Zn2+ in GTP-CH-I. 6.6 mg of H2F were produced from 9 mg of glucose 
with an overall yield of 30%.
Figure 4.12. (A) In nature, H2F is assembled from HMDPpp, pABA and Glu by 
dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS). (B) In vitro, a 
shorter route to H2F is made possible by DHPS tolerance to alternative substrates like 
pABAGlu.     
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4.4Synthesis and characterization of labelled H2Fs
Five isotopically labelled H2Fs were synthesised using the H2F chemo-enzymatic 
synthesis described in this chapter (Table 4.1). All compounds were 
characterised by a combination of NMR spectroscopy and high-resolution mass
spectrometry (HR-MS). 
Table 4.1. Isotopically labelled H2Fs synthesised in this work. 13C is highlighted in red.
Starting Material Labelled H2F Accurate Mass 
[M+H]+ (amu)
D-Glucose 
[7-15N]-Guanine
pABA-Glu
445.1624
[3-13C]-D-Glucose 
Guanine
pABA-Glu
445.1624
[3-13C]-D-Glucose 
[7-15N]-Guanine
pABA-Glu
446.1575 
D-13C6-Glucose 
Guanine
pABA-Glu
447.1721
D-13C6-Glucose 
[7-15N]-Guanine
pABA-Glu
448.1694
HRMS spectrum of [6-13C]-H2F produced from from [3-13C]-D-glucose shows an 
increase of molecular weight of ~1 amu, and 13C-NMR spectroscopic 
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characterisation reveals a singlet at 152 ppm. Additionally, 1H-13C-HMBC 
spectroscopy illustrates long-range couplings between 6-13C and hydrogens 
attached to C7 and C9 positions (H7 and H9) (figure 4.13 A). To incorporate a 
15N label into the pterin moiety, the labelled substrate [7-15N]-guanine was used; 
the resulting product also showed ~1 amu increase in HRMS analysis and a 15N 
signal at 285 ppm coupling with H7 and H9 in the 1H-15N HMBC experiment 
(Figure 4.13 B). When [3-13C]-D-glucose and [7-15N]-guanine are combined in the 
biosynthetic pathway, both the N5 and C6 positions of H2F are isotopically 
enriched. This is evident by a mass increase of ~2 amu and 13C-NMR which 
shows a doublet at ~152 ppm with a coupling constant 1JCN of 7.5 Hz. 1H-13C 
HMBC and 1H-15N HMBC spectroscopic characterisation also reveals the 
anticipated long range C7 and C9 hydrogens coupling (Figure 4.14). Similarly, 
[6,7,9-13C3]-H2F and [5-15N][6,7,9-13C3]-H2F have been made using 13C6-D-
glucose and [7-15N]-guanine and verified by HRMS and NMR spectroscopy 
analyses (Figures 4.15 and 4.16). 
All isotopically labelled H2FS were also characterised by 1H-NMR (Figure 4.17 
and 4.18). While 1H-NMR spectrum of [5-15N]-H2F is identical to that of natural 
abundance H2F (Figure 4.17 A), chemical shift of both H7 (3.95 ppm) and H9 
(3.87 ppm) result perturbed in [6-13C]-H2F, [5-15N, 6-13C]-H2F, [6-13C3]-H2F and 
[5-15N, 6-13C3]-H2F (Figure 4.18). When the C6 position of H2F is 13C-enhriced
([6-13C]-H2F and [5-15N, 6-13C]-H2F), both H7 and H9 split as doublets on 1H-NMR
spectrum with a coupling constant 2JCH of 6 Hz (Figure 4.18 B). In addition to the 
C6 long-range coupling, when C6, C7 and C9 are all 13C-labelled, such as in [6-
13C3]-H2F and [5-15N, 6-13C3]-H2F, H7 and H9 further split as doublet of doublets 
(Figure 4.18 C).
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Figure 4.13. (A) 1H-13C HMBC of [6-13C]-H2F and (B) 1H-15N HMBC (right panel) of [5-
15N]-H2F.
Figure 4.14. 1H-13C HMBC (left panel) and 1H-15N HMBC (right panel) of [5-15N][6-13C]-
H2F.
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Figure 4.15. 1H-13C HMBC (left panel) and 1H-15N HSQC (right panel) of [6,7,9-13C3]-
H2F.
Figure 4.16. 1H-13C HMBC (left panel) and 1H-15N HMBC (right panel) of [5-15N][6,7,9-
13C3]-H2F
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Figure 4.17. (A) 1H-NMR spectrum of natural abundance H2F. (B) 2D-NMR NOESY 
experiment allows to unambiguously assign H7 and H9 protons, as highlighted in panels 
(C) and (D). In the NOESY experiment, H7 protons strongly correlate through space to 
5’ and 3’ protons from pABA moiety whereas cross-correlations between H9 protons and 
5’/3’ are weaker or not detectable.
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Figure 4.18. Sections from 1H-NMR spectra of isotopically labelled H2Fs.  (A) In 1H-NMR 
spectrum of [5-15N]-H2F, both H7 and H9 are singlets as in natural abundance H2F. (B) 
When H2F C6 position is 13C-ehriced, as in [6-13C]- and [5-15N,6-13C]-H2F, H7 and H9 
protons split as a doublet (2JCH= 6 Hz) due to the long-range coupling to C6 (C). In 
addition to C6, further isotopic enrichment of C7 and C9 positions results in additional 
splitting of H7 and H9 protons as doublet of doublets because of the short-range coupling 
of C7 to H7 (1JCH = 144 Hz) and C9 to H9 (1JCH = 132 Hz).
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4.5Single and multiple heavy-atom isotope effect studies on EcDHFR
EcDHFR, the enzyme sustaining the one-carbon metabolic cycle in E. coli by 
catalysing the reduction of H2F to H4F (Figure 4.19), is one of the most 
investigated natural catalyst in enzymology and a well-established model for the 
discovery of antimicrobial drugs (Chapter 1, section 1.4). Nevertheless, several 
aspects of its reaction mechanism remain unclear as the transition state 
structure(s) and the order of chemical transformation events have not been fully 
elucidated (87, 222). Solvent and hydrogen KIE measurements combined with 
site-directed mutagenesis have suggested a stepwise mechanism where 
protonation precedes hydride transfer (Figure 4.19 C) (83, 96). 
However, D2O increases the viscosity of the reaction buffer relative to H2O (98, 
99) and site-directed modification can alter the catalytic behaviour of an enzyme 
(97). Accordingly, to derive unambiguous information about the nature of the 
transition-state, [5-15N]-H2F, [6-13C]-H2F and [5-15N][6-13C]-H2F were used to 
measure the 15N- and 13C-KIE. Recombinant EcDHFR used for pre-steady-state 
kinetics was overproduced in BL21-Star(DE3) cells (Chapter 6, section 6.3.4.2.1) 
and purified by a combination of anion exchange and size-exclusion 
chromatography techniques to ensure high purity (Figure 4.20).
Pre-steady-state kinetic measurements by fluorescence resonance energy 
transfer from a tryptophan nearby the active site to the reduced cofactor yields 
hydride transfer rate constants (kH) with an accuracy up to 0.7%. While the 
measured 15N-KIE is one at all temperatures (Table 4.2 and Figure 4.21 A), the 
corresponding average 13C-KIE value at the same temperature range is 1.022 
(Table 4.2 and Figure 4.21 B). The double labelled [5-15N][6-13C]-H2F yielded an 
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average heavy-atom isotope effect of 1.018, close to that obtained with 13C-
labeled substrate.
Considering the three possible scenarios for the reduction pathway of H2F in the 
EcDHFR catalysed reaction (Figure 4.19), if the reduction proceeds through a 
concerted mechanism, where the N5 of H2F is protonated concomitantly to the
step of hydride transfer from the C4 of NADPH to the C6 of H2F (Figure 4.19 B), 
isotopic labelling of either the reacting nitrogen or carbon atoms in H2F would 
lead to a measurable kinetic difference from that of natural abundance substrate.
Additionally, a concerted transition state would be reflected in the multiple heavy-
atom KIE measurement when using the double labelled [5-15N][6-13C]-H2F. 
Instead, as the measured 13C- and 15N13C-KIEs yield similar values and the 
observed 15N-KIE is close to unity, the heavy-atom isotope effect data reported 
in this PhD thesis rules out the possibility of a concerted mechanism. The KIE 
data strongly supports that the steps of protonation and hydride transfer are 
largely independent of each other and occur in a stepwise fashion. Whether the
N5 protonation event occurs either after (Figure 4.19 A) or before (Figure 4.19 C) 
the hydride transfer step, previous experimental (77, 83, 85, 88-90, 96) and 
computational (91, 93-95) evidences indicate that N5 protonation is required for 
hydride transfer to occur but not vice versa. Notably (as mentioned in Chapter 1, 
section 1.4), while H2F N5 pKa raises within EcDHFR Michaelis complex from 2.6 
to 6.5 (77, 89, 90), the Asp27-mutated enzyme is still capable to function at acidic 
pH although catalytically compromised (85). In addition, Wan et al. recently 
proved through neutron and ultrahigh-resolution X-ray crystallography that folate 
N5 atom is indeed protonated when bound to EcDHFR (88).
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Figure 4.19. Possible scenarios for the EcDHFR catalysed reaction. (A) Hydride 
from C4 of NADPH is transferred to C6 of H2F, followed by protonation in a 
stepwise fashion. (B) Hydride transfer is concomitant to protonation. (C) H2F is 
firstly protonated, then hydride transfer occurs.
Figure 4.20. (A) SDS-PAGE and (B) positive ESI-MS of recombinant EcDHFR
(theoretical MW = 17,999 amu, found = 18,000 amu) used for pre-steady-state kinetic 
measurements.
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Table 4.2. Heavy-atom KIEs measured on EcDHFR using [6-13C]-H2F, [5-15N]-H2F and 
[5-15N][6-13C]-H2F.
T (°C) kH14N/ kH15N kH12C/ kH13C kH14N12C/ kH15N13C
5 0.996 ± 0.018 1.018 ± 0.009 1.020 ± 0.011
10 0.995 ± 0.018 1.018 ± 0.011 1.023 ± 0.010
15 0.999 ± 0.005 1.015 ± 0.006 1.014 ± 0.008
20 1.000 ± 0.009 1.021 ± 0.013 1.011 ± 0.007
25 0.993 ± 0.009 1.028 ± 0.007 1.018 ± 0.006
30 1.000 ± 0.022 1.023 ± 0.012 1.011 ± 0.009
35 1.000 ± 0.016 1.029 ± 0.012 1.034 ± 0.016
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Figure 4.21. Heavy-atom KIEs measured on EcDHFR using (A) [5-15N]-H2F, (B) [6-13C]-
H2F and (C) [5-15N][6-13C]-H2F. (D) Comparison between heavy-atom KIEs indicate a 
substantial difference between relative contributions of N5 and C6 positions in stabilizing 
the transition state during hydride transfer.
4.6Conclusion
Isotopically labelled folate derivatives are useful, non-invasive probes to gain 
insight into the mechanism of DHFR, which may lead to improved design of drugs 
(Chapter 1). Previous chemical syntheses of folate are low yielding, require 
multiple purification steps and are characterized by poor regio- and stereo-
selectivity (116, 117, 146, 147). Here, H2F was produced enzymatically in a one-
pot reaction from D-glucose, guanine and pABA-Glu, whose isotopically labelled 
counterparts are either commercially available or can be prepared easily (150, 
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208); only the final product was purified. Due to the improved reaction setup for 
GTP-CH-I, which converts GTP to DHNTP via four chemical steps, the cascade 
reaction which involves 17 enzymes, is also high yielding (223). The synthesis
developed here shows the enormous potential of using enzymes in multistep
reactions for the efficient synthesis of complex molecular structures. H2Fs 
labelled in specific positions with stable isotopes could be prepared with an 
average overall yield of 30%. With this powerful biochemical setup, five 
isotopically labelled H2Fs were synthesised including [5-15N]-H2F, [6-13C]-H2F 
and [5-15N][6-13C]-H2F. These compounds were used to measure, for the first 
time, heavy-atom kinetic isotope effects for the reaction catalysed by EcDHFR, 
providing strong evidence that protonation at the N5 position of H2F and hydride 
transfer to the C4 position occur in a stepwise mechanism. 
With this newly developed synthesis it is possible to measure a wide range of
primary and secondary heavy-atom isotope effects on DHFR and to derive 
transition-state maps for the catalysed reaction. However, accuracy of the non-
competitive method used in this work is 0.7% whereas it should fall below 0.5% 
to have an accurate map of the transition-state (31). Accordingly, development of 
an alternative methodology to yield more accurate heavy-atom isotope effects is 
currently under progress in our research group. Besides the investigation of 
DHFR catalysis, labelled folates have many potential applications in both 
mechanistic enzymology and cell biology (90, 116, 117, 146, 224, 225). The work 
described here can be applied in nutritional, medical and cell biological research 
to address in vivo bioavailability and to perform kinetic investigation of folate 
metabolism in whole organisms including humans (119, 123, 225-228).
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DHFR, one of the most studied enzymes in chemical biology, serves as model in 
both fundamental enzymology and drug discovery research. Nevertheless, its 
mechanism of catalysis is not fully understood, mainly because information about 
the transition-state is missing. Measuring heavy-atom KIEs is the only technique 
available that can unambiguously provide detailed knowledge about the 
transition-state of the DHFR-catalysed reaction. However, current synthetic 
strategies to produce site-specific isotopically labelled H2Fs are impractical and 
allow only a restrained pattern of isotopic substitutions. 
This PhD programme has developed a versatile and cost-effective strategy for 
the production of H2F labelled with stable isotopes (15N, 13C) at precise positions 
by re-designing the de novo folate biosynthetic pathway from E. coli in vitro. This
methodology, which employs seventeen enzymes in a one-pot system, enables 
the production of highly purified labelled H2Fs from D-glucose, guanine and 
pABA-Glu in less than a week, with a single purification step and 30% overall 
yield.
In the process of developing the in vitro biosynthetic pathway of H2F, we have 
addressed several technical issues which are also frequently encountered in the 
scientific community. A novel NADP+ recycling scheme based on the GR/GRX 
enzymatic redox couple was developed. The previously reported regeneration 
systems of NADP+ are either oxygen-dependent (NOX, laccase/mediator system) 
or poorly efficient (GDH and LDH system), and so they are not applicable in folate 
biosynthesis. The GR/GRX system was engineered to overcome these issues, 
enabling NADP+ to be recycled in the absence of oxygen with an improved total 
turn-over number (TTN). We discovered a maximal TTN of 5 x 105, noticeably 
higher than those of other NADP+-recycling systems (TTN = 102 - 103). NADP+
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recycling via the GRX system also provides other significant advantages. The 
GRX system utilises electrons from NADPH to reduce small organic disulfides 
(e.g. cystine and HED) into thiols, with the possibility to choose the latent 
oxidising reagent on a case-by-case basis. Production of thiol is an additional
benefit to the biosynthetic process, as it established a reducing environment 
preventing both enzymes and oxygen-sensitive intermediates (e.g. H2F) from 
oxidative damages. Importantly, the GRX system does not depend on oxygen to 
function, implying that it can be used both in aerobic and anaerobic conditions. 
Overall, the development of GR/GRX system represents a substantial advance 
in the biocatalysis field and it will have wide applications in both academic and 
industrial settings. 
In chapter 3, the synthesis of isotopically labelled GTP, a key branching 
intermediate to multiple biosynthetic pathways was reported (166, 205). Previous 
procedures of guanine nucleotides using enzymes from the salvage pathway are 
considered inadequate because of the poor reproducibility (205). Herein, a 
chemo-enzymatic approach to the synthesis of labelled guanine nucleotides 
using a combination of enzymes from the pentose phosphate and purine salvage 
pathways was reported with two major modifications: (1) GDH was replaced by 
GRX to recycle the NADP+ cofactor; (2) the formation of GMP from PRPP and 
insoluble guanine was optimised in an automated and reproducible way. Various 
isotopically labelled GMPs were produced with overall yields ranging between 
70% and 80%. The optimised biosynthetic setup described in this thesis is not 
only beneficial to the synthesis of isotopically labelled H2Fs, but also to a wide 
range of biochemical investigations. Isotopically labelled guanosine nucleotides 
are extensively used for biochemical studies, notably nucleic acids 
characterisation (202-204). Also, isotopically labelled GMPs synthesised in this 
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work are currently being used for studying flavin coenzymes including flavin 
adenine dinucleotide (FAD) (229).
The optimised biosynthetic setup of guanine nucleotides has allowed the
synthesis of isotopically labelled H2Fs in a one-pot procedure. Operating in an 
oxygen-free environment helped to stabilise reduced pterins, while DHNTPase 
was found to improve the overall yield by enhancing GTP-CH-I activity. Also, 
DHPS substrate tolerance permitted to further simplify H2F synthesis by avoiding 
an additional biosynthetic step. Site-specific labelled D-glucose, guanine and 
pABA-Glu are relatively simple to be either obtained from commercial sources or 
produced in-house. With the research described here it is now possible to prepare 
folate isotopically-enriched at any desired position using the same biosynthetic 
strategy. In this work, attention was focused at positions N5, C6, C7 and C9 of 
H2F, as these atoms are involved into the formation of the transition-state in the 
DHFR-catalysed reaction. [5-15N]-, [6-13C]- and [5-15N,6-13C]-H2F were produced 
to measure, for the first time, single and multiple heavy-atom kinetic isotope 
effects on EcDHFR. Our data obtained here strongly support a step-wise 
mechanism where H2F N5 is protonated before a hydride from NADPH C4 is 
transferred to H2F C6. 
Because we aim to map the transition-state of the DHFR-catalysed reaction to 
design novel anti-DHFR drugs, we have developed a one-pot 14-steps in vitro 
chemo-enzymatic pathway of isotopically labelled H2F for heavy atom KIE 
measurement. Whilst gaining important insights into the DHFR reaction, our work 
has also allowed us to develop a versatile NADP+-recycling system and a 
reproducible high-yielding GMP synthetic pathway. These achievements have 
created new opportunities in other areas research. The mechanistic 
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characterisations of other one-carbon enzymes, such as SHMT and TS, both of 
which are also important antiproliferative targets. This work also allows us to 
develop new high-yielding synthesis of isotopically labelled nucleotide-derived 
biomolecules, such as DNA, RNA, cofactors such as FAD and other pterin-
containing natural products, including pigments and natural “sun-screen” like
biopterin-α-glucoside (230). In conclusion, the completion of this PhD programme
has opened the doors for many new research ideas and opportunities.
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6.1Materials
L-Ascorbic acid (99%), 2,4-diamino-6-hydroxypyrimidine, 2-hydroxyethyl 
disulfide, L-cystine, D-(13C6)-glucose, D-(3-13C)-glucose (99 atom%), L-
glutathione (reduced), guanosine 5’-monophospahte disodium salt hydrate (from 
yeast, >99%), deuterium oxide (99.9 atom%), guanine, sodium dithionite, sodium 
nitrite-15N (Na15NO2, 98 atom%), were purchased from Sigma-Aldrich. NADP+
monosodium salt (>98%) and ATP disodium salt trihydrate (>98%) were 
purchased from Apollo Scientific Ltd (UK). Phosphoenolpyruvic acid 
monopotassium salt, 99% was purchased from Alfa Aesar. 6-Phosphogluconic 
acid dihydrate and isopropyl-β-D-thiogalactopyranoside (IPTG) were obtained 
from Melford Laboratories Ltd (Ipswich, UK). 4-Aminobenzoic acid (99%), 
NADPH tetrasodium salt hydrate and guanosine 5’-triphosphate disodium salt 
hydrate (90%, for biochemistry) were purchased from ACROS Organics. Alkaline 
phosphatase from bovine intestinal mucosa (ALP, buffered aqueous glycerol 
solution), pyruvate kinase from rabbit muscle (PK, type II, ammonium sulfate 
suspension), myokinase from rabbit muscle (MK, ammonium sulfate 
suspension), glutathione reductase from baker’s yeast (GR, S. cerevisiae, 
ammonium sulfate suspension), hexokinase from S. cerevisiae (HK, type F-300, 
lyophilized powder), glucose-6-phosphate dehydrogenase from L. 
mesenteroides (G6PDH, recombinant, expressed in E. coli, ammonium sulfate 
suspension) and phosphoriboisomerase from spinach (PRI, type I, partially 
purified powder) were purchased from Sigma-Aldrich. Crimson Taq DNA 
polymerase was purchased from New England Biolabs.
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6.2Preparation of solutions, buffers and growth mediums
6.2.1 Luria-Bertani (LB) liquid medium
Tryptone (10 g), NaCl (10 g) and yeast extract (5.0 g) were dissolved in 950 mL 
of deionised water (dH2O). When the solutes have dissolved, volume of the 
solution was adjusted to 1 L. The final solution was sterilised by autoclaving at 
121°C for 20 min. The sterile solution was stored at 4°C.
6.2.2 Luria-Bertani (LB) solid medium
Tryptone (10 g), NaCl (10 g) and yeast extract (5.0 g) were dissolved in 950 mL 
dH2O. When the solutes have dissolved, volume of the solution was adjusted to 
1 L and agar (15.0 g) was added. The suspension was sterilised by autoclaving 
at 121°C for 20 min. After sterilisation, the resulting homogeneous solution was 
cooled to 40°C and added with the appropriate antibiotic (e.g. kanamycin) before 
being poured into sterile petri dishes. Further cooling at room temperature 
resulted into solidification of the medium which has been stored at 4°C.
6.2.3 Sterile glycerol solution (50% v/v)
A 50% v/v glycerol solution was prepared by mixing 50 mL of glycerol to 50 mL 
of dH2O. The resulting solution was sterilised by autoclaving at 121°C for 20 min 
and stored at 4°C.
6.2.4 Sterile antibiotic solutions
Three antibiotics (tetracycline, ampicillin and kanamycin) were used as selection 
markers for molecular cloning or gene expression into E. coli hosts. Tetracycline 
solution was prepared by dissolving 100 mg of the antibiotic in 10 mL of 70% 
ethanol solution. All remaining antibiotic sterile solutions (ampicillin and 
kanamycin) were made by dissolving 200 mg of the appropriate antibiotic in 4 mL 
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of dH2O and sterilised by filtration using a 0.2 µm syringe filter. Sterile solutions 
were stored at -20°C.
6.2.5 Bradford reagent
20 mg brilliant blue G250 dissolved in a small amount of ethanol were mixed with 
20 mL of 80% H3PO4. The solution was diluted to 200 mL with dH2O, filtered and 
stored at 4°C protected from light.
6.2.6 Molecular cloning buffers
6.2.6.1 Transformation buffer I (Tfb-I)
0.588 g of potassium acetate (30 mM), 2.42 g of rubidium chloride (100 mM), 
0.294 g of calcium chloride (10 mM) and 2.0 g of manganese chloride (50 mM) 
are dissolved in 100 mL of dH2O and the pH adjusted with diluted acetic acid to 
5.8. 30 mL of glycerol (15% v/v) are thereafter added and the volume adjusted to 
200 mL with additional dH2O. The final solution is sterilised by filtration using a 
0.2 µm syringe filter and stored at +4°C
6.2.6.2 Transformation buffer II (Tfb-II)
0.21 g of 3-(N-Morpholino)propanesulfonic acid (MOPS, 10 mM), 1.1 g of calcium 
chloride (75 mM) were dissolved in 50 mL of dH2O and the pH adjusted with 
diluted NaOH to 6.5. 15 mL of glycerol (15% v/v) are thereafter added and the 
volume adjusted to 100 mL with additional dH2O. The final solution is sterilised 
by filtration using a 0.2 µm syringe filter and stored at +4°C.
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6.2.6.3 Transformation buffer III (Tfb-III)
1.11 g of calcium chloride (100 mM) was dissolved in 90 mL of dH2O. After 
dissolution, the volume was adjusted to 100 mL and the final solution sterilised 
by autoclaving at 121°C for 20 min. Sterile buffer was stored at 4°C. 
6.2.6.4 Transformation buffer IV (Tfb-IV)
1.11 g of calcium chloride (100 mM) was dissolved in 50 mL of dH2O. After 
dissolution, 15 mL of glycerol (15% v/v) were added and the volume was adjusted 
to 100 mL with dH2O.The final solution sterilised by autoclaving at 121°C for 20 
min. Sterile buffer was stored at 4°C. 
6.2.6.5 Tris-acetate-EDTA (TAE) 50X buffer
242 g of Tris free base, 18.61 g of EDTA disodium salt were added to 700 mL of 
dH2O under stirring. When Tris and EDTA fully dissolved, 57.1 mL of glacial acetic 
acid were added and the volume adjusted to 1 L.
6.2.7 Enzyme purification buffers
6.2.7.1 Enzyme purification buffer 1 (EPB-1)
6.1 g Tris free base (50 mM), 17.5 g NaCl (300 mM) and 1.4 g imidazole (20 mM) 
were dissolved in 900 mL of dH2O. After dissolution, pH was adjusted to 8.00 with 
diluted HCl. The volume was to 1 L with addition dH2O and the solution was 
filtered and degassed before use. 
6.2.7.2 Enzyme purification buffer 2 (EPB-2)
6.1 g Tris free base (50 mM), 17.5 g NaCl (300 mM) and 17 g imidazole (250 
mM) were dissolved in 900 mL of dH2O. After dissolution, pH was adjusted to 
8.00 with diluted HCl. The volume was to 1 L with addition dH2O and the solution 
was filtered and degassed before use. 
Materials and methods
108
6.2.7.3 Enzyme purification buffer 3 (EPB-3)
EBF-3 was prepared as for EPB-1 (section 6.2.7.1) but for the addition of 50 mL 
of 1M KH2PO4 (50 mM) before adjusting the pH.
6.2.7.4 Enzyme purification buffer 4 (EPB-4)
EBF-4 was prepared as for EPB-2 (section 6.2.7.2) but for the addition of 50 mL 
of 1M KH2PO4 (50 mM) before adjusting the pH.
6.2.7.5 Enzyme purification buffer 5 (EPB-5)
30.75 mL of 1M K2HPO4, 19.25 mL of 1M KH2PO4 and 350 µL β-
mercaptoethanol (β-ME) were added to 800 mL of dH2O. The pH was therefore 
adjusted to 7.00 and the solution diluted to 1 L yielding a 50 mM PO4, 5 mM β-
ME solution. The solution was filtered and degassed before use.
6.2.7.6 Enzyme purification buffer 6 (EPB-6)
6.06 g Tris free base (100 mM), 7.45 g KCl (100 mM), 350 µL β-ME (5 mM) were 
added to 800 mL of dH2O. The pH was therefore adjusted to 8.00 and the solution 
diluted to 1 L. The solution was filtered and degassed before use.
6.2.7.7 Enzyme purification buffer 7 (EPB-7)
61.5 mL of 1M K2HPO4, 38.5 mL of 1M KH2PO4, 5.84 g NaCl, 350 µL β-ME were 
added to 800 mL of dH2O. The pH was therefore adjusted to 7.00 and the solution 
diluted to 1 L yielding a 100 mM PO4, 100 mM NaCl, 5 mM β-ME solution. The 
solution was filtered and degassed before use.
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6.2.8 SDS-PAGE buffers
6.2.8.1 SDS resolving buffer
6.0 g Tris free base (0.5 M) was dissolved in 80 mL of dH2O. After dissolution, 
pH was brought to 6.8 with diluted HCl and the volume was adjusted to 100 mL 
with dH2O.
6.2.8.2 SDS stacking buffer
27.23 g Tris free base (1.5 M) was dissolved in 80 mL of dH2O. After dissolution, 
pH was brought to 8.8 with diluted HCl and the volume was adjusted to 150 mL 
with dH2O.
6.2.8.3 SDS sample buffer
1.25 mL SDS resolving buffer (section 6.2.8.1), 2.5 mL glycerol, 2 m 10% (w/v) 
SDS, 0.2 mL 0.5% (w/v) bromophenol blue and 3.55 m dH2O were mixed together 
and stored at room temperature.
6.2.8.4 10X Running buffer
30.3 g of Tris free base, 144.0 g glycine and 10.0 of sodium-dodecyl sulphate 
(SDS) were dissolved in 900 mL of dH2O at 37°C. After dissolution, volume was 
adjusted to 1 L with dH2O.
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6.3Molecular cloning
6.3.1 TAE agarose gel electrophoresis
1X TAE buffer diluted from 50X stock solution (section 6.1.6.5) was mixed with 
agarose at percentages ranging between 0.8% (large fragments separation) and 
1.5% (small fragments separation), depending on the size of the DNA fragment 
to be separated. The mixture was heated near the boiling point until agarose fully 
dissolved and resulting solution poured on gel-caster system and left to solidify 
at room temperature. The gel was placed in an electrophoresis chamber 
immersed in 1X TAE buffer. DNA samples were loaded on the gel and separated 
by applying a constant electric current (80 mA) for 40 min. When separation was 
complete, the agarose gel was stained with dilute ethidium bromide solution and 
DNA fragments were visualised using a UV light box compared to a 100 bp and 
1 kb standard size marker.
6.3.2 Purification of DNA by agarose gel extraction
The target DNA fragment separated by agarose gel electrophoresis (section 
6.2.1) was cut with a scalpel and separated from agarose using an agarose gel 
extraction kit (QIAGEN, UK) following instruction provided by the supplier.
6.3.3 Purification of DNA by spin miniprep column
EconoSpin All-in-1 mini prep spin columns (Epoch Biolabs, USA), QIAprep spin 
miniprep kit (QIAGEN, UK) and QIAquick purification kit (QIAGEN, UK) were 
used to isolate either plasmid or PCR DNA following instruction provided by the 
manufacturer.
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6.3.4 Preparation of XL1-Blue super-competent cells
XL1-Blue cells from a 50% glycerol stock solution stored at -80°C were incubated 
in 50 mL of LB medium containing tetracycline (50 mg/L) overnight at 37°C. The 
day after, 100 mL of fresh LB medium with tetracycline (50 mg/L) was inoculated 
with 1 mL from the overnight culture and incubated at 37°C. Cell growth was 
monitored by measuring optical density at 600 nm (OD600). When OD600 reached 
0.6-0.7, 50 mL of culture was cooled on ice for 15 min and cells were separated 
from the medium by centrifugation at 3400 g for 6 min. The supernatant was 
discarded and cells were gently resuspended in 5 mL of Tfb-I buffer (section 
6.1.6.1). Cells were left on ice for 15 min, centrifugated, and resuspend in 4 mL 
of Tfb-II buffer (section 6.1.6.2). Cells were left on ice for further 15 min to be then 
aliquoted in sterilised Eppendorf tubes (100 µL each tube) and stored at -80°C. 
6.3.5 Amplification of target genes from E.coli chromosomal DNA by 
polymerase chain reaction (PCR)
Genes encoding for 6-phosphogluconate dehydrogenase (gnd), glutaredoxin 2 
(grxB), guanylate kinase (gmk), 7,8-dihydroneopterin triphosphate 
pyrophosphatase (nudB) were amplified from E.coli chromosomal DNA prepared 
following to the method described by Syn et al. (231). All genes were amplified 
using Crimson Taq polymerase (New England Biolabs) according to the 
instructions provided by the supplier. Gene sequences for primers design were 
obtained through GenBank database (Table 6.1). In a typical PCR reaction setup, 
10 µL of 5X Crimson Taq buffer, 1 µL of deoxynucleotide triphosphates (final 
concentration 200 µM), 2.5 µL of forward and 2.5 µL of reverse complement 
primers (final concentration 1.25 µM), 0.3 µL of chromosomal DNA, 0.3 µL of 
Crimson Taq polymerase and 33.4 µL of sterilised dH2O were mixed together in 
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a PCR tube. PCR reactions were performed using a Biometra thermocycler 
(Germany). Optimal annealing temperatures were determined experimentally 
through gradient PCRs. To ensure maximum selectivity, PCR products were all 
purified through DNA agarose gel extraction (section 6.2.2) to be then digested 
with NdeI and XhoI fast-digest restriction enzymes (Thermo Scientific, UK). 
Digested amplicons were then separated from the restriction fragments through 
DNA spin miniprep column (section 6.2.3).
Table 6.1. Primers designed for PCR amplification. Restriction sites for NdeI 
(CATATG) and XhoI (CTCGAG) are shown in bold.
Enzyme E. coli
gene 
(NCBI ID)
PCR Primers
6-Phosphogluconate 
dehydrogenase 
(6PGDH)
gnd
(946554)
Fwd: 5’-GTTGTTCATATGTCCAAGCAACAGATCG-3’
Bwd:5’-CACCACCTCGAGTTATTATCCAGCCATTCGG-3’
Glutaredoxin 2 (GRX2) grxB 
(946926)
Fwd: 5’-GTTGTTCATATGAAGCTATACATTTACGATCACTGC-3’
Bwd:5’-CACCACCTCGAGTTAAATCGCCATTGATGAT-3’
Guanylate kinase (GK) gmk 
(948163) Fwd: 5’-GTTGTTCATATGGCTCAAGGCAC-3’Bwd:5’-CACCACCTCGAGTCAGTCTGCCAACAATTT-3’
7,8-Dihydroneopterin 
triphosphate 
pyrophosphatase 
(DHNTPase)
nudB 
(946383) Fwd: 5’- GTTGTTCATATGAAGGATAAAGTGTATAAGCGTC -3’Bwd:5’-CACCACCTCGAGTCAGGCAGCGTTAATTACAAACTG-3’
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Table 6.2. PCR protocol for the amplification of gnd, grxB, gmk and nudB genes. After 
the initial denaturation step, denaturation, annealing and elongations (highlighted) were 
repeated 30 times before the final elongation.
Target gene
gnd grxB gmk nudB
Initial denaturation 180 s, 95°C
Denaturation 20 s, 95°C
Annealing 30 s, 61°C 30 s, 55°C 30 s, 57°C 30 s, 63°C
Elongation 120 s, 68°C
Final elongation 300 s, 68°C
6.3.6 Preparation of pET28-a empty vector 
XL1-Blue cells containing a pET28-a vector were grown overnight in 100 mL of 
LB medium containing 50 mg/L kanamycin. The day after, cells were separated 
by centrifugation at 3400 g for 5 min. The supernatant was discarded and the 
pET28-a plasmid was purified from the cell pellet using QIAprep spin miniprep kit 
(QIAGEN, UK) following instructions from the supplier. Purified pET28-a was then 
digested with NdeI and XhoI fast-digest restriction enzymes (Thermo Scientific, 
UK) following the protocol described by the supplier. Digested pET28-a was then 
purified by agarose gel extraction (Section 6.2.2).
6.3.7 Ligation of target genes into pET28-a empty vector 
gnd, grxB, gmk and nudB genes (section 6.2.5) were all ligated into a pET28-a 
empty vector at NdeI and XhoI restriction sites using T4 DNA ligase (Thermo 
Scientific, UK). In a typical ligation reaction, 60 µg of the empty vector were mixed 
with the DNA insert in 1:3 and 1:7 ratio in the buffer provided by supplier reaching 
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10 µL final volume. After addition of the T4 ligase enzyme, the reaction mixture 
was incubated at 37°C overnight. The day after, the ligation product was used to 
transform XL1-Blue super-competent cells. Briefly, 100 µL of thawed XL1-Blue 
super-competent cells (section 6.2.4) were incubated on ice with 10 µL of the 
ligation reaction mixture for at least 30 min. Cells were then transformed with the 
exogenous DNA by heat-shock at 40°C for 44 s. 1 mL of LB medium antibiotic-
free was added and heat-shocked cells were incubated at 37°C for 1 hour under 
shacking. Cells were then centrifugated for 1 minute at 3300 g and 900 µL of the 
supernatant were discarded. The remaining 100 µL of supernatant left into the 
Eppendorf tube were used to gently resuspend cells into the media. 
Resuspended cells were then plated on LB solid medium containing kanamycin 
as the selection maker and incubated at 37°C overnight. A successful ligation will 
provide after the overnight incubation small XL1-Blue colonies bearing the 
kanamycin-resistant pET28-a plasmid ligated with the target gene.
6.3.8 Analysis of ligation products
A single colony deriving by the transformation of XL1-Blue cells with the pET28-
a ligation product (section 6.2.7) was inoculated in 50 mL of LB liquid medium 
containing 50 mg/L of kanamycin and grown overnight. The day after, ½ mL from 
the culture was mixed with a solution of 50% sterile glycerol (section 6.1.3) and 
stored at -80°C. The remaining part was harvested and the plasmid extracted. 
Sequencing analysis of pET28a-gnd, pET28a-grxB, pET28a-gmk and pET28a-
nudB was performed by Eurofins Genomics.
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6.4Production and purification of recombinant enzymes
6.4.1 Preparation of BL21(DE3)pLysS and BL21-CodonPlus(DE3)RP 
competent cells
BL21(DE3)pLysS or BL21-CodonPlus(DE3)RP cells from a 50% glycerol stock 
solution stored at -80°C were incubated in 50 mL of LB medium overnight at 37°C 
with 35 µg/mL of chloramphenicol or without antibiotic, respectively. The day 
after, 100 mL of fresh LB medium was inoculated with 1 mL from the overnight 
culture and incubated at 37°C. Cell growth was monitored by measuring optical 
density at 600 nm (OD600). When OD600 reached 0.6-0.7, 50 mL of culture was 
cooled on ice for 15 min and cells were separated from the medium by 
centrifugation at 3400 g for 6 min. The supernatant was discarded and cells were 
gently resuspended in 5 mL of Tfb-III buffer (section 6.1.6.3). Cells were left on 
ice for 15 min, centrifugated, and resuspend in 4 mL of Tfb-IV buffer (section 
6.1.6.4). Cells were left on ice for further 15 min to be then aliquoted in sterilised 
Eppendorf tubes (100 µL each tube) and stored at -80°C. 
6.4.2 Transformation of competent cells with pET28a-gnd, pET28a-grxB, 
pET28a-gmk and pET28a-nudB vectors
BL21(DE3)pLysS competent cells were transformed with pET-28a-gnd, pET-28a-
grxB and pET-28a-gmk plasmids, while BL21-CodonPlus(DE3)-RP cells were 
transformed with pET28a-nudB. 1 µL of plasmid was incubated with BL21(DE3) 
competent cells (section 6.3.1) on ice for at 30 min. Transformation with the 
exogenous DNA was performed by heat shocking at 44°C for 45 s. 1 mL of LB 
medium antibiotic-free was then added and heat-shocked cells were incubated 
at 37°C for 1 hour under shacking. Cells were then centrifugated for 1 minute at 
3300 g and 900 µL of the supernatant were discarded. The remaining 100 µL of 
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supernatant left into the Eppendorf tube were used to gently resuspend cells into 
the media. Resuspended cells were then plated on LB solid medium containing 
kanamycin as the selection maker and incubated at 37°C overnight. The day 
after, a single colony is inoculated in 50 m of LB liquid medium containing 
kanamycin (50 mg/L) and incubated at 37°C under shacking. ½ mL from the 
overnight culture was mixed with a solution of 50% sterile glycerol (section 6.1.3) 
and stored at -80°C.
6.4.3 Production of recombinant enzymes 
All recombinant enzymes were overproduced in E. coli strains at optimised 
temperatures and induction times (table 6.3). All E. coli strains for gene 
expression were prepared as described in Section 6.3.2. In a typical procedure, 
the E. coli strain transformed with a given pET plasmid carrying the target gene 
to express (e.g. pET-28a-grxB) is incubated at 37°C overnight in 50 mL LB liquid 
medium containing the appropriate antibiotic. The day after, 5 mL from the 
overnight culture are used to inoculate 1 L of LB liquid medium containing the 
appropriate antibiotic. The resulting culture is incubated at 37°C until OD600 
reaches 0.6. Depending on the recombinant enzyme, temperature of the culture 
was adjusted according to the values reported in Table 6.3 and 120 mg of 
isopropyl-β-D-1-thiogalactopyrnoside (IPTG, 0.5 mM) was added to induce 
expression of the target gene. After addition of IPTG, cells were left to produce 
the recombinant enzymes according to the times reported in Table 6.3. Cells were 
then harvested through centrifugation at 3400 g for 10 min. The supernatant was 
discarded and the pellet was used either to extract the recombinant enzyme as 
described in section 6.3.4 or conserved at -20°C.  
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Table 6.3 Recombinant enzymes used in this work overproduced in E.coli strains.
Enzyme (plasmid-gene) E. coli strain Temperature 
and 
induction time
GRX2 (pET-28a-grxB) BL21(DE3)pLysS 37°C, 4 h
6PGDH (pET-28a-gnd) BL21(DE3)pLysS 37°C, 4 h
PRS (pET-22HT-prsA)* BL21-Star(DE3)pLysS 37°C, 4 h
XGPRT (pET-28a-gpt)** BL21(DE3)pLysS 25°C, Overnight
GK (pET-28a-gmk) BL21(DE3)pLysS 37°C, 4 h
GTP-CH-I (pET-21d-folE)** BL21-Star(DE3) 25°C, Overnight
DHNTPase (pET-28a-nudB) BL21-CodonPlus(DE3)RP 30°C, Overnight
DHNA (pET-28a-folB)** BL21-CodonPlus(DE3)RP 37°C, 4 h
HPPK (pET28a-folK)** BL21-CodonPlus(DE3)RP 37°C, 4 h
DHPS (pET-21a-folP)** BL21-Star(DE3) 25°C, Overnight
EcDHFR (pET-11c-folA)*** BL21-Star(DE3) 37°C, Overnight
GRX2 = glutaredoxin 2, 6PGDH = 6-phosphogluconate dehydrogenase, PRS = ribose-
phosphate pyrophosphokinase, XGPRT = xanthine-guanine phosphoribosyl transferase, GK 
= guanylate kinase, GTP-CH-I = GTP-cyclohydrolase I, DHNTPase = 6-hydroxymethyl 7,8-
dihydropterin pyrophosphokinase, DHNA = 7,8-dihydroneopterin aldolase, HPPK = 6-
hydroxymethyl 7,8-dihydropterin pyrophosphokinase, DHPS = dihydropteroate synthase, 
EcDHFR = Escherichia coli dihydrofolate reductase.
*Gene cloned by Schultheisz et al. (166)
** Gene cloned by Dr. William Dawson (213)
*** Gene cloned by Swanwick et al. (232)
6.4.4 Purification of recombinant enzymes
6.4.4.1 Purification of recombinant enzymes bearing an hexahistidine 
tag (His-tag)
6.4.4.1.1 Purification of GRX2, 6PGDH, XGPRT, GK, DHNA and HPPK
Recombinant enzymes bearing an hexahistidine tag, including GRX2, 6PGDH, 
XGPRT, GK, DHNA and HPPK, were all purified through affinity chromatography. 
A pellet of cells containing the overproduced recombinant enzyme (section 6.3) 
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was resuspended in 20 mL of EBF-1 (section 6.1.7.1) and lysed by sonication on 
ice. Cell debris were removed by by centrifugation at 4 °C, 24300 g for 30 min. 
The supernatant was filtered with a 0.2 µm syringe filter and loaded on a Ni-NTA 
Agarose resin (Qiagen) pre-equilibrated with the Hig-Tag washing buffer. The 
resin was then washed three times with EBF-1. The recombinant enzyme bound 
to the resin was eluted with 20 mL of EBF-2 (section 6.1.7.2). Samples of lysate, 
flow-through and eluted enzyme were taken for SDS-PAGE analysis (section 
6.3.4.3). 
6.4.4.1.2 Purification of PRS
PRS was found to aggregate if purified through the method described in section 
6.4.4.1.1. However, presence phosphate was found to prevent precipitation of the 
recombinant enzyme. Accordingly, the purification procedure described in section 
6.4.4.1.1 was modified by replacing EBF-1 (section 6.1.7.1) and EBF-2 (section 
6.1.7.2) with EBF-3 (section 6.1.7.3) and EBF-4 (section 6.1.7.4), respectively.
6.4.4.2 Purification of recombinant wild-type enzymes
6.4.4.2.1 Purification of GTP-CH-I, DHPS and EcDHFR
Recombinant wild-type GTP-CH-I and DHPS were purified by anion exchange 
followed by size exclusion chromatography. Cells containing the overproduced 
enzyme (section 6.3) were re-suspended in EBF-5 (section 6.1.7.5) and lysed by 
sonication on ice. Cell debris was removed by centrifugation at 4 °C, 24300 g for 
30 min. The supernatant solution was then loaded onto a Q-sepharose fast flow 
resin (GE Healthcare Life Sciences) and the recombinant enzyme eluted with a 
linear gradient from 0 to 1 M NaCl. Fractions containing the enzyme were merged 
and concentrated by ultrafiltration using a 10 kDa cut-off membrane (Merck 
Millipore). Ion-exchanged GTP-CH-I and DHPS were further purified using 
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Superdex 200 and Superdex 75 prep grade size exclusion resin (GE Healthcare 
Life Sciences), respectively, equilibrated with EBF-6 (section 6.1.7.6). Size-
exclusion chromatography purification of EcDHFR was instead performed on a 
Superdex 75 grade size exclusion resin equilibrated with EBF-7 (section 6.1.7.7). 
Samples from lysate and fractions were taken for SDS-PAGE analysis. 
6.4.4.3 SDS-PAGE analysis
6.4.4.3.1 SDS-PAGE gel preparation
Resolving gel (10%) was prepared by mixing 3.3 mL acrylamide/bis-acrylamide 
solution, 2.5 mL SDS resolving buffer (section 6.1.8.1), 100 µL 10% (w/v) SDS 
and 4.1 mL dH2O. 50 µL of 10% (w/v) ammonium persulfate and 20 µL N,N,N’,N’-
tetramethylenediamine (TEMED) were then added to trigger polymerisation, and 
the resolving gel solution was poured into the gel caster. The solution was 
covered with a layer of isopropanol and left to polymerise for 15 min. After 
polymerisation, the isopropanol layer was removed and the stacking gel (4%) 
solution, made by mixing 1.3 mL 30% acrylamide/bis-acrylamide solution, 2.5 mL 
SDS stacking buffer (section 6.1.8.2), 100 µL 10% (w/v) SDS, 6.1 mL dH2O, 50 
µL 10% APS and 20 µL TEMED, was poured. A comb was used to shape 14 
wells where samples can be loaded.  
6.4.4.3.2 SDS-PAGE samples preparation
50 µL BME were mixed with 950 µL of SDS sample buffer (section 6.1.8.3). For 
each sample to be analysed, 50 µL of the resulting solution were mixed with 50 
µL of protein sample and heated at 95°C for 4 min.
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6.4.4.3.3 SDS-PAGE running protocol
SDS-PAGE gel, prepared as described in section 6.4.4.3.1, was loaded with 7 µL 
of unstained protein molecular weight marker (Thermo Scientific) and 5 µL of 
samples to be analysed (section 6.4.4.3.2). The gel was put in a chamber 
containing 10X SDS running buffer (section 6.1.8.4) diluted to 1X with dH2O. The 
gel was run by applying a current at 150 V for 45 min.
6.4.4.4 Enzymes storage
Recombinant GRX2, 6PGDH, GK, DHNTPase, DHNA and HPPK from affinity 
chromatography purification (section 6.3.4.1.1) were dialysed against 50 mM Tris 
(pH = 7.6), 50 mM NaCl and 5 mM β-ME buffer and stored in 50% glycerol 
solution at 20°C maximum for maximum three months. Recombinant PRS 
(section 6.3.4.1.2) was instead dialysed against 50 mM PO4 (pH = 7.6), 50 mM 
NaCl and 5 mM β-ME and stored at -20°C in 50% glycerol for maximum 3 months.
Recombinant GTP-CH-I and DHPS from size exclusion chromatography 
purification (section 6.3.4.2.1) were stored in 50% glycerol as well for maximum 
1 month. 
6.4.4.5 Determining protein and substrates concentration 
6.4.4.5.1 Bradford assay
The principle of the assay developed by Bradford (233) is based on Coomassie 
dye color change upon binding to a protein under acidic conditions.  Bovine serum 
albumine (BSA) diluted with the Bradford reagent (section 6.1.5) in six samples 
ranging between 10 µg/mL and 100 µg/mL were used to determine a standard 
calibration curve. UV-vis spectra were collected for each sample between 600 
nm and 400 nm, and variation of absorbance at 590 nm and 450 nm were 
extrapolated to determine the calibration curve. Protein samples of unknown 
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concentration were then prepared by mixing them with 1 mL of Bradford reagent 
and their respective absorbance at 590 nm and 450 nm were compared to the 
standard curve to calculate the concentration. All recombinant enzymes 
concentration was determined using the Bradford assay except for EcDHFR, 
which concentration was determined applying the Beer-Lambert law (section 
6.4.4.5.2),
6.4.4.5.2 Beer-Lambert law 
The Beer-Lambert law establishes a relationship between UV-vis absorption of a 
given sample and its concentration through the formula:
where A is the absorption, C is the analyte concentration (M) and ε is the 
extinction coefficient (M-1 cm-1) and l is the path length (cm). The value of ε is 
wavelength dependent and it can be used to determine samples concentration 
by measuring A at the given wavelength. EcDHFR (ε = 31117 M-1 cm-1 at λ = 280 
nm), GMP (ε = 17300 M-1 cm-1 at λ = 253 nm), H2F (ε = 28000 M-1 cm-1 at λ = 280 
nm) and NADPH (ε = 28000 M-1 cm-1 at λ = 340 nm) concentrations were 
determined applying the Beer-Lamber law by measuring A at the given 
wavelength in 50 mM PO4 buffer (pH = 7.00).
6.4.5 Enzyme activity assays
GRX2, 6PGDH, PRS, XGPRT, GK and GTP-CH-I activities were assayed 
following published procedures (171, 190, 205, 214, 234, 235) All anion exchange 
chromatography analyses were performed using a ProPac SAX-10 analytical or 
semi-preparative column (Fisher Scientific) with a linear gradient from 0 to 400 
mM NaCl over 60 min in 20 mM bicarbonate buffer (pH 8.0). Liquid 
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chromatography – mass spectrometry (LC-MS) analyses were performed using 
a Bruker amaZon SL ion-trap mass spectrometer equipped with an ultra-
performance liquid chromatography (UPLC) system. All UPLC separations were 
performed with a linear gradient of 5% to 95% aqueous acetonitrile containing 
0.1% HCOOH over 20 min using a C18 analytical column.
6.4.5.1 Comparison of GTP-CH-I activity with and without DHNTPase
0.2 mg of GTP were incubated with GTP-CH-I in 1 mL of 50 mM Tris (pH 7.6), 
100 mM KCl, 5 mM MgCl2, 5 mM β-ME at 37 °C. Formation of 7,8-
dihydroneopterin triphosphate (DHNTP) was monitored by UV-vis spectroscopy 
at 330 nm for 1 h. After 2 h, the mixture was analysed by anion exchange 
chromatography. DHNTPase was assayed by coupling with GTP-CH-I following 
the same procedure described above. 
6.3.5.2 DHNA, HPPK, DHPS activity assay
Because 7,8-dihydroneopterin (DHN), 6-hydroxymethyl-7,8-dihydropterin 
(HMDP) and 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (HMDPpp) are 
chemically unstable, substrates were generated enzymatically from GTP. 1 mg 
of GTP placed in a 1.5 mL Eppendorf tube was incubated with GTP-CH-I and 
DHNTPase in 1 mL of 50 mM Tris (pH 8.0), 100 mM KCl, 5 mM MgCl2, 5 mM 
BME at 37 °C for 3 h. ALP was added and the mixture left to react for further 30 
min. Enzymes were removed using a 10 kDa spin column (GE Healthcare Life 
Sciences); the filtrate containing DHN was analysed by LC-MS and used to assay 
DHNA, HPPK and DHPS activities in a sequential order. Addition of DHNA 
triggers conversion of DHN to HMDP which was detected by LC-MS. 100 µL of 
ATP solution (10 mg/mL, pH ~7.6) was then added together with HPPK, and 
formation of HMDPpp was monitored by anion exchange chromatography. 
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Addition of DHPS to 100 µL solution of containing p-aminobenzoic acid (2 mg/mL) 
leads to the formation of dihydropteroic acid as detected by LC-MS.  
6.5Determining GRX system total turnover number (TTN)
In a falcon tube 0.05 mmol of 13C6-D-glucose (9.3 mg), 0.11 mmol of HED (17 
mg), 0.06 mmol (13 mg) of PEP were mixed in 10 mL of 50 mM potassium 
phosphate, 50 mM NaCl, 10 mM MgCl2, 2 mM GSH buffer at 37°C, and the pH 
was adjusted to 7.6 with NaOH(aq). 0.005 mmol ATP (3 mg) was then added 
together with 10 nmol PK, 20 nmol GRX2, 5 nmol GR and 5 nmol G6PDH. NADP+
concentration was varied in order to assess the TTN at 50 (0.001 mmol), 103 (5 
x 10-5 mmol), 104 (5 x 10-6 mmol), 105 (5 x 10-7 mmol), 5 x 105 (10-7 mmol) and 
106 (5 x 10-8 mmol) respectively. Formation of 13C6-PG was triggered by addition 
of HK (10 nmol) and the progress of the enzymatic reaction was monitored by 
13C-NMR spectroscopy by mixing 450 μL from the reaction mixture with 50 μL of 
D2O. 
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6.6Synthesis of isotopically labelled guanines
6.6.1 Traube purine synthesis
6.6.1.1 Synthesis of [5-15N]-2,4,5-triamino-6-hydroxypyrimidine
A solution of 2,4-diamino-6-hydroxypyrimidine (1.64 g, 12.99 mmol) in 10% acetic 
acid (30 mL) was cooled on ice and Na15NO2 (1 g, 14.29 mmol) dissolved in a 
small amount of deionized water (dH2O) was added dropwise under stirring. [5-
15N]-2,4-diamino-5-nitroso-6-hydroxypyrimidine precipitated as a purple solid.
formed. The precipitate was centrifuged, washed twice with cold dH2O and re-
suspended in hot dH2O. When the suspension was close to boil, sodium dithionite 
(9.95 g, 57.16 mmol) divided in four portions were added every 15 min. The 
reaction mixture discolored as the nitroso compound reduced to [5-15N]-2,4,5-
triamino-6-hydroxypyrimidine. The solution was then cooled to room temperature. 
Addition of conc. H2SO4 caused precipitation of the final compound. The solid 
was filtered and crystallized in 1 N H2SO4. Crystals were collected and dried 
under vacuum yielding 2.36 g (9.86 mmol, 69% yield) of [5-15N]-2,4,5-triamino-6-
hydroxypyrimidine sulphate salt. 
13C NMR (125 MHz, 90% H2O + 10% D2O) δ 168.87 (s), 157.92 (s), 154.07 (s), 
101.12 (d, JC-N = 8.9 Hz) ppm.
6.6.1.2 Synthesis of [7-15N]-guanine 
[5-15N]-2,4,5-triamino-6-hydroxypyrimidine (2.27 g, 9.49 mmol) were mixed with 
4-formylmorpholine (9.45 mL, 94.4 mmol) and refluxed in 98% HCOOH (15 mL) 
under nitrogen for 3 hours. After this time, the mixture was cooled to room 
temperature and then put on ice. Ammonium hydroxide was slowly added until 
the pH reached 9.0. [5-15N]-guanine precipitated out and was collected by 
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centrifugation, washed three times with cold dH2O then twice with acetone, and 
dried under vacuum to yield 1.23 g of off-white powder (8.06 mmol, 85% yield).
1H NMR (500 MHz, 90% H2O + 10% D2O) δ 7.56 (d, 1H, JC-N = 10 Hz) ppm. 13C 
NMR (125 MHz, H2O + 10% D2O) δ 167.22 (d, JC-N = 3.8 Hz), 159.96 (s), 159.44 
(s), 146.61 (s), 117.19 (d, JC-N = 3.8 Hz) ppm.
6.6.1.3 Synthesis of [6-13C,7-15N]-guanine
Synthesis of [6-13C,7-15N]-guanine was performed as for [7-15N]-guanine (section 
6.5.1.2) using [5-15N]-2,4,5-triamino-6-hydroxypyrimidine (1.07 g, 4.25 mmol) and 
H13COOH (1 g, 0.85 mmol) as starting material. 1 mL morpholine was used as 
solvent.
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 7.43 (dd, 1H, 1JC-H = 198 Hz, 2JN-H = 
12 Hz) ppm. 13C NMR (150 MHz, 90% H2O + 10% D2O) δ 147.89 (d, JC-N = 3 Hz)
ppm.
6.6.2 Synthesis of guanine from 5-amino-4-imidazolecarboxamide
6.6.2.1 Synthesis of [2-13C]-guanine
Benzoyl chloride (592 µL, 5.09 mmol) and KS13CN (495 mg, 5.09 mmol) were 
placed in a round bottom flask and put under a stream of N2. ~10 mL of anhydrous 
CH3CN was added, and the mixture was stirred at 70°C. A white solid, KCl,
precipitated. After 1 h, the solid was filtered and the solvent was evaporated 
under reduced pressure. Crude 13C-benzoyl isothiocyanate formed during the 
reaction appeared as a faint yellow oil. 5-amino-4-imidazolecarboxamide (642, 
5.09 mmol) dissolved in ~ 50mL dH2O was mixed with crude 13C-benzoyl 
isothiocyanate, and the solution was stirred at room temperature overnight. The 
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day after, 1 mL of NaOH 6M was added to the reaction mixture to dissolve 5-(N’-
benzoyl-isothiocarbamoyl)amino-4-imidazolecarboxamide precipitated from the 
solution in the course of the reaction. The solution was filtered and methyl iodide 
(1.3 mL, 20 mmol) was added. The solution was vigorously stirred for 2 h at room 
temperature, and 5-(N’-benzoyl-S-methylisothiocarbamoyl)amino-4-
imidazolecarboxamide appeared as a white solid. The precipitate was filtered and 
washed twice with water to be then put in a round bottom flask. 15 mL of 6M 
NaOH were added and the mixture was heated at 100°C for 1 h. The solution 
was left to cool at room temperature to be then put on ice. Concentrated HCl was 
added with caution into the mixture until the pH reached ~7.00. [2-13C]-guanine 
precipitated. The solid was separated from the solution by centrifugation, washed 
with water, ethanol and then dried under vacuum to yield 226 mg (29 % overall) 
of final product.
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 7.52 (1H, s) ppm. 13C NMR (150
MHz, 90% H2O + 10% D2O) δ 159.17 (s) ppm.
6.7General procedure for the synthesis of isotopically labelled GMPs
In a falcon tube 0.05 mmol 13C6-D-glucose (9.3 mg), 0.11 mmol HED (17 mg) or 
cystine (26 mg), 0.2 mmol PEP (41 mg) were mixed in 5 mL of 100 mM Tris, 50 
mM NaCl, 10 mM MgCl2, 2 mM GSH buffer at 37°C, and the pH was thereafter 
adjusted to 7.6 with NaOH(aq). 0.005 mmol ATP (3 mg) and 0.001 mmol NADP+
(0.8 mg) were then added together with 10 nmol PK, 10 nmol MK(171), 20 nmol 
GRX2, 5 nmol GR, 5 nmol G6PDH and 5 nmol PRI, and the volume adjusted to 
10 mL with further addition of reaction buffer. The enzymatic cascade was 
triggered by addition of HK (10 nmol) which was monitored by UV-vis 
spectroscopy following NADPH absorbance at 340 nm. When the absorbance 
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declined to the baseline (or solid cystine was fully dissolved to reduced cysteine), 
PRS (10 nmol) and XGPRT (30 nmol) were added. The reaction was left to 
proceed for further 15 min. in order to generate sufficient amounts of the 
intermediate PRPP in situ. 0.05 mmol of guanine (7.6 mg) dissolved 50 μL of 
KOH (5.0 M) were diluted to 10 mL with deionized water and loaded in a 10 mL 
syringe. Alkaline guanine was then flowed into the reaction mixture at the rate of 
0.2 mL/min (1 μmol/min). After 50 min., when addition of guanine was complete, 
the reaction mixture was allowed to proceed for further 10 min. The pH shifted 
from 7.6 to ~8.0. The final product was purified from the crude mixture by anion 
exchange chromatography with a linear gradient from 0 to 40% of 1M NaCl in 60 
min in 20 mM bicarbonate buffer (pH = 8.0) using a ProPac SAX-10 preparative 
column (Fisher Scientific). GMP eluted after ~16 min. Fractions containing the 
product were merged and, prior to freeze drying, GMP was quantified by the beer-
Lambert law (section 6.3.4.5.2). Yields ranged between 70% and 80%.
6.8General procedure for the synthesis of isotopically labelled H2Fs
Chemo-enzymatic synthesis of 7,8-dihydrofolate (H2F) was performed inside a 
LABstar glove box station (MBraun, Germany) equipped with a 50 mL falcon tube 
Thermomixer (Eppendorf), pH meter and syringe pump. Oxygen concentration 
was constantly kept below 0.5 ppm. Solutions were extensively degassed prior 
to their introduction into the glovebox system, and left to equilibrate to the inert 
atmosphere overnight before use. In a falcon tube, D-glucose (9 mg, 0.05 mmol), 
cystine (26 mg, 0.11 mmol) and PEP (62 mg, 0.3 mmol) were mixed in 5 mL of 
100 mM Tris, 100 mM KCl, 10 mM MgCl2, 2 mM GSH buffer at 37°C, and the pH 
was adjusted to 7.6 with NaOH(aq). ATP (3 mg, 0.005 mmol) and NADP+ (0.8 mg, 
0.001 mmol) were added together with PK (10 nmol), MK (10 nmol),(171) GRX2 
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(20 nmol), GR (5 nmol), G6PDH (5 nmol) and PRI (5 nmol). After adjusting the 
total volume of 10 mL with the reaction buffer, the enzymatic cascade was 
triggered by addition of HK (10 nmol) and left to react overnight (or until solid 
cystine was fully dissolved) at 37 °C. The day after, PRS (10 nmol), XGPRT (30 
nmol) and GK (20 nmol) were added. The reaction was left to proceed for further 
15 min in order to generate sufficient amounts of the intermediate PRPP in situ. 
Guanine (7.6 mg, 0.05 mmol) dissolved in 50 μL of 5 M KOH was diluted to 10 
mL with deionized water and loaded in a 10 mL syringe. Alkaline guanine was 
then flowed into the reaction mixture at the rate of 0.2 mL/min (1 μmol/min). 
During guanine addition, the reaction vessel was agitated at 400 rpm. After 50 
min, when addition of guanine was complete, the reaction mixture was allowed 
to proceed for further 10 min; the pH shifted from 7.6 to ~8.0. GTP-CH-I (100 
nmol) and DHNTPase (25 nmol) were added and the reaction was left to proceed 
overnight protected from light. After the overnight reaction with GTP-CH-I and 
DHNTPase, ALP (15 nmol) was added and the reaction mixture incubated for 1 
h and 30 min. The reaction mixture pH must be under strict control and never 
reach values below 7.0. This is to avoid pH-dependent degradation of 7,8-
dihydropterin intermediates including the final product H2F. Enzymes were 
removed by ultrafiltration using a 50 mL 10 kDa spin column (GE Healthcare Life 
Sciences). The filtrate was put in a clean 50 mL falcon tube, and a solution of 
ATP (6 mg, 0.01 mmol), MK (10 nmol), PK (10 nmol), 0.015 mmol of PEP (31 
mg, 0.15 mmol) and pABA-Glu (16 mg, 0.06 mmol) was added to the main 
mixture making sure the pH was adjusted between 7.6 and 8.0 before addition. 
Then, DHNA (20 nmol), HPPK (20 nmol) and DHPS (30 nmol) were added, and 
the reaction mixture was left overnight. During H2F formation, the reaction mixture 
turns faint yellow. The final product was purified from the crude mixture by anion 
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exchange chromatography. Briefly, the crude product was diluted to 200 mL with 
dH2O. The diluted solution was put on ice and accurately protected from light, for 
being loaded on a ProPac SAX-10 preparative column (Fisher Scientific) 
equilibrated with 20 mM Tris buffer (pH 7.6). After loading, the column was 
washed with buffer until absorbance at 210 nm declined to the baseline. H2F was 
thereafter eluted from the anion exchange column with a linear gradient from 0 to 
400 mM NaCl over 60 min, following 7,8-dihydropterin absorbance at 330 nm. 
H2F eluted after ~33 min. Fractions containing the product were merged. The H2F 
solution was immediately put in a flask and the product (and other salts) 
precipitated with cold acetone. The acetone solution was left on ice for 10 min to 
ensure complete precipitation, and the solid was separated through centrifugation 
by collecting it in a 50 mL falcon tube. The faint yellow solid collected at the 
bottom of the falcon tube was gently dried from residual acetone using a stream 
of N2. When sufficiently dry, the tube was put on ice and the pellet treated with a 
1-2 mL of ice-cold 10% ascorbic acid (pH 2.8). While salts are dissolved in the 
ascorbic acid solution, H2F remains insoluble and it can be therefore separated 
by centrifugation in a 1.5 mL Eppendorf tube. The solid was washed 3 times with 
ice-cold dH2O and once with ice-cold acetone. Eventually, the acetone-washed 
product was dried under vacuum for 30 min and stored at -20 °C. The average 
overall yield was 30% (6.7 mg, 0.015 mmol).
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6.9Characterisation of isotopically labelled GMPs and H2Fs
6.9.1 NMR spectroscopy
All NMR experiments were performed at 25 °C on a Bruker AVANCE III 600 MHz 
(1H) spectrometer with a QCI-P cryoprobe. All samples were prepared in 10% 
deuterium oxide by dissolving samples with 0.1 M NaOH.
6.9.1.1 [1’,2’,3’4’,5’-13C5]-GMP
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 8.00 (s), 5.77 (1H, d, JC-H = 164 Hz), 
3.93 (5H, m) ppm. 13C NMR (150 MHz, 90% H2O + 10% D2O) δ 86.25 (d, JC-C = 
42.6 Hz), 84.45 (m), 74.23 (dd, JC-C = 37, 5 Hz), 71.05 (t, JC-C = 38 Hz), 63.77 (d, 
JC-C = 43 Hz) ppm.
6.9.1.2 [1’,2’,3’4’,5’-13C5, 7-15N]-GMP
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 8.00 (d, 1H, 2JN-H = 10.8 Hz), 5.78 
(1H, d, JC-H = 165 Hz), δ 3.93 (5H, m) ppm. 13C NMR (150 MHz, 90% H2O + 10% 
D2O) δ 86.25 (d, JC-C = 42.6 Hz), 84.45 (m), 74.23 (dd, JC-C = 37, 5 Hz), 71.05 (t, 
JC-C = 38 Hz), 63.77 (d, JC-C = 43 Hz) ppm.
6.9.1.3 [1’,2’,3’4’,5’,8-13C6, 7-15N]-GMP
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 8.06 (dd, 1H, 1JC-H = 205 Hz, 2JN-H = 
11 Hz), δ 5.78 (1H, d, JC-H = 169 Hz), δ 3.93 (5H, m) ppm. 13C NMR (150 MHz, 
90% H2O + 10% D2O) δ 135.71 (s), 86.25 (d, JC-C = 42.6 Hz), 84.45 (m), 74.23 
(dd, JC-C = 37, 5 Hz), 71.05 (t, JC-C = 38 Hz), 63.77 (d, JC-C = 43 Hz).
6.9.1.4 [2-13C]-GMP
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 8.04 (s), 5.77 (1H, d, JH-H = 6 Hz), 
4.31 (2H, dd, JH-H =3.4, 1.6 Hz), 4.21 (2H, m), 3.89 (1H, m) ppm. 13C NMR (150 
MHz, 90% H2O + 10% D2O) δ 161.38 (s) ppm.
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6.9.1.5 [5-15N]-H2F
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 7.63 (2H, d, JH-H = 8.8 Hz), 6.74 (2H, 
d, JH-H = 8.8 Hz), 4.21 (1H, dd, JH-H = 9 Hz, 5 Hz), 3.95 (2H, s), 3.87 (2H, s), 2.20 
(2H, m), 1.98 (2H, m) ppm.
6.9.1.6 [6-13C]-H2F
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 7.63 (2H, d, JH-H = 8.8 Hz), 6.74 (2H, 
d, JH-H = 8.8 Hz), 4.21 (1H, dd, JH-H = 9 Hz, 5 Hz), 3.95 (2H, d, 2JC-H 6.1 Hz), 3.87 
(2H, d, 2JC-H 6.1 Hz), 2.20 (2H, m), 1.98 (2H, m) ppm. 13C NMR (150 MHz, 90% 
H2O + 10% D2O) δ 152.07 (s) ppm.
6.9.1.7 [5-15N][6-13C]-H2F
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 7.63 (2H, d, JH-H = 8.8 Hz), 6.74 (2H, 
d, JH-H = 8.8 Hz), 4.21 (1H, dd, JH-H = 9 Hz, 5 Hz), 3.95 (2H, d, 2JC-H 5.8 Hz), 3.87 
(2H, d, 2JC-H 5.8 Hz), 2.20 (2H, m), 1.98 (2H, m) ppm. 13C NMR (150 MHz, 90% 
H2O + 10% D2O) δ 152.08 (d, JC-N 7.0 Hz) ppm.
6.9.1.8 [6,7,9-13C3]-H2F
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 7.63 (2H, d, JH-H = 8.8 Hz), 6.74 (2H, 
d, JH-H = 8.8 Hz), 6.74 (1H, s), 4.21 (1H, dd, JH-H = 9, 5 Hz), 3.95 (2H, dd, 1JC-H = 
132 Hz, 2JC-H 6 Hz), 3.87 (2H, dd, 1JC-H = 147 Hz, 2JC-H 6 Hz), 2.20 (2H, m), 1.98 
(2H, m) ppm. 13C NMR (150 MHz, 90% H2O + 10% D2O) δ 152.05 (dd, JC-C = 52,
40 Hz), 47.84 (d, JC-C = 52 Hz), 47.84 (d, JC-C = 52 Hz) ppm.
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6.9.1.9 [5-15N][6,7,9-13C3]-H2F
1H NMR (600 MHz, 90% H2O + 10% D2O) δ 7.63 (2H, d, JH-H = 8.8 Hz), 6.74 (2H, 
d, JH-H = 8.8 Hz), 4.21 (1H, dd, JH-H = 9 Hz, 5 Hz), 3.95 (2H, dd, 1JC-H = 132 Hz, 
2JC-H 6 Hz), 3.87 (2H, dd, 1JC-H = 147 Hz, 2JC-H 6 Hz), 2.20 (2H, m), 1.98 (2H, m)
ppm. 13C NMR (150 MHz, 90% H2O + 10% D2O) δ 152.03 (ddd, JC-C = 51, 40 Hz,
JC-N 7.2 Hz), 47.84 (d, JC-C = 52 Hz), 47.84 (d, JC-C = 52 Hz) ppm.
6.9.2 Liquid chromatography – high resolution mass spectrometry (LC-
HRMS)
All LC-HRMS analyses were run on a Waters Synapt G2-Si time-of-flight mass 
spectrometer (Surrey, UK) equipped with a Acquity UPLC system.
6.10 Pre-steady state kinetics (PSSK) and heavy-atom kinetic isotope 
effect measurements on EcDHFR
6.10.1 Preparation of natural abundance H2F for PSSK measurements
Natural abundance H2F was prepared with a modified version of the method 
described by Blakley (236). 8 g ascorbic acid were placed in a three-neck round 
bottom flask and dissolved with 80 mL dH2O. pH was adjusted to 6.00 and the 
solution constantly purged with a stream of N2 protected from light. 400 mg folic 
acid dissolved in 40 mL NaOH were added to the ascorbic acid solution, and after 
5 min pH was re-adjusted to 6.00. The reaction mixture was put on ice under 
stirring for 5 min, and 4.4 g sodium dithionite were added. When sodium dithionite 
was completely dissolved, the reaction was allowed to proceed for 15 min. A fresh 
solution of 1 M HCl was added to the reaction mixture dropwise using a peristaltic 
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pump until pH drops to 2.8. H2F will precipitate out from the solution. The 
precipitate is separated from the solution by centrifugation, and precipitated again 
in 10% sodium ascorbate as described before. To ensure sample homogeneity 
in PSSK measurements, H2F is then purified by anion exchange chromatography 
following the same procedure described for isotopically labelled H2Fs (section 
6.8). 
6.10.2 Single-turnover experiments
Single-turnover experiments were performed on an Applied Phothophysics 
SX20/LED stopped-flow spectrophotometer (UK) optimized for measuring DHFR 
reaction rate through fluorescence resonance energy transfer (FRET) by exciting 
tryptophan residues at 292 nm, which were in turn exciting NADPH at 340 nm 
and measuring the subsequent emission at 450 nm. NADPH and H2F 
concentrations were determined spectrophotometrically as described in section 
6.3.4.5.2. Experiments were performed in 100 mM phosphate, 100 mM NaCl, 5 
mM β-ME, pH 7.0. The buffer was filtered and extensively degassed before use. 
Solutions were constantly kept on ice and protected from light during 
measurements. EcDHFR (20 µM) was preincubated with NADPH (8 µM) for at 
least 5 min before measurements by rapidly mixing with H2F (200 µM). 
Measurements were repeated at least three times. Rate constants were 
extrapolated by fitting the kinetic data to the equation for a triple-exponential 
decay using Applied Photophysics Pro-Data SX software. Isotopically labelled 
H2Fs were checked by NMR before use.
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6.10.3 Errors and their propagation
6.10.3.1 Standard deviation and standard error of the mean
Uncertainty for the measured pre-steady-state values are reported as standard 
deviation (σ) which is defined as:
where X is the value of each measurement, M is the mean value of the sample 
and n is the total number of repetitions.
6.10.3.2 Propagation of uncertainty 
Errors of the KIE data presented in this work were calculated using the error 
following propagation formula:
where X and Y represent the independently measured values, ΔZ and ΔY the 
uncertainty values for X and Y respectively.
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8. APPENDICES
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8.1 Apprendix 1. High-resolution mass spectrometry data
8.1.1 HRMS of isotopically labelled guanosine monophosphates
Figure A.1. Positive TOF HRMS of natural abundance GMP.
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Figure A.2. Positive TOF HRMS of [1’,2’,3’,4’,5’-13C5]-GMP.
Figure A.3. Positive TOF HRMS of [1’,2’,3’,4’,5’,8-13C6,7-15N]-GMP.
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Figure A.4. Positive TOF HRMS of [1’,2’,3’,4’,5’-13C5,7-15N]-GMP
Figure A.5. Positive TOF HRMS of [2-13C]-GMP.
Appendices
154
8.1.2. HRMS of isotopically labelled dihydrofolates
Figure A.6. Positive TOF HRMS of natural abundance H2F. 
 
Figure A.7. Positive TOF HRMS of [5-15N]-H2F. 
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Figure A.8. Positive TOF HRMS of [6-13C]-H2F. 
 
Figure A.9. Positive TOF HRMS of [6-13C,5-15N]-H2F. 
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Figure A.10. Positive TOF HRMS of [6,7,9-13C3]-H2F
Figure A.11. Positive TOF HRMS of [6,7,9-13C3,5-15N]-H2F. 
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8.2. Apprendix 2. Pre-steady state kinetic data
Table A.1. Pre-steady-state kinetic data for determining 15N-KIE on EcDHFR using [5-
15N]-H2F. 
T(°C) kH14N (s-1) kH15N (s-1)
5 83.229 ± 1.045 83.560 ± 1.089
10 107.963 ± 1.250 108.400 ± 1.461
15 144.056 ± 0.793 144.200 ± 0.059
20 182.443 ± 1.595 182.500 ± 0.630
25 228.902 ± 1.297 230.300 ± 1.634
30 281.197 ± 3.883 281.200 ± 4.868
35 338.237 ± 3.005 338.000 ± 4.395
Table A.2. Pre-steady-state kinetic data for determining 13C-KIE on EcDHFR using [6-
13C]-H2F.
T(°C) kH12C (s-1) kH13C (s-1)
5 93.397 ± 0.675 91.717 ± 0.547
10 120.504 ± 0.916 118.407 ± 0.900
15 157.535 ± 0.568 155.171 ± 0.822
20 195.551 ± 1.346 191.540 ± 2.143
25 246.174 ± 0.894 239.506 ± 1.501
30 286.3681 ± 1.587 279.970 ± 2.968
35 357.173 ± 0.965 347.012 ± 3.773
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Table A.3. Pre-steady-state kinetic data for determining 15N,13C-KIE on EcDHFR using         
[5-15N][6-13C]-H2F.
T(°C) kH14N,12C (s-1) kH15N,13C (s-1)
5 94.208 ± 0.724 92.336 ± 0.685
10 121.883 ± 1.000 119.133 ± 0.680
15 157.775 ± 1.032 155.535 ± 1.162
20 198.094 ± 1.152 195.862 ± 0.720
25 241.495 ± 1.111 237.226 ± 0.806
30 282.080 ± 0.760 279.100 ± 2.41
35 351.533 ± 3.340 339.801 ± 4.247
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8.3 Appendix 3. Additional SDS-PAGE analyses
Figure A.12. SDS-PAGE of purified PRS (MW = 34,2 kDa; fractions 1-3) compared to 
cell lysate (Lys) before and after (FT) purification.
Figure A.13. SDS-PAGE of purified XGPRT (MW = 16,8 kDa; fractions 1-2) compared 
to cell lysate (Lys) before and after (FT) purification.
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Figure A.14. SDS-PAGE of purified GTP-CH-I (MW = 24,8 kDa; fractions 1-6) compared 
to cell lysate (Lys) after size exclusion chromatography. 
Figure A.15. SDS-PAGE of purified DHNA (MW = 13,6 kDa; fractions 1) compared to 
cell lysate (Lys) before and after (FT) purification.
Figure A.16. SDS-PAGE of purified HPPK (MW = 18,1 kDa; fractions 1-3) compared to 
cell lysate (Lys) before and after (FT) purification.
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Figure A.17. SDS-PAGE of purified DHPS (MW = 30,6 kDa; fractions 5-8) compared to
cell lysate (Lys) after size exclusion chromatography. 
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8.4 Apprendix 4. Sequencing data
8.4.1 Sequencing of gmk
> gmk2_T7term -- unclipped
TGAATACGCCTTCTTTTTCGGGCTTTGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAGTCAGTCTGCCAACAATT
TGCTGATTAAAGCGTCATGACGCTGCTTTTGGCGGCTCATGCGCAGACGTTCGGCGCGAATAATGGTCTTCAAATCGGTCAACGC
GGTATCGAAGTCATCATTCACAATCAGATAATCATATTCGGCGTAATGGCTCATTTCTGCAACAGCTTGCGCCATACGCTTTGCAAT
GACCTCTTCGCTGTCCTGACCGCGACCGCGTAGACGGCCGTCCAGTTCAATTTTGGACGGCGGTAAAATAAAGATACTCCGCGC
GTGCGGCATCTTCTGGCGAATTTGCTGCGCGCCCTGCCAGTCGATATCGAGAAAAACATCGACACCGGTCGCCAGTACTTGCTCT
ATGGCCTCACGCGAAGTGCCATAGTAATTACCAAAAACTTCTGCGTGTTCGAGGAACGCATCTCTGCTAATCATTTCTTTAAATTCA
TCATGATTAACAAAGAAATAATGTTCACCGTGGACTTCACCAGGACGCGGTTGGCGTGTGGTGTGTGAAACAGAAACCTGGGTGT
CATACAACGGTTGGGTTTTTAATAAAGCCTGAATCAGGCTGGATTTACCCGCGCCACTGGGGGCAGAAACAATATAAAGCGTGCC
TTGAGCCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGATGATGGCTGCTGCCCATGGTATATCTCCTTCTT
AAAGTTAAACAAAATTATTTCTAGAGGGGAATTGTTATCCGCTCACAATTCCCCTATAGTGAGTCGTATTAATTTCGCGGGATCGAG
ATCTCGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATC
ACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTTCGCGTGGGTATGGGGGCAGGCCCCGTGGCCGG
GGGAATGTTGGGCGCCTTCCCTTGGAGGACCATTCTTGGGGGGGGGGGGTAACGGGCTCATCT
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8.4.2 Sequencing of gnd
>[1]-gndT7P_T7 -- 23..848 of sequence
CTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCC
GCGCGGCAGCCATATGTCCAAGCAAAATATCGGCGTAGTCGGTATGGCAGTGATGGGACGCAACCTTGCGCTCAACATCGAAAG
CCGTGGTTATACCGTCTCTATTTTCAACCGTTCCCGTGAGAAGACGGAAGAAGTGATTGCCGAAAATCCAGGCAAGAAACTGGTT
CCTTACTATACGGTGAAAGAGTTTGTCGAATCTCTGGAAACGCCTCGTCGCATCCTGTTAATGGTGAAAGCAGGTGCAGGCACGG
ATGCTGCTATTGATTCCCTCAAACCATATCTCGATAAAGGAGACATCATCATTGATGGTGGTAACACCTTCTTCCAGGACACTATTC
GTCGTAATCGTGAGCTTTCAGCAGAGGGCTTTAACTTCATCGGTACCGGTGTTTCTGGCGGTGAAGAGGGGGCGCTGAAAGGTC
CTTCTATTATGCCTGGTGGCCAGAAAGAAGCCTATGAATTGGTAGCACCGATCCTGACCAAAATCGCCGCCGTAGCTGAAGACGG
TGAACCATGCGTTACCTATATTGGTGCCGATGGCGCAGGTCACTATGTGAAGATGGTTCACAACGGTATTGAATACGGCGATATG
CAGCTGATTGCTGAAGCCTATTCTCTGCTTAAAGGTGGCCTGAACCTCACCAACGAAGAACTGGCGCAGACCTTTACCGAGTGGA
ATAACGGTGAACTGAGCAGTTACCTGATCGACATCACCAAAGATATCTTCACCAAAAAAG
>1]-gndT7T_T7term -- 7..1021 of sequence
CGCTTCTTTCGGGCTTTGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAGTTATTAATCCAGCCATTCGGTATGGA
ACACACCTTCTTTATCAATACGCTTATAAGTATGCGCACCAAAATAGTCACGCTGTGCCTGGATCAGGTTCGCAGGCAGAACAGCA
GCACGGTAGCTGTCGTAATAGGCAACCGCTGCGGAGAAGGTCGGAACCGGAATACCGTTCTGTACTGCATAAGCAACGACATCA
CGCAGCGCCTGCTGGTAGTCATCGGCAATTTGCTTGAAGTACGGAGCCAGCAACAGGTTAGCGATCTGTGGATTTTCGGCATAAG
CATCGGTGATTTTCTGCAGGAACTGCGCACGGATGATGCAGCCAGCACGGAAAATCTTCGCGATTTCGCCGTAGTTCAGATCCCA
GTTGTACTCTTCAGACGCAGCACGCAGCTGAGAGAAGCCCTGGGCGTAAGAAACGACTTTGCCCAGATACAGCGCACGACGAAC
TTTTTCGATGAACTCAGCCTTGTCGCCTGCTGGCTGTGCTTGCGGACCAGAGAGAACTTTAGATGCGGCAACACGCTGATCTTTC
AGAGAAGAGATATAACGTGCAAACACAGACTCGGTAATCAGCGACAGCGGTTCGCCGAGATCCAGCGCGCTCTGGCTGGTCCAT
TTACCGGTACCTTTGTTAGCCGCTTCATCCAGGATCACATCAACCAGGTAGTTACCGTCTTCATCTTTTTTGGTGAAGATATCTTTG
GTGATGTCGATCAGGTAACTGCTCAGTTCACCGTTATTCCACTCGGTAAAGGTCTGCGCCAGTTCTTCGTTGGTGAGGTTCAGGC
CACCTTTAAGCAGAGAATAGGCTTCAGCAATCAGCTGCATATCGCCGTATTCAATACCGTTGTGAACCATCTTCACATAGTGACCT
GCGCCATCGGCACCAATATAGGTAACGCATGGTTCACCGTCTTCAGCTACGGCGGCGATTTTGGTCAGGATCGGTGCTA
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8.4.3 Sequencing of grxB
>grxB_T7 -- 33..766 of sequence
TTTTGTTTAACTTTAAGAAGGAGGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGC
AGCCATATGAAGCTATACATTTACGATCACTGCCCTTACTGCCTCAAAGCCCGCATGATTTTCGGCCTGAAAAATATCCCCGTCGA
ATTACATGTTCTGCTCAACGACGACGCAGAAACACCCACCCGGATGGTCGGTCAAAAACAGGTTCCCATTCTGCAAAAAGATGAC
AGCCGCTATATGCCAGAAAGCATGGACATCGTTCACTATGTCGATAAACTCGACGGCAAACCGTTACTGACCGGCAAACGTTCCC
CTGCCATTGAAGAGTGGCTGCGCAAGGTCAATGGCTACGCCAACAAACTGCTGTTGCCGCGTTTTGCCAAATCGGCATTTGATGA
GTTTTCTACTCCCGCCGCGCGCAAATATTTCGTCGACAAGAAAGAGGCCAGCGCGGGTAATTTTGCCGACCTGCTGGCCCACTCT
GACGGTCTGATTAAGAATATCAGCGATGATTTACGTGCGCTGGACAAACTGATCGTCAAACCGAACGCCGTGAATGGCGAACTTT
CGGAAGATGATATTCAGCTATTCCCGCTACTGCGTAATCTGACGCTGGTAGCCGGAATTAACTGGCCAAGCCGCGTTGCTGATTA
CCGCGATAATATGGCGAAAACAGACACAAATCAAATTTGTTATCATCAATGGC
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8.4.4 Sequencing of nudB
>nudB[3]_T7
AAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCG
CGGCAGCCATATGAAGGATAAAGTGTATAAGCGTCCCGTTTCGATCTTAGTGGTCATCTACGCACAAGATACGAAACGGGTGCTG
ATGTTGCAGCGGCGTGACGATCCCGATTTCTGGCGGTCGGTAACCGGCAGCGTGGAAGAGGGTGAAACCGCGCCGCAAGCTGC
CATGCGCGAAGTAAAGGAAGAGGTCACCATTGATGTTGTCGCTGAACAACTGACCTTAATTGACTGTCAGCGCACGGTAGAGTTT
GAAATTTTTTCACATTTACGTCATCGCTATGCGCCGGGCGTGACGCGTAATACGGAATCATGGTTCTGTCTTGCGCTTCCGCACGA
GCGGCAGATCGTTTTCACTGAACATCTGGCTTACAAGTGGCTTGATGCGCCTGCTGCGGCGGCGCTCACTAAGTCCTGGAGCAA
CCGGCAGGCGATTGAACAGTTTGTAATTAACGCTGCCTGACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAA
GCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGG
GGTTTTTTGCTGAAAGGAGGAACTATATCCGGATTGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAACCGCGGC
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8.5 Apprendix 5. Published articles
A Versatile Disulﬁde-Driven Recycling System for NADP+ with High
Cofactor Turnover Number
Antonio Angelastro, William M. Dawson,† Louis Y. P. Luk, and Rudolf K. Allemann*
School of Chemistry and Cardiﬀ Catalysis Institute, School of Chemistry, Cardiﬀ University, Park Place, Cardiﬀ CF10 3AT, United
Kingdom
*S Supporting Information
ABSTRACT: NADP+-dependent enzymes are important in
many biocatalytic processes to generate high-value chemicals
for the pharmaceutical and food industry; hence, a cost-
eﬀective, eﬃcient, and environmentally friendly recycling
system for the relatively expensive and only marginally stable
enzyme cofactor NADP+ oﬀers signiﬁcant beneﬁts. NADP+
regeneration schemes have previously been described, but their
application is severely limited by the low total turnover
numbers (TTN) for the cofactor. Here, we report a glutathione-based recycling system that combines glutaredoxin from E. coli
(EcGRX) and the glutathione reductase from S. cerevisiae (ScGR) for NADP+ regeneration. This system employs inexpensive
latent organic disulﬁdes such as oxidized cysteine or 2-hydroxyethyl disulﬁde (HED) as oxidizing agents and allows NADP+
recycling under both aerobic and anaerobic conditions with a TTN in excess of 5 × 105, indicating that each regeneration cycle is
99.9998% selective toward forming the cofactor. Accordingly, for each 1 mol of product generated, less than $0.05 of cofactor is
needed. Finally, the EcGRX/ScGR pair is compatible with eight enzymes in the guanosine monophosphate (GMP) biosynthetic
pathway, giving the corresponding isotopically labeled nucleotide in high yield. The glutathione-based NADP+ recycling system
has potential for biocatalytic applications in academic and industrial settings.
KEYWORDS: biocatalysis, biosynthesis, cofactor/coenzyme recycling, enzyme oxidation, biotechnology
■ INTRODUCTION
Reﬁning the performance of enzyme-catalyzed redox processes
remains at the frontier of biocatalysis research1,2 and is of
central importance to the development of sustainable chemical
production processes.3 Oxidoreductases are a large group of
enzymes,4 which due to their good catalytic eﬃciency, general
applicability, and nontoxic nature have been used widely in
industrial processes, ranging from kilogram-scale chiral
resolutions5 to intricate syntheses of pharmaceuticals.6,7 Since
oxidoreductases almost exclusively require the use of
structurally complex and expensive cofactors such as
nicotinamide adenine dinucleotide phosphate NADP(H),
cost-eﬃcient recycling schemes have been developed. Cur-
rently, there are a number of in situ enzymatic systems that
eﬃciently recycle NADPH, including engineered glucose/
glucose 6-phosphate dehydrogenase,8,9 formate dehydrogen-
ase,10,11 and phosphite dehydrogenase.12 These recycling
schemes have been extensively used in NADPH-dependent
enzymatic reductions, such as the production of the HMG-CoA
reductase inhibitor atorvastatin.6 On the other hand, the
current options for the regeneration of the corresponding
oxidized cofactor NADP+ are limited,13 even though enzymatic
oxidation processes play an important role in contemporary
synthetic chemistry and should be fully integrated into chemical
manufacturing.14−23 Hence, there is a pressing need for the
design of a ﬂexible, noninterfering NADP+ recycling
system.24−27
The industrial relevance of any cofactor-regenerating scheme
is primarily assessed by its total turnover number (TTN),
which is deﬁned as the total number of moles of product
formed per mole of cofactor.2,28,29 While the minimal TTN
required for each speciﬁc cofactor depends on its cost and the
value of the product yielded from the biocatalytic process, it is
generally anticipated that the TTN should fall in the range of
104−106 to be economically viable on an industrial scale.2,28,29
This generalization is applicable to the use of NADP+; its
current cost is ∼$22k per mole (Table S1 in the Supporting
Information) and it cannot be used as a stoichiometric reagent
for large-scale synthetic reactions. Additionally, in order to be
practical, the cofactor-recycling process needs to be speciﬁc yet
compatible with the designed chemical reactions. Enzymes are
often characterized by high chemical selectivity and speciﬁcity,
and they are biodegradable, so that enzymatic methods to
regenerate a cofactor have signiﬁcant advantages.29 Therefore,
it is perhaps surprising that there are only a few published
enzymatic NADP+ recycling schemes, but all of these have
drawbacks that limit their applications. The glutamate
dehydrogenase (GDH) system is the most widely used method
to regenerate NADP+ (Figure 1).25,30−32 In this system, a
stoichiometric amount of ammonium α-ketoglutarate is
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converted to glutamate to regenerate the oxidized cofactor. A
major drawback of this system is the modest activity of GDH
whose maximum steady-state turnover number of approx-
imately 40 s−1 restricts the maximal TTN to less than 1 ×
103,25,33 signiﬁcantly lower than the value required for an
economically viable process. Furthermore, α-ketoglutarate
contains a highly electrophilic carbonyl group that is prone to
cross reaction with other components of the system, resulting
in the production of unwanted byproduct(s); in addition, the
byproduct glutamate has been shown to complicate product
isolation.29 Consequently, other regeneration schemes, includ-
ing the D-lactate dehydrogenase (LDH),34 NADPH oxidase
(NOX),35,36 and the laccase/mediator system,37 have been
developed. The calculated TTNs of the LDH and NOX
systems are rather low, however, and range from 1 × 102 to 3 ×
102,35,36 whereas the laccase/mediator system has not been
optimized for NADP+ and its TTN has not been determined.37
Moreover, both NOX and the laccase/mediator system are
oxygen-dependent and hence not suitable for most anaerobic
biocatalysts such as cytochrome P450 dependent enzymes.
Hence, a recycling system that uses simple, inert, latent
oxidizing reagents and is characterized by high TTNs is
urgently required.
In nature, NADP+ can be generated by coupling to enzymatic
disulﬁde bond reduction.38 One major example of this
chemistry is the glutathione (GSH) reductase system, which
plays an essential role in maintaining a reducing environment
within the cell.39 In plants, mammals, some bacteria, and
archea, this system is composed of a pair of enzymes,
glutaredoxin (GRX) and glutathione reductase (GR), and a
pair of redox reagents, glutathione (GSH) and its oxidized
counterpart GSSG.40 GRX contains catalytic cysteine resi-
due(s), which are used to reduce organic disulﬁde bonds.41,42
The resulting oxidized disulﬁdes within the active site of GRX
are then recycled by reduced glutathione to regenerate the
enzyme in its reducing form (Figure 2A). In turn, to maintain a
suﬃcient pool of glutathione, GSSG is reduced by GR, an
enzymatic process that oxidize a stoichiometric amount of
NADPH to NADP+ (Figure 2B).
The glutathione coupling system presents itself as an ideal
surrogate for a NADP+ recycling system. Glutathione and its
oxidized counterpart are relatively inert in comparison to
oxygen and α-ketoglutarate and are thus more compatible with
most biocatalytic processes. Importantly, while GR is directly
responsible for generating NADP+, GRX is capable of
generating GSSG by reducing a wide range of disulﬁde species
from oxidized proteins to small, inexpensive organic molecules
such as 2-hydroxyethyl disulﬁde (HED or oxidized β-
mercaptoethanol) and cystine (Figure 2A).43,44 Such substrate
promiscuity can be exploited in that the oxidizing agent can be
carefully chosen to suit a particular transformation and
complications in product isolation can be minimized. The
reduced thiol byproduct (e.g., β-mercaptoethanol and cysteine)
will also protect the substrates and biocatalysts from oxidative
damages. This system requires the use of two cooperating
enzymes, and it provides clear competitive advantages over
what is oﬀered by all of the currently used systems.
We have developed a glutathione-based recycling system that
employs the enzymes GR and GRX and is capable of using
small, latent organic disulﬁdes as oxidizing reagents to
regenerate NADP+ with a maximal TTN in excess of 5 ×
105, a value noticeably higher than those of the existing NADP+
recycling system and acceptable at an industrial standard. This
system is compatible with various enzymes and can be used to
generate important sugar intermediates such as 6-phosphogluc-
onate (6-PG), ribulose 5-phosphate (Ru5P), and GMP.
Figure 1. Currently available NADP+-recycling systems and their
corresponding total turnover number (TTNs): glutamate dehydrogen-
ase (GDH), lactate dehydrogenase (LDH), NADPH oxidase (NOX)
and laccase/mediator system. N/D = not determined. For a−e see refs
25 and 34−37, respectively.
Figure 2. (A) Coupling of the glutaredoxin (GRX) and glutathione reductase (GR) reactions and (B) the disulﬁde bond reduced in the GR reaction.
ACS Catalysis Research Article
DOI: 10.1021/acscatal.6b03061
ACS Catal. 2017, 7, 1025−1029
1026
■ RESULTS AND DISCUSSION
Glutathione reductase from S. cerevisiae (ScGR) and
glutaredoxin 2 from E. coli (EcGRX2) were chosen to construct
a glutathione recycling system.45−48 ScGR is commercially
available at a reasonable price with a relatively high turnover
number kcat of 240 s
−1 at pH 7.0,46 while recombinant EcGRX2
can be produced in large quantities by expression in E. coli
(Table S2 in the Supporting Information),47 which yields an
enzyme with a high kcat value (∼550 s−1).47 On the basis of
their kinetic parameters, the functional pair of EcGRX2 and
ScGR should recycle NADP+ 8.64 × 105 times within 1 h,
resulting in a high TTN.
Oxidized sugar intermediates are often used in both
traditional chemoenzymatic synthesis and contemporary
synthetic biology developments.31,32,49−52 Hence, the eﬃciency
of the ScGR/EcGRX2 recycling system was tested for the
production of 6-phosphogluconate (6-PG), a common
intermediate in glucose-utilizing metabolic pathways such as
the pentose−phosphate53 and Entner−Doudoroﬀ pathways.54
To this end D-glucose was incubated with the commercially
available enzymes hexokinase (HK), which catalyzes the
addition of phosphate to C-6 of D-glucose, and glucose 6-
phosphate dehydrogenase (G6PDH) (Figure 3). The gluta-
thione coupling enzymes ScGR and EcGRX2, the recycling
reagent GSH, and the latent oxidizing reagent HED were added
to regenerate NADP+. A downﬁeld shift from ∼96 and 92 ppm
(64% β and 36% α anomer, respectively) of the resonance of C-
1 to ∼178 ppm in the 13C NMR spectrum showed that the
substrate was eﬃciently converted to 6-PG (Figure S1 in the
Supporting Information). The maximum TTN achieved with
the enzyme pair ScGR/EcGRX2 recycling system was 5 × 105
(Table S3 in the Supporting Information), which together with
the low cost of HED ($3.27 per mole) shows that ScGR/EcGR
can form a NADP+ recycling system that is commercially viable
on an industrial scale. This system is also compatible with
pyruvate kinase, which is used to recycle ATP in the ﬁrst step of
the pathway.50 Cystine, though sparingly soluble, can also act as
a latent oxidizing agent; it eﬃciently recycled NADP+ and
converted glucose to 6PG (see Supporting Information).
To further examine the potential of the ScGR/EcGRX2
recycling system, an additional NADP+-dependent enzyme, 6-
phosphogluconate dehydrogenase (6-PGDH), on the pathway
to guanosine monophosphate (GMP) was added (Figure 4). 6-
PGDH catalyzes the conversion of 6-PG to ribulose 5-
phosphate (Ru5P).53 Two characteristic downﬁeld chemical
shifts corresponding to C-2 of Ru5P (δ 213 ppm) and the
byproduct bicarbonate (δ 160 ppm) indicated complete
oxidative decarboxylation (Figure S2 in the Supporting
Information).
The ScGR/EcGRX2 recycling system was then combined
with eight enzymes to produce in a one-pot reaction 13C-
labeled GMP,31,32,49 which is used in many biochemical studies,
including structural and functional analysis of RNA51,55,56 and
metabolomic investigations.57−59 The above Ru-5P biosyn-
thetic pathway was extended by incorporating phosphoribo-
isomerase (PRI) and ribose-phosphate pyrophosphokinase
(PRS), which catalyze the isomerization of Ru-5P and the
addition of pyrophosphate to the C-1 position, respectively
(Figure 5). The resulting intermediate phosphoribose pyro-
phosphate (PRPP) is chemically labile at room temperature
and was transformed into GMP in situ with xanthine-guanine
phosphoribosyl transferase (XGPRT). Guanine is only
sparingly soluble at neutral pH, and while it has been suggested
previously that the reaction can proceed as a slurry,49 the
heterogonous nature of the reaction led to poor reproducibility
and increased reaction times of up to 1 day. Hence, guanine
was dissolved at increased pH (50 mM KOH), where it shows
good solubility, and added in a dropwise fashion to the reaction
mixture. Under these conditions 70−80% GMP (Figure S3 in
the Supporting Information) was reproducibly obtained within
2 h from D-glucose. Because PRPP formation requires ATP,
which is converted to AMP as the byproduct, myokinase (MK)
was included to generate ADP, which is subsequently converted
to ATP in a PK-catalyzed reaction that uses phosphoenol
pyruvate (PEP) as the phosphate donor. Together, this work
illustrated that ScGR/EcGRX2 pair is compatible with eight
enzymes, including six biosynthetic enzymes and two ATP-
recycling enzymes.
■ CONCLUSIONS
Developing an eﬃcient and highly compatible NADP+
recycling process is an essential step toward integrating
enzymatic oxidation into the production of high-value
chemicals.14,15 With small, inert organic disulﬁdes as oxidizing
agents, the ScGR/EcGRX2 pair can regenerate NADP+ up to 5
× 105 times, well in excess of the best TTNs of 1 × 103
reported so far.25 Accordingly, each cycle of regeneration is
99.9998% selective for the formation of the active cofactor.
With such selectivity, the cost of NADP+ can be reduced to <
$0.05 per mole of product formed. In practice, the ScGR/
EcGRX2 pair was shown to be compatible with several
biosynthetic enzymes, including ATP-recycling kinases, in the
production of crucial synthons such as 6-PG, 5RuP, and GMP.
This system also oﬀers an attractive synthetic pathway for the
production of isotopically labeled compounds. In addition,
GRX is able to produce useful “byproducts” such as β-
mercaptoethanol, which can protect enzymes, reagents, and
Figure 3. Conversion of D-glucose to 6-phosphogluconate by
hexokinase (HK) and glucose 6-phosphate dehydrogenase
(6GPDH). The ATP/ADP and NADP+ recycling systems are
composed of pyruvate kinase (PK), glutathione reductase (ScGR),
,and glutaredoxin (EcGRX2).
Figure 4. Conversion of D-glucose to ribulose 5-phosphate (Ru5P) by
hexokinase (HK), glucose 6-phosphate dehydrogenase (G6PDH), and
6-phosphogluconate dehydrogenase (6PGDH). Details of the ATP
and NADP+ recycling systems are described in Figure 3 and in the text.
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products from unwanted oxidative damage. GRX has previously
been shown to enhance protein stability by preventing proteins
from oxidative misfolding and aggregation.60−62 The system
developed here is atom eﬃcient in that there are reagents
serving more than one role. Finally, unlike other NADP+
recycling schemes, including the NOX and laccase/mediator
systems, the ScGR/EcGRX2 pair is oxygen-independent and is
functional in aerobic as well as anaerobic environments and is
therefore compatible with oxygen-sensitive biocatalysts such as
P450s. The ScGR/EcGRX2 based NADP+ recycling systems is
superior to all existing methods for cofactor regeneration and
oﬀers many advantages for commercial and academic users.
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ABSTRACT: Pterin-containing natural products have diverse functions in life, but an eﬃcient and easy scheme for their in vitro
synthesis is not available. Here we report a chemoenzymatic 14-step, one-pot synthesis that can be used to generate 13C- and
15N-labeled dihydrofolates (H2F) from glucose, guanine, and p-aminobenzoyl-L-glutamic acid. This synthesis stands out from
previous approaches to produce H2F in that the average yield of each step is >91% and it requires only a single puriﬁcation
step. The use of a one-pot reaction allowed us to overcome potential problems with individual steps during the synthesis.
The availability of labeled dihydrofolates allowed the measurement of heavy-atom isotope eﬀects for the reaction catalyzed
by the drug target dihydrofolate reductase and established that protonation at N5 of H2F and hydride transfer to C6 occur
in a stepwise mechanism. This chemoenzymatic pterin synthesis can be applied to the eﬃcient production of other folates and a
range of other natural compounds with applications in nutritional, medical, and cell-biological research.
■ INTRODUCTION
Pterin is a common motif found in natural products. Folate,
the essential vitamin that fuels the one-carbon cycle for the
biosynthesis of nucleotide and amino acid building blocks, was
one of the ﬁrst natural products found to contain pterin.1,2
The metabolic importance of pterins is illustrated by their
integration into enzyme cofactors such as molybdopterin and
tetrahydrobiopterin.3−5 Pterin natural products are also used as
pigments in the butterﬂies Catopsilia argante and Appias nero,6
whereas biopterin-α-glucoside serves as a natural sunscreen
that protects cellular contents from photoinduced damage in
photosynthetic cyanobacteria.7
5,6,7,8-Tetrahydrofolic acid (H4F), which in addition to the
pterin ring system contains p-aminobenzoic acid (pABA) and
L-glutamic acid (Glu), is required for the biosynthesis of
metabolites that are key for cell survival and replication.2
A one-carbon unit in diﬀerent oxidation states can be added at
N5 and/or N10 of H4F and used to produce metabolites such as
thymidylate, purines, glycine, serine, and S-adenosylmethionine
(SAM) (Figure 1).8 Because of the central importance of
folate biochemistry for cell replication and survival, dihydrofolate
reductase (DHFR), thymidylate synthase (TS), and serine
hydroxymethyltransferase (SHMT) have long been exploited as
important drug targets in the treatment of bacterial infections,9
malaria,10,11 and cancer,12,13 and the DHFR-targeting drugs
trimethoprim, proguanil, pyrimethamine, and methotrexate are
listed as essential medicines by the World Health Organization
(WHO).14 Nevertheless, as with many clinically used drugs,
resistance to antifolates has begun to emerge,15−17 and investi-
gation of the enzymes of the one-carbon cycle is an important
part of inhibitor design strategies.18
Detailed mechanistic insight into enzyme-catalyzed reactions
is often obtained by isotopic labeling and measurement of kinetic
isotope eﬀects (KIEs)19−22 or spectroscopic analysis.23,24
Information derived from regio- and stereospeciﬁc substrate
labeling has been used to design inhibitors with dissociation
constants in themicro- to picomolar range.25 However, the use of
these techniques to investigate folate-dependent enzymes is
hindered by the absence of a general and eﬃcient method to
speciﬁcally label atoms of the pterin ring system, particularly at
N5, C6, C7, and C9, which are directly linked to the chemistry
of the catalyzed reactions. Folate and its derivatives can be
synthesized by connecting the pterin, pABA, and glutamate
groups in sequential order,26 and several synthetic strategies
to incorporate an isotopic label into pterin in a regiospeciﬁc
manner have been reported.27−30 Pterins have been synthesized
by condensing guanidine or dihydroxyacetone with the respec-
tive heterocyclic starting materials, and N5-, C2-, and C6-labeled
folates have beenmade previously.27,28However, because symmetric
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reagents are used in these syntheses, regioselective isotope
labeling of C7 and C9 cannot easily be achieved.28,30 In all cases,
the yields of labeled folate or derivatives are low (<5% overall
yield), and the procedures depend on multiple puriﬁcation
steps. Chemoenzymatic strategies have also been described,31−33
whereby H4F was condensed with
11C-formaldehyde or
14C-formic acid to yield the corresponding isotopically labeled
[11C]5,10-methylene-H4F, [
14C]5-formyl-H4F, and [
14C]10-form-
yl-H4F. However, a general and eﬃcient method to label the pterin
ring in folates has never been developed.
In nature, the pterin ring in folate is formed from guanosine
triphosphate (GTP) in one biochemical step catalyzed by GTP
cyclohydrolase (GTP-CH),34,35 an enzyme found in all king-
doms of life ranging from archaebacteria, insects, plants to
humans. In all GTP-CH-catalyzed reactions, GTP is converted to
a pterin via a set of tandem reactions that have no equivalent in
organic chemistry. GTP cyclohydrolase I (GTP-CH-I) catalyzes
the formation of 7,8-dihydroneopterin triphosphate (DHNTP)
from GTP by mediating four distinct chemical reactions
(Figure S1): hydrolysis of the purine ring yielding an N-formyl
intermediate, N-deformylation, a stereospeciﬁc Amadori rear-
rangement of the ribose moiety, and ring closure to form
the pterin.36−38 Because no symmetric reagent is used in this
reaction, GTP-CH-I can be used to synthesize the pterin ring
system of folate with heavy isotopes incorporated regio- and
stereoselectively.39 It is therefore surprising that GTP-CH-I has
not been used in any in vitro enzymatic pathway to synthesize
folates. Perhaps the low catalytic turnover (kcat = 0.05 s
−1)40 and
the rather low stability of the product 7,8-dihyropterin41 toward
oxygen and light have limited the use of GTP-CH-I in synthesis.
Here we report a 14-step one-pot chemoenzymatic synthesis of
7,8-dihydrofolic acid (H2F) that exploits the well-established
procedures to isotopically label GTP39,42,43 by using GTP-CH-I to
site-speciﬁcally isotope-label pterins. The low enzymatic activity
and product instability of GTP-CH-I were addressed by enzymatic
coupling. By means of our methodology, H2F enriched with stable
isotopes at N5 and C6 could be synthesized eﬃciently in pure
form in >30% yield from isotopically enriched D-glucose and
guanine. Given the high degree of purity and isotopic enrichment
(>97%; see the Supporting Information), heavy-atom KIEs could
be measured to investigate the mechanism of the Escherichia coli
DHFR (EcDHFR)-catalyzed reduction of H2F to H4F.
■ RESULTS AND DISCUSSION
In Vitro Synthesis of Folate. The biosynthetic pathway to
folate in E. coli uses the building blocks D-glucose, guanine, and
Figure 1. Folate coenzymes in one-carbon metabolism. Folic acid is converted to 7,8-dihydrofolic acid (H2F) and 5,6,7,8-tetrahydrofolic acid (H4F).
One-carbon units attached to H4F are highlighted. Abbreviations: 1, dihydrofolate reductase (DHFR); 2, 10-formyl-H4F synthetase (FTHFS);
3, 10-formyl-H4F dehydrogenase (FDH); 4, 5,10-methenyl-H4F cyclohydrolase (MTHFC); 5, 5,10-methylene-H4F dehydrogenase (MTHFD);
6, 5,10-methylene-H4F reductase (MTHFR); 7, methionine synthase (MS); 8, serine hydroxymethyltransferase (SHMT); 9, thymidylate synthase
(TS); 10, 5,10-methenyl-H4F synthetase (MTHFS); 11, 5-formimino-H4F cyclodeaminase (FTCD); SAM, S-adenosylmethionine.
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p-aminobenzoyl-L-glutamate (pABA-Glu). In the biosynthetic
scheme of H2F (Figure 2), C2, C3, and C4 of glucose correspond
to C7, C6, and C9 of H2F and N1, C2, N3, C4, C5, C6, N7, and
N9 of guanine correspond to N3, C2, N1, C4b, C4a, C4, N5, and
N8 in H2F. GTP is the key intermediate in this synthetic
pathway, connecting the purine salvage pathway to de novo
folate biosynthesis. Accordingly, a minimum of 14 enzymes need
to be assembled in vitro to produce H2F.
The GTP biosynthetic pathway is composed of enzymes from
the pentose phosphate and purine salvage pathways (Figures 2
and S2). D-Glucose serves as the starting material, which is
transformed into phosphoribose pyrophosphate (PRPP) in
ﬁve steps that are catalyzed by hexokinase (HK), glucose
6-phosphate dehydrogenase (G6PDH), 6-phosphogluconate
dehydrogenase (6PGDH), phosphoriboisomerase (PRI), and
ribose-phosphate pyrophosphokinase (phosphoribosylpyro-
phosphate synthetase, PRS).44 PRPP is then combined with
guanine to form GMP under xanthine guanine phosphoribosyl
transferase (XGPRT) catalysis. The resulting GMP is con-
verted to the corresponding nucleotide triphosphate in reactions
catalyzed by guanylate kinase (GK) and pyruvate kinase (PK).
Since HK and GK use ATP as the phosphate source, PK can also
function as the recycling enzyme. On the other hand, PRS uses
ATP as the pyrophosphate source, so myokinase (MK) was
included to regenerate ATP fromAMP.45 A signiﬁcant amount of
NADP+ is also needed for GTP biosynthesis. Hence, the recently
developed glutathione reductase (GR)/glutaredoxin 2 (GRX2)
recycling system was used to regenerate the oxidized cofac-
tor.44 The GR/GRX2 system uses disulﬁdes like 2-hydroxyethyl
Figure 2. Strategy for the synthesis of 7,8-dihydrofolate (H2F).
Guanosine triphosphate (GTP) was made via the pentose phosphate
and purine salvage pathways under hexokinase (HK), glucose
6-phosphate dehydrogenase (G6PDH), 6-phosphogluconate dehydro-
genase (6PGDH), phosphoriboisomerase (PRI), ribose-phosphate
pyrophosphokinase (PRS), xanthine guanine phosphoribosyl trans-
ferase (XGPRT), guanylate kinase (GK), and pyruvate kinase (PK)
catalysis. In the folate de novo pathway, GTP is converted to
7,8-dihydroneopterin (DHN) under catalysis by GTP cyclohydrolase
I (GTP-CH-I), 7,8-dihydroneopterin pyrophosphatase (DHNTPase),
and alkaline phosphatase (ALP); DHN is then converted to H2F under
catalysis by dihydroneopterin aldolase (DHNA), 6-hydroxymethyl
7,8-dihydropterin pyrophosphokinase (HPPK), and dihydropteroate
synthase (DHPS). The additional enzymes myokinase (MK),
glutathione reductase (GR), and glutaredoxin 2 (GRX2) are used for
the regeneration of ATP and NADP+.44,45 The pterin atoms of
H2F derived from glucose (red) and guanine (blue) are highlighted.
Details of each biosynthetic step are described in Figure S2.
Figure 3. Conversion of guanosine triphosphate (GTP) into
7,8-dihydroneopterin triphosphate (DHNTP) and monophosphate
(DHNMP). Shown are anion-exchange chromatography analyses of
GTP incubated for 2 h at 37 °C with (a) GTP cyclohydrolase I
(GTP-CH-I), which shows partial conversion to DHNTP, and (b) both
GTP-CH-I and 7,8-dihydroneopterin triphosphate pyrophosphohydro-
lase (DHNTPase), resulting in essentially complete conversion to
DHNMP. Production of guanosine diphosphate (GDP) is most likely
due to the nonenzymatic hydrolysis of GTP during incubation.
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disulﬁde (HED or oxidized β-mercaptoethanol) or cystine as
regenerating reagents and produces thiols as useful byproducts
that protect the enzymes and intermediates from oxidative
damage.
The conversion of GTP to DHNTP by GTP-CH-I marks the
entry point of the folate de novo pathway. It has been reported
that potassium and magnesium ions are positive allosteric
eﬀectors that can increase the rate of the GTP-CH-I reaction
up to 5-fold.46 The addition of these cations, however, was
insuﬃcient, as the reaction was found to be incomplete, giving a
poor yield of DHNTP (Figure 3a). In folate de novo
biosynthesis, dephosphorylation of DHNTP to 7,8-dihydro-
neopterin monophosphate (DHNMP) by DHNTP pyrophos-
phohydrolase (DHNTPase) is the biochemical step followed
by the GTP-CH-I reaction (Figure 2).47,48 Knockout of the
DHNTPase gene signiﬁcantly impairs folate metabolism in
E. coli,48 which suggests that DHNTP phosphohydrolysis is a
key regulatory step in folate metabolism. In other words, the
activity of GTP-CH-I is most likely inhibited by its own product,
DHNTP, which therefore needs to be immediately converted to
DHNMP in order to sustain the activity of GTP-CH-I. In the
presence of DHNTPase, GTP-CH-I showed a marked rate
enhancement (Figure S3), with nearly complete conversion of
GTP and a high yield of DHNMP (Figure 3b).
Additional enzymes are needed to convert DHNMP into
folate. To the best of our knowledge, the natural enzyme
responsible for the conversion of DHNMP to 7,8-dihydroneop-
terin (DHN) is unknown,37,48 and alkaline phosphatase (ALP)
was used instead as a surrogate. DHN is subjected to a retro-aldol
reaction catalyzed by dihydroneopterin aldolase (DHNA) to
yield 6-hydroxymethyl-7,8-dihydropterin (HMDP),49,50 which
then reacts with ATP in the presence of 6-hydroxymethyl
7,8-dihydropterin pyrophosphokinase (HPPK) (Figure 4).51
In E. coli, the resulting intermediate, 6-hydroxymethyl-7,8-
dihydropterin pyrophosphate (HMDPpp), is ﬁrst condensed
with pABA and then with glutamate, catalyzed by dihydropter-
oate synthase (DHPS)52 and dihydrofolate synthase (DHFS),53
respectively, to ﬁnally generate H2F. However, DHPS accepts
preassembled pABA-Glu as a substrate,54 so DHFS is not
required in the in vitro reaction. The entire H2F synthetic
pathway requires only one puriﬁcation step of the product, but
ALP needs to be removed by ultraﬁltration prior to the addition
of DHNA, HPPK, and DHPS because the phosphatase can also
catalyze the phosphorolysis of ATP and HMDPpp. Two addi-
tional modiﬁcations were made to further improve the overall
yield. A N2-ﬁlled glovebox system was used because all reduced
pterin-containing compounds, DHNTP, DHNMP, DHN,
HMDP, HMDPpp, and the ﬁnal product H2F, are oxygen-
sensitive.41 Also, cystine was found to be the preferred reagent
over HED for the NADP+ regeneration system operated by GR
andGRX2. Perhaps β-mercaptoethanol made from the reduction
of HED interferes with other enzymatic reactions, such as the
chelation of Zn2+ in GTP-CH-I. The total turnover numbers for
the regeneration of ATP from ADP by pyruvate kinase and
from AMP by pyruvate kinase/myokinase are both ∼100,55
while the total turnover number for our GR/GRX2-based
NADP+ recycling system can reach 5× 105.44 In general, a typical
biosynthetic cascade produced 6.6 mg of H2F from 9 mg of
glucose in an overall yield of 30%, i.e., the average yield of each
chemical transformation is in excess of 91%.
Synthesis of Selectively Labeled Folates. Five isotopi-
cally labeled H2Fs were synthesized using the newly developed in
vitro pathway (Figure 5a). Liquid chromatography−high-resolu-
tion mass spectrometry (LC-HRMS) analysis of [6-13C]H2F,
produced from [3-13C]D-glucose, showed an increase of ∼1
amu; 13C NMR spectroscopy revealed a singlet at 152 ppm.
Figure 4. Conversion of 7,8-dihydroneopterin (DHN) to dihydrofolate (H2F). Dihydroneopterin aldolase (DHNA) catalyzes the transformation of
DHN to 6-hydroxymethyl-7,8-dihydropterin (HMDP), which is pyrophosphorylated by 6-hydroxymethyl 7,8-dihydropterin pyrophosphokinase
(HPPK). The resulting 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (HMDPpp) is converted to H2F by dihydropteroate synthase (DHPS),
whose promiscuity allows the use of preassembled pABA-Glu as the substrate and the omission of dihydrofolate synthase (DHFS) in the in vitro
synthetic pathway.
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Additionally, long-range coupling between 6-13C and protons on
C7 and C9 of [6-13C]H2F were observed in the
1H,13C HMBC
spectrum (Figure 5b).
To incorporate an 15N label into the pterin moiety at N5,
[7-15N]guanine was used. The resulting product showed∼1 amu
increase in LC-HRMS analysis and an 15N signal at 285 ppm
coupling to C7 and C9 protons in the 1H,15N HMBC spectrum
(Figure 5c).
When [3-13C]D-glucose and [7-15N]guanine were combined
to produce [5-15N][6-13C]H2F, a mass increase of ∼2 amu was
measured. The 13CNMR spectrum showed a doublet at 152 ppm
with a coupling constant 1JCN of 7.5 Hz; long-range coupling
between the protons on C7 and C9 was observed in the
1H,13C HMBC and 1H,15N HMBC spectra (see the Supporting
Information), indicating that both N5 and C6 of H2F were
isotopically enriched.
Similarly, [6,7,9-13C3]H2F and [5-
15N][6,7,9-13C3]H2F were
synthesized from 13C6-D-glucose and [7-
15N]guanine, and their
identities were conﬁrmed by HRMS and NMR spectroscopy
(see the Supporting Information).
Heavy-Atom Kinetic Isotope Eﬀects on the Reaction
Catalyzed by EcDHFR.The preparation of 13C- and 15N-labeled
Figure 5. H2Fs labeled with stable isotopes on the pterin ring system. (a) Patterns of isotopic distribution are determined by the starting material
isotopic enrichment used during H2F biosynthetic assembly. (b)
1H,13CHMBC and (c) 1H,15NHMBC spectra of [6-13C]H2F and [5-
15N]H2F. Protons
attached to C7 (3.95 ppm) and C9 (3.87 ppm) correlate to C6 (152 ppm) or N5 (285 ppm). 1H NMR spectra of all compounds and additional 2D
NMR characterization of [5-15N][6-13C]H2F, [6,7,9-
13C3]H2F and [5-
15N][6,7,9-13C3]H2F are reported in Figures S12−S15. HRMS data for all of the
compounds are given in Table S3 and Figures S16−S21. Isotopic enrichment was calculated to be at least 97% from the mass spectrometric data
(as illustrated in Figures S22−S24).
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dihydrofolates allowed the measurement of heavy-atom isotope
eﬀects for the reactions catalyzed by dihydrofolate reductase
(DHFR), a key enzyme in one-carbon metabolism and a vali-
dated target for the treatment of bacterial infections, malaria, and
cancer.56 DHFR catalyzes the reduction of H2F to H4F via
transfer of the pro-R hydride from C4 of NADPH to the Re face
on C6 accompanied by protonation of N5 of H2F (Figure 6).
57,58
Several aspects of the reaction mechanism warrant additional
investigation. In particular, the transition state structure and the
order of chemical transformation events have not been fully
determined.59,60 The active site of DHFR provides a favorable
environment for protonation of N5 by elevating the pKa from 2.6
to 6.5 and using an active-site water as the proton source.61,62
Solvent and hydrogen KIE measurements combined with site-
directed mutagenesis have suggested a stepwise mechanism in
which protonation precedes hydride transfer.63,64 However, D2O
increases the viscosity of the reaction buﬀer relative to H2O,
65,66
and site-directed modiﬁcation can alter the catalytic behavior
of an enzyme.67 Thus, additional mechanistic investigations
are needed to establish the order of events. Since isotopic
substitution does not alter the chemistry of the reaction but only
the kinetics, [6-13C]H2F and [5-
15N]H2F were used to measure
the 15N and 13C heavy-atom kinetic isotope eﬀects. Pre-steady-
state kinetic measurements at 15 °C by ﬂuorescence resonance
energy transfer from the active-site tryptophan in DHFR to the
reduced cofactor yield ﬁrst-order hydride transfer rate constants
with an accuracy of up to 0.7% (Figures S25−S27 and Table S4).
While a 13C KIE of 1.015 ± 0.006 was observed for the reduction
of [6-13C]H2F, the corresponding
15N KIE for [5-15N]H2F was
essentially unity (0.999 ± 0.006) under the same conditions.
To conﬁrm this ﬁnding, [5-15N][6-13C]H2F was used to probe
both positions at the same time, and the measured value for the
corresponding multiple heavy-atom KIE was 1.014 ± 0.008,
which is statistically identical to that obtained when the substrate
was labeled with 13C only.
The observed 15N KIE on hydride transfer indicates that
protonation of N5 is not isotopically sensitive, likely because
it is not rate-limiting under pre-steady-state conditions (as the
reaction is essentially irreversible,58 the observed KIE will tend to
unity rather than to the equilibrium isotope eﬀect).22 On the
other hand, the measured 13C KIE indicates that the hydride
transfer step is rate-determining. This strongly suggests a
stepwise mechanism. If the protonation and hydride transfer
steps were concerted, 15N- and 13C-labeled H2Fs should both
yield measurable KIEs;19,21,22 this interdependence may also lead
to an additive eﬀect in the multiple heavy-atom isotope eﬀect
measurement with the double-labeled substrate.19,21,22 In other
words, our results suggest that the pre-steady-state kinetic
measurement at pH 7.0 reveals only the step of hydride transfer
because protonation of N5 is in rapid equilibrium and the
ensemble of reaction-ready conformations is mostly populated
with protonated H2F. Importantly, these results conﬁrm the
validity of previous solvent KIE and site-directed mutagenesis
studies, which also concluded that the sequence of chemical
events (protonation and hydride transfer) is distinct and strictly
ordered.64,68 Overall, the results provided here strongly support
a mechanism where protonation and hydride transfer are
independent of each other and occur in a stepwise fashion.
■ CONCLUSIONS
Dihydrofolate was produced enzymatically in an easy one-pot,
high-yielding reaction sequence from glucose, guanine, and
pABA-Glu that required only a single puriﬁcation step. Potential
problems with individual steps during the synthesis could be
overcome through the use of a one-pot reaction. This metho-
dology can be used to generate dihydrofolates labeled in speciﬁc
positions with stable isotopes with average overall yields of
>30%, facilitating many applications in cell biology and
mechanistic enzymology.27−29,61,69,70 For the ﬁrst time, heavy-
atom KIEs for the DHFR-catalyzed reduction of H2F could be
measured to provide strong support for a stepwise reduction of
the substrate in which protonation at N5 and hydride transfer
from C4 of the NADPH to C6 of protonated dihydrofolate
proceed independently. This chemoenzymatic pterin synthesis
can be integrated into other enzymatic procedures to generate
folate derivatives31,32 and other high-value natural products that
are not easily accessible by conventional synthesis.71 It can be
applied to nutritional, medical, and cell-biological research to
address questions of in vivo bioavailability and to explore the
kinetics of folate metabolism in intact cells and organisms.70,72−76
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